Loma Linda University

TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Loma Linda University Electronic Theses, Dissertations & Projects

6-1-2011

Novel Molecules that Regulate Bone Formation
and Bone Resorption
Gabriel Robert Linares
Loma Linda University

Follow this and additional works at: http://scholarsrepository.llu.edu/etd
Part of the Medical Physiology Commons
Recommended Citation
Linares, Gabriel Robert, "Novel Molecules that Regulate Bone Formation and Bone Resorption" (2011). Loma Linda University
Electronic Theses, Dissertations & Projects. 40.
http://scholarsrepository.llu.edu/etd/40

This Dissertation is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative
Works. It has been accepted for inclusion in Loma Linda University Electronic Theses, Dissertations & Projects by an authorized administrator of
TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works. For more information, please contact
scholarsrepository@llu.edu.

LOMA LINDA UNIVERSITY
School of Medicine
in conjunction with the
Faculty of Graduate Studies

____________________

Novel Molecules that Regulate Bone Formation and Bone Resorption
by
Gabriel Robert Linares

____________________

A Dissertation submitted in partial satisfaction of
the requirements for the degree of
Doctor of Philosophy in Physiology

____________________

June 2011

© 2011
Gabriel Robert Linares
All Rights Reserved

Each person whose signature appears below certifies that this dissertation in his/her
opinion is adequate, in scope and quality, as a dissertation for the degree Doctor of
Philosophy.

, Chairperson
Subburaman Mohan, Research Professor of Medicine and of Biochemistry and
Physiology, Director Musculoskeletal Disease Center at Jerry L. Pettis Memorial
Veterans Affairs Medical Center

Marino De Leon, Associate Professor of Physiology and Pharmacology, Director Center
for Health Disparities and Molecular Medicine

Alan P. Escher, Associate Professor of Biochemistry and Microbiology

David Hessinger, Professor of Physiology and Pharmacology, of Biochemistry and
Natural Sciences

Lubo Zhang, Professor of Physiology and Pharmacology

iii

ACKNOWLEDGEMENTS
I would like to express my deepest gratitude to my mentor Dr. Subburaman
Mohan. It has truly been a distinct honor and high privilege to receive training from a
world-renowned scientist. Thank you providing me with an outstanding research
environment that was enriching and stimulating both on a professional and personal level.
I am grateful for your steadfast encouragement and efforts in challenging me to strive for
my best. Through your work, time, and patience I have realized my dream of becoming a
scientist.
I would also like to thank my committee members Dr. Marino De Leon, Dr. Alan
Escher, Dr. David Hessinger, and Dr. Lubo Zhang for their personal advice, support, and
guidance.
I would also like to express my gratitude to the current and past members of the
Mohan laboratory and the Musculoskeletal Disease Center at the Jerry L. Pettis Memorial
Veterans Affairs Medical Center. Thank you for providing me with excellent training,
critical reviews, suggestions, and support.
I also want to thank Loma Linda University School of Medicine Basic Sciences
Program and the Center for Health Disparities and Molecular Medicine, for providing
guidance, support, facilities, and the opportunity to pursue my doctorate at this wonderful
institution.
To my family and friends, thanks for your unwavering love and support through
this long endeavor—I could not have finished without you. And finally, I would like to
thank God for his spiritual guidance throughout this journey.

iv

CONTENTS
Approval Page .................................................................................................................... iii
Acknowledgements ............................................................................................................ iv
Table of Contents .................................................................................................................v
List of Tables .......................................................................................................................x
List of Figures .................................................................................................................... xi
List of Abbreviations ....................................................................................................... xiii
Abstract ..............................................................................................................................xv
Chapter
1. Introduction ..............................................................................................................1
Osteoporosis Risk Factors..................................................................................2
Cells of the Bone................................................................................................7
Osteoblasts ...................................................................................................7
Regulation ..................................................................................................10
Transcription Factors ...........................................................................10
Hormones .............................................................................................11
Growth Factors.....................................................................................11
Intercellular Communication ...............................................................12
Osteoclasts .................................................................................................15
MCSF/RANKL/OPG Regulatory Axis................................................16
Transcriptional Regulation of Osteoclast Differentiation ....................17
Factors that Modulate Osteoclastogenesis ...........................................21
Osteocytes ..................................................................................................23
Bone Remodeling.............................................................................................23
Activation...................................................................................................24
Resorption ..................................................................................................25
Reversal......................................................................................................26
Formation ...................................................................................................26

v

Termination ................................................................................................27
Novel Molecules That Regulate Bone Formation and Bone Resorption .........27
Oxidative Stress and Bone ...............................................................................28
Protection Against Oxidative Stress ..........................................................29
Glutaredoxins .............................................................................................31
Glutaredoxins and Apoptosis .....................................................................34
Rationale and Hypothesis ..........................................................................35
Thyroid Hormone.............................................................................................36
Hypothalamic-Pituitary Thyroid Axis .......................................................36
TH Effects on Bone ...................................................................................36
TH Action ..................................................................................................38
Thyroid Hormone Receptors (TRs) ...........................................................38
Non-genomic and Genomic Actions of TH ...............................................39
Nongenomic Mechanisms ....................................................................39
Genomic Mechanisms ..........................................................................40
Thyroid Hormone Response Elements (TRE) ...............................41
Mechanisms of Transcriptional Regulation ...................................42
Nuclear Receptor Coregulators ......................................................42
Diabetes and Obesity Related Protein (DOR) ...........................................45
Rationale and Hypothesis ..........................................................................46
Tight Junctions .................................................................................................47
Claudins (Cldns) are Essential for TJ Formation .......................................48
Claudin Protein Structure...........................................................................48
Cldn Expression and Interaction ................................................................52
Mechanisms of Regulation for Cldn Levels and Actions ..........................53
Phenotypic Effects of Cldn Loss of Function ............................................55
Cldn-18 ......................................................................................................57
Rationale and Hypothesis ..........................................................................58
2. Glutaredoxin 5 Regulates Osteoblast Apoptosis by Protecting Against
Oxidative Stress .....................................................................................................59
Abstract ............................................................................................................60
Introduction ......................................................................................................61
Materials and Methods .....................................................................................63
Cell Culture ................................................................................................63

vi

RNA Isolation and Extraction....................................................................64
Gene Expression Analysis .........................................................................64
Gene Transfection ......................................................................................65
Cloning of Grx5 into MLV Vector ............................................................66
MLV-Based Vector Production and MLV Transduction ..........................67
Western Blot Analysis ...............................................................................67
Determination of Apoptosis .......................................................................68
MultiTox-Fluor Multiplex Cytoxicity Assay .............................................69
ROS Assay .................................................................................................70
Enzymatic Activities ..................................................................................70
10-N-nonyl Acridine Orange (NAO) .........................................................70
Statistical Analysis .....................................................................................71
Results ..............................................................................................................71
Characterization of Glutaredoxin Expression in Mouse Tissues and
Cells ...........................................................................................................71
Grx5 Deficient Cells are Sensitized to H2O2 Induced Apoptosis ..............74
TNF-α Treatment Sensitizes Grx5 shRNA Osteoblasts to
Apoptosis ...................................................................................................77
Grx5 Overexpression Protects Against H2O2 Induced Apoptosis .............77
Grx5 Mediates H2O2 Induced ROS Generation ........................................80
Grx5 Deficient Cells Exhibit Increased Caspase 3,7 Activation in
the Presence of H2O2 and TNF-α ...............................................................85
Grx5 siRNA Treatment Decreases Aconitase and MnSOD Activity ........88
Discussion ........................................................................................................91
Acknowledgements ..........................................................................................94
References ........................................................................................................97
3. Role of Diabetes and Obesity Related Protein (DOR) in the Regulation of
Osteoblast Differentiation ....................................................................................102
Abstract ..........................................................................................................103
Introduction ....................................................................................................104
Materials and Methods ...................................................................................106
Reagents ...................................................................................................106
Cell Culture ..............................................................................................106
RNA Isolation and Gene Expression Analysis ........................................107
Cloning of DOR .......................................................................................107
Murine Leukemia Virus-Based Viral Vectors (MLV-based vector)
and Lentivirus-Based Vectors (HIV-based vectors) Production and
Transduction ............................................................................................108
Alkaline Phosphatase (ALP) Activity Assay ...........................................108
Western Blot ............................................................................................109

vii

Subjects ....................................................................................................109
Genotyping ...............................................................................................110
Statistical Analysis ...................................................................................110
Results ............................................................................................................110
DOR Expression Increases During Osteoblast Differentiation ...............110
DOR Modulates TH-Induced Osteoblast Differentiation ........................113
Inhibition of DOR Impairs TH-Induced Expression of Osteogenic
Markers ....................................................................................................122
A SNP in DOR Promoter Associates with Circulating Osteocalcin
in Healthy Subjects ..................................................................................125
Discussion ......................................................................................................129
Acknowledgements ........................................................................................135
Grants .............................................................................................................135
Disclosures .....................................................................................................135
References ......................................................................................................136
4. Claudin-18 (Cldn-18) is a Novel Negative Regulator of Bone Resorption
and Osteoclast Differentiation .............................................................................141
Summary ........................................................................................................142
Introduction ....................................................................................................142
Results ............................................................................................................143
Discussion ......................................................................................................167
Methods..........................................................................................................168
Mice .........................................................................................................168
Cell Culture ..............................................................................................170
Analysis of Skeletal Morphology ............................................................171
ELISA ......................................................................................................171
Mineralized Nodule Formation ................................................................171
Gene Expression Analysis .......................................................................171
Cloning of Claudin 18a2.1 .......................................................................172
Murine Leukemia Virus Based Viral Vector (MLV-based vector)
Production and Transduction ...................................................................172
Lentivirus Transduction ...........................................................................172
In vitro Osteoclast Formation ..................................................................173
Immunoblotting Analysis.........................................................................173
Immunoprecipitation ................................................................................174
Cell Proliferation ......................................................................................175
Statistical Analysis ...................................................................................175
Acknowledgements ........................................................................................175
Author Contributions .....................................................................................176

viii

Competing Interests Statement ......................................................................176
References ......................................................................................................177
5. Discussion ............................................................................................................180
Summary and Conclusions ............................................................................186
Future Directions ...........................................................................................188
References ........................................................................................................................192

ix

TABLES
Tables

Page

1. Risk Factors of Osteoporosis ...................................................................................3
2. Claudin Loss of Function Mutations in the Mouse................................................56
3. Clinical Characteristics of Subjects .....................................................................128
4. Primer Sequences .................................................................................................169

x

FIGURES
Figures

Page

1. Regulation of Osteoblast Differentiation by Transcription Factors .........................9
2. Cell-Cell Interaction Between Osteoblasts and Osteoclasts ..................................14
3. Regulation of Osteoclast Differentiation ...............................................................19
4. Model for Transcriptional Activation of TH Receptor Regulated Genes ..............44
5. Schematic Representation of Claudin (Cldn) Structure .........................................50
6. Glutaredoxin Expression in Mouse Tissues and Cells ...........................................73
7. Inhibition of Grx5 Augments Cell Death...............................................................76
8. Lentiviral Grx5 shRNA Transduction in MC3T3-E1 Cells Induces
Cytotoxicity in the Presence of TNF-α ..................................................................79
9. Grx5 Overexpression Attenuates H2O2 Induced Apoptosis in MC3T3-E1
Cells .......................................................................................................................82
10. Effect of Grx5 Overexpression or Inhibition on H2O2 Induced ROS
Generation in MC3T3-E1 Cells .............................................................................84
11. Grx5 Deficient Cells Exhibit Increased Caspase 3,7 Activity ...............................87
12. Grx5 siRNA Treatment Reduces the Activities of Aconitase and MnSOD ..........90
13. Proposed Model for Mechanism of Grx5 Action ..................................................96
14. DOR Expression During Osteoblast Proliferation and Differentiation ...............112
15. DOR Overexpression Exacerbates T3-Induced Increase in ALP Activity ..........116
16. Inhibition of DOR Reduces TH Stimulation of ALP Activity in MC3T3E1 Cells ................................................................................................................118

xi

17. TH-Induced Increase in ALP Activity is Severely Reduced in Primary
Calvaria Osteoblasts Transduced with DOR shRNA ..........................................121
18. DOR Deficiency Decreases the Gene Expression of Osteoblast Specific
Markers ................................................................................................................124
19. Ninety-five Percent Confidence Interval (95% CI) of Circulating
Osteocalcin Levels According to DOR/Tp53inp2 Gene Polymorphism .............127
20. Generation of Cldn-18 -/- Mice .............................................................................145
21. Cldn-18 -/- Mice Exhibit Reduced Bone Mineral Density .............................148, 50
22. Cldn-18 -/- Mice Exhibit Reduced Bone Mineral Density ...................................152
23. Serum Chemistry Measurements in Cldn-18 -/- Mice and WT Mice ...................154
24. Bone Formation is Unaffected by Cldn-18 Deficiency .......................................157
25. Disruption of Cldn-18 Increases Bone Resorption and Osteoclast
Formation .............................................................................................................159
26. Cldn-18 Variant 18a2.1 is Expressed in Bone and Influences Osteoclast
Formation .............................................................................................................162
27. Cldn-18 Regulates RANKL Signaling in Osteoclasts .........................................166

xii

ABBREVIATIONS
AA

Ascorbic acid

ALP

Alkaline phosphatase

BMD

Bone mineral density

BMMs

Bone marrow macrophages

BMP-2

Bone morphogenic protein-2

BMSCs

Bone marrow stromal cells

BV

Bone volume

Cldn

Claudin

DOR

Diabetes and obesity related protein

DXA

Dual energy x-ray absorption

Fe-S

Iron-sulfur

GFP

Green fluorescent protein

Grx

Glutaredoxin

H2O2

Hydrogen peroxide

IGF

Insulin-like growth factor

MCSF

Macrophage colony stimulating factor

MLV

Murine leukemia virus

MnSOD

Manganese superoxide dismutase

RANKL

Receptor activator of nuclear factor kappa B ligand

ROS

Reactive oxygen species

SD

Standard deviation

SEM

Standard error of the mean

xiii

shRNA

Short hairpin RNA

siRNA

Small interfering RNA

SNP

Single nucleotide polymorphism

TH

Thyroid hormone

TNF-α

Tumor necrosis factor-α

TR

Thyroid hormone receptor

TRAP

Tartrate resistant acid phosphatase

TRE

Thyroid hormone response element

TV

Tissue volume

T3

3,3′,5-Triiodo-L-thyronine

T4

L-Thyroxine

µCT

Micro-computed tomography

WT

Wild type

ZO

Zonula occluden

xiv

ABSTRACT OF THE DISSERTATION
Novel Molecules that Regulate Bone Formation and Bone Resorption
by
Gabriel Robert Linares
Doctor of Philosophy, Graduate Program in Physiology
Loma Linda University, June 2011
Dr. Subburaman Mohan, Chairperson
Osteoporosis is a disease characterized by decreased bone mass and
microarchitectural deterioration of bone. Bone loss occurs when the increased bone
resorption that occurs with age is not compensated by a corresponding increase in bone
formation. Therefore, understanding the mechanisms which regulate bone formation and
bone resorption is important for developing diagnostic and treatment strategies for
osteoporosis. In my dissertation, we investigated the role of Glutaredoxin 5 (Grx5),
Diabetes and Obesity Related protein (DOR), and Claudin 18 (Cldn-18), novel molecules
involved in regulating bone formation and bone resorption. We demonstrated that Grx5
protects osteoblasts from oxidative stress induced apoptosis via a molecular pathway that
involves regulation of reactive oxygen species production, cardiolipin oxidation, caspase
activity, iron-sulfur cluster formation, and manganese superoxide dismutase activity. We
found that DOR is an important regulator of osteoblast differentiation. In addition, a
single nucleotide polymorphism (SNP) in the promoter of human DOR gene associated
with plasma levels of the bone formation marker, osteocalcin, in men. Targeted
disruption of the tight junction protein, Cldn-18, in mice led to significant deficits in peak
bone mass due to increased bone resorption with no effect on bone formation. Cldn-18 is
a novel negative regulator of osteoclast differentiation that interacts with ZO-2 to

xv

modulate RANKL signaling in osteoclasts. Collectively, these findings may provide
insight into the molecular mechanisms which regulate bone formation and bone
resorption, and may be useful in developing therapeutic strategies to prevent low bone
mass.

xvi

CHAPTER ONE
INTRODUCTION
Osteoporosis poses a major public health threat not only in the United States but
throughout the world. Osteoporosis is characterized by two defining features—decreased
bone mineral density and microarchitectural deterioration of bone tissue which result in
the formation of porous bone. Due to the lack of outward symptoms associated with low
bone mass, osteoporosis is known as a “silent disease.” Generally, the condition becomes
evident when an impact or fall that would not damage normal and healthy bone, results in
a fracture (Tinetti, Speechley, & Ginter, 1988). Therefore, early diagnosis of the disease
by screening bone mineral density (BMD) is important (Stone et al., 2003). Although
any bone can fracture when considering osteoporosis, the most common sites of fracture
are the hips, wrists, and spine (Stone et al., 2003). Depending on the site of fracture, the
physical appearance of the patient can be altered. For example, damage to the bones of
the vertebral column can result in spinal deformities leading to a loss of height or a
hunched posture. Fractures can also reduce the quality of life by rendering an individual
immobilized (N. Harvey, Dennison, & Cooper, 2010; T. C. Wong, Wu, Cheng, Cheng, &
Yam, 2007). Loss of the ability to move and function independently can cause
significant social and emotional strain (Bischoff-Ferrari, Lingard, et al., 2004).
An estimated 10 million Americans already have osteoporosis and 34 million
more have low bone mass (http://www.nof.org/aboutosteoporosis/bonebasics
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/whybonehealth, 2011). Increased bone fragility results in increased risk for osteoporotic
fracture. According to the National Osteoporosis Foundation, one out of every two
women and 1 out of every four men will experience an osteoporosis related fracture in
their lifetime (http://www.nof.org/aboutosteoporosis/bonebasics/whybonehealth, 2011).
In terms of economics, osteoporosis is a costly disease. An estimated two million
fractures resulted in staggering costs of $19 billion in 2005 (http://www.nof.org/
aboutosteoporosis/bonebasics/whybonehealth, 2011). Experts predict that by 2025
osteoporosis will be responsible for approximately three million fractures and $25.3
billion in costs each year for treatment of osteoporosis (http://www.nof.org/
aboutosteoporosis/bonebasics/whybonehealth, 2011). These data highlight the need for
improvements in the prevention, diagnosis, and treatment of osteoporosis.

Osteoporosis Risk Factors
Although the development of osteoporosis cannot be pinpointed to a single
causative factor, numerous risk factors are associated with osteoporosis risk. Table 1 lists
the most important risk factors. Of these factors, genetics is the main determinant of
peak bone mass. In twin and family studies, genetics was shown to contribute 60%-80%
to the heritability of BMD (Dequeker, Nijs, Verstraeten, Geusens, & Gevers, 1987;
Pocock et al., 1987; D. M. Smith, Nance, Kang, Christian, & Johnston, 1973). Numerous
studies have documented that relatives of osteoporotic individuals also displayed
decreased BMD (Seeman et al., 1989; Sowers, Burns, & Wallace, 1986). Recent
genomic studies have also shown that polymorphisms in Type I collagen (COL1A1),
lipoprotein receptor related protein (LRP5), sclerostin (SOST), estrogen receptor (ERα),
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Table 1. Risk Factors of Osteoporosis
Genetics
Age
Gender
Diet
Smoking
Alcohol intake
Exercise

3

bone morphogenetic proteins (BMPs), Runx2, and vitamin D receptor (VDR) are
associated with BMD and fracture risk in humans (Ferrari et al., 2004; Grant et al., 1996;
Morrison et al., 1994; Morrison, Yeoman, Kelly, & Eisman, 1992; Ralston &
deCrombrugghe, 2006; Styrkarsdottir et al., 2003). However, it is unlikely that a single
gene would be the sole contributor of osteoporosis and therefore it has become widely
accepted that multiple genes regulate bone mass and contribute to this complex disease.
Besides genetics, age is another important risk factor for osteoporosis. An agerelated increase in the loss of bone is well established (Ensrud et al., 1995; Prisby et al.,
2007; Rosen, 1994). In addition, aging is associated with an increase in fracture risk.
The risk for falling and obtaining a fracture is substantially higher in the elderly who
generally exhibit decreased muscle strength, postural stability, sensory function, and/or
poor vision (Cummings et al., 1995; Douglas P. Kiel, 2008). Also elderly individuals
often take medications for other age-related illnesses. Use of certain medications such as
benzodiazepines and anti-convulsants may alter sense of balance and thus increase
propensity to fall whereas glucocorticoids used in treating inflammation can directly
affect bone loss (Canalis, Mazziotti, Giustina, & Bilezikian, 2007; Tinetti, Gordon,
Sogolow, Lapin, & Bradley, 2006; Weinstein, 2001). Advancing age favors adipogenesis
instead of osteoblastogenesis in the bone marrow of osteoporotic individuals. Diversion
of bone marrow stromal cells along an adipocyte lineage decreases bone formation
(Justesen et al., 2001; Verma, Rajaratnam, Denton, Hoyland, & Byers, 2002). In
addition, levels of reactive oxygen species (ROS) increase with age which can decrease
bone formation (Almeida, Han, Martin-Millan, O'Brien, & Manolagas, 2007; Almeida,
Han, Martin-Millan, Plotkin, et al., 2007; Basu, Michaëlsson, Olofsson, Johansson, &
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Melhus, 2001; Maggio et al., 2003; Ozgocmen, Kaya, Fadillioglu, Aydogan, & Yilmaz,
2007).
Another risk factor associated with osteoporosis is gender. Females attain less
peak bone mass during puberty compared to males and typically have a smaller frame
than males. By virtue of a small frame, females tend to have thinner bones relative to
males and are therefore at an increased risk for developing osteoporosis (Rollins, Imrhan,
Czajka-Narins, & Nichols, 2003). A major cause of accelerated bone loss in females is
estrogen deficiency that occurs during menopause (Syed & Khosla, 2005). Loss of
estrogen is deleterious to bone since it increases osteoblast apoptosis, ROS production,
and activation /differentiation of osteoclasts (Cenci et al., 2003; J. Chow, Tobias,
Colston, & Chambers, 1992; J. W. Chow, Lean, & Chambers, 1992; Gohel, McCarthy, &
Gronowicz, 1999; S. C. Manolagas & M. Almeida, 2007; Okazaki et al., 2002; Rogers &
Eastell, 1998; Syed & Khosla, 2005). Furthermore, the production of inflammatory
cytokines such as TNF-α and IL-1 is increased in the absence of estrogen (Iqbal, Sun,
Kumar, Blair, & Zaidi, 2006; Jagger, Lean, Davies, & Chambers, 2005; J. Lean et al.,
2003; Zhou, Foster, Zhou, Cowin, & Xian, 2006). Collectively these changes from loss
of estrogen result in net bone loss. Males may also experience bone loss due to changes
in sex steroids. Testosterone deficiency results in bone loss in males (Falahati-Nini et al.,
2000; Köhn, 2006; Syed & Khosla, 2005). These findings indicate that sex steroids
namely estrogen and testosterone, play an important role in maintenance of bone mass.
Lifestyle factors also contribute to the risk of getting osteoporosis (Lock,
Lecouturier, Mason, & Dickinson, 2006). In regards to diet, deficiencies in calcium and
vitamin D can cause adverse effects on bone (Bischoff-Ferrari, Dawson-Hughes, et al.,
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2004; Bischoff-Ferrari, Dietrich, Orav, & Dawson-Hughes, 2004; Holick, 2007; Lips,
2001). Besides dietary intake, malabsorption of these important dietary factors can also
negatively impact bone (Kiel, 2008). Furthermore, inadequate sun exposure also
contributes to Vitamin D deficiency (Kiel, 2008). It is well known that bone is a major
reservoir of calcium ion. In times of calcium deficiency the body will obtain calcium
from bone by breaking it down (Weaver, 2008). Bone loss can occur if this is a chronic
persistence. Deficiencies in vitamin B and vitamin C have also been linked to increased
osteoporotic risk (Baines et al., 2007; S. L. Hall & Greendale, 1998; Mohan et al., 2005;
Morton, Barrett-Connor, & Schneider, 2001; J. A. Simon & Hudes, 2001). Studies have
also shown excessive vitamin A is harmful to bone thus indicating the importance of a
well balanced diet (Michaëlsson, Lithell, Vessby, & Melhus, 2003; Promislow,
Goodman-Gruen, Slymen, & Barrett-Connor, 2002). Smoking and excessive alcohol
consumption cause adverse effects to bone and may act by decreasing absorption of
calcium (González-Reimers et al., 2011; Shimizu et al., 2011; P. K. Wong, Christie, &
Wark, 2007). A sedentary lifestyle is not amenable to good bone health. Inactive people
tend to have weaker bones and decreased muscle mass compared to active individuals.
Exercise increases bone density and strength in humans (Frost, 1987a, 1987b; Jones,
Priest, Hayes, Tichenor, & Nagel, 1977; Leichter et al., 1989). Mechanical stimulation
increases proliferation and differentiation of bone cells, and mechanical loading via
weight bearing exercises also aids in mitigating bone loss (Kapur, Baylink, & Lau, 2003;
Kesavan et al., 2006; Lau, Kapur, Kesavan, & Baylink, 2006; Triplett, O'Riley, Tekulve,
Norvell, & Pavalko, 2007; Wadhwa et al., 2002). Thus, development of peak bone mass
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as well as loss rate with age are determined by genetic, dietary, and environmental
factors.

Cells of the Bone
The three types of cells found in bone are the bone-forming osteoblasts, boneresorbing osteoclasts, and mechanosensory osteocytes.

Osteoblasts
Osteoblasts are the effector cells for bone formation. They are derived from
mesenchymal stem cells which have the potential to differentiate into myocytes,
adipocytes, chondrocytes, and osteoblasts. Figure 1 illustrates that the specific lineage
commitment of mesenchymal stem cells is determined by the selective expression of
master transcriptional regulators (Jensen, Gopalakrishnan, & Westendorf, 2010).
Osteoblasts are important because they produce bone matrix proteins (type I collagen,
proteoglycans, osteocalcin), produce critical factors for osteoclastogenesis, and express
several genes that are necessary and sufficient for the formation and mineralization of
bone (Glass & Karsenty, 2006). Osteoblast specific markers include alkaline
phosphatase (ALP), type I collagen, bone sialoprotein (BSP), osteocalcin, and
osteopontin (Marie, 2008). Serum levels of osteocalcin are used as an index of bone
formation (Christenson, 1997). Expressed on the surface of the osteoblast membrane,
ALP, is another marker commonly used to evaluate osteoblast differentiation (Whyte,
1994). Thus, these regulatory molecules enable the osteoblast to accomplish bone
formation.
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Figure 1. Regulation of osteoblast differentiation by transcription factors. Osteoblasts
are derived from mesenchymal stem cells. Based on mineralized nodule formation in
vitro, the process has been divided into proliferation, matrix maturation, mineralization,
and termination. Mature osteoblasts may become osteocytes embedded within the bone
matrix or undergo apoptosis. Selected stage-specific markers of osteoblast differentiation
are shown.

8

Matrix maturation
Lineage
Commitment Proliferation and mineralization

Termination

Mature
OsteoImmature
Mesenchymal
osteoblast
progenitor
osteoblast
stem cell
Runx2

Runx2

Runx2

Osx

Markers

Osteocyte

Osx

ALP, Type I collagen, osteopontin
BSP
Osteocalcin

9

Cell
death

Regulation
Transcription Factors
A crucial factor for the differentiation of osteoblasts is the master transcriptional
regulator Runx2. This is shown by the fact that Runx2 deficient mice do not form
mineralized bone and lack osteoblasts (Otto et al., 1997). Also forced expression of
Runx2 in non-osteoblast cells induced the expression of osteoblast specific genes (Ducy,
Zhang, Geoffroy, Ridall, & Karsenty, 1997). Runx2 interacts with many transcriptional
activators and repressors and other co-regulatory proteins to regulate the expression of
osteoblast specific genes (Marie, 2008). The Runx2 regulatory element is present in the
promoters of major osteoblast marker genes (Marie, 2008). Osx is another major
transcription factor in osteoblasts that is required for osteoblast differentiation and bone
formation (Nakashima et al., 2002). Ablation of Osx results in the absence of mature
osteoblasts and little or no bone formation, a phenotype similar to that observed in Runx2
KO mice. Whereas, Runx2 levels are normal in Osx KO mice, Osx is not detected in
Runx2 KO mice (Nakashima et al., 2002). These results indicated that Runx2 acts
upstream of Osx and was confirmed by presence of a Runx2 regulatory element in Osx
promoter (Nishio et al., 2006). Other transcription factors involved in mediating
osteoblast differentiation include Msx2, Dlx3, Dlx5, Dlx6, ATF4, and AP-1. However,
genetic disruption of these factors do not result in the severe phenotypes observed in
Runx2 and Osx KO mice, thereby indicating that Runx2 and Osx are master regulators of
osteoblast differentiation.
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Hormones
Several hormones regulate osteoblast differentiation. Parathyroid hormone (PTH)
promotes bone formation and activates Runx2 via phosphorylation and promoting
interactions with other transcription factors (D'Alonzo, Selvamurugan, Karsenty, &
Partridge, 2002; Selvamurugan, Pulumati, Tyson, & Partridge, 2000). It also increases
Runx2 stability by inhibiting degradation by the proteasome (Bellido et al., 2003). PTH
also increases Osx expression (Wang et al., 2006). Estrogen is important in the
development and maintenance of bone. It promotes osteoblastogenesis by activating
Wnt/β-catenin signaling pathway and Runx2 (Kousteni et al., 2007; McCarthy, Chang,
Liu, & Centrella, 2003). Short term treatment with glucocorticoids promotes osteoblast
differentiation in part by Runx2. However, long term exposure is deleterious because it
decreases bone formation (E. Smith & Frenkel, 2005). Vitamin D upregulates the
expression of many osteoblast specific genes (van Leeuwen, van Driel, van den Bemd, &
Pols, 2001). Growth hormone stimulates the proliferation and differentiation of
osteoblasts and modulates the transcriptional activity of Runx2 and other transcription
factors (K. E. Govoni et al., 2006; Ziros, Georgakopoulos, Habeos, Basdra, &
Papavassiliou, 2004). Therefore, multiple hormones are involved in regulating osteoblast
cell functions and perturbations in these hormones may be harmful to bone.

Growth Factors
Several growth factors regulate osteoblast differentiation in part by regulating
transcription factor expression or activity. Bone morphogenetic proteins (BMPs) belong
to TGF-β superfamily of growth factors and are critical inducers of bone formation (Wu,
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Shi, & Cao, 2007). BMPs promote Runx2 and Osx expression, important transcription
factors involved in osteoblast differentiation. BMP signaling also activates SMAD
transduction pathway which associates with other transcription factors to regulate gene
expression (Jensen et al., 2010). Transforming growth factor (TGF-β) is an abundant
cytokine of the bone matrix that is important in the development and maintenance of
bone (Sowa, Kaji, Yamaguchi, Sugimoto, & Chihara, 2002). TGF-β increases bone
formation in vivo by increasing Runx2 (Ahdjoudj, Lasmoles, Holy, Zerath, & Marie,
2002). IGF-I an abundant growth factor stored in bone and is considered to be an
autocrine and paracrine regulator of osteoblast functions (Canalis, McCarthy, &
Centrella, 1991). IGF-I increases Osx expression and stimulates type I collagen
expression as well as cell proliferation (Celil & Campbell, 2005; Glass & Karsenty,
2006). FGF-2 increases Runx2 phosphorylation and activity as well as Msx2 expression
(Marie, 2008). Wnt pathway promotes osteoblastogenesis and bone formation by
upregulating Runx2 expression (Bennett et al., 2005; Gaur et al., 2005). Thus, numerous
growth factors are critical in regulating osteoblast functions.

Intercellular Communication
Not only are osteoblasts important in directing bone formation but these cells also
regulate bone resorption (Figure 2). Two positive regulators and one negative regulator
of osteoclast differentiation have been identified and these factors are produced by
osteoblasts. Macrophage colony stimulating factor (MCSF) and receptor activator of
nuclear factor kappa B ligand (RANKL) are necessary and sufficient for induction of
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Figure 2. Cell-cell interaction between osteoblasts and osteoclasts.
Osteoclast
differentiation is regulated by osteoblasts which produce MCSF, RANKL, and OPG.
MCSF binds to c-FMS on osteoclast precursors to promote their proliferation and
survival. RANKL binds to RANK on osteoclasts to stimulate differentiation. OPG can
prevent this interaction by binding to RANKL.
Parathyroid hormone (PTH),
prostaglandins, interleukin-1 (IL-1), cytokines, and vitamin D induce RANKL expression
in osteoblasts and therefore indirectly promote bone resoprtion.
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osteoclast differentiation and function (B. R. Wong et al., 1999; Yasuda, Shima,
Nakagawa, Mochizuki, et al., 1998; Yasuda, Shima, Nakagawa, Yamaguchi, et al., 1998).
Osteoprotegerin (OPG) encodes a soluble decoy receptor for RANKL, which is an
inhibitor of RANKL and therefore a negative regulator of osteoclast differentiation
(Lacey et al., 1998; Simonet et al., 1997). Other factors, also regulate osteoblast
mediated production of MCSF and RANKL which will be reviewed in detail in the
following section on osteoclasts. Thus, osteoblasts produce important cytokines that
support osteoclastogenesis and thereby indirectly regulate bone resorption.
In summary, much progress has been made in identifying factors that regulate
osteoblast differentiation. However, the molecular pathways that regulate osteoblast
functions is incompletely understood. In order to achieve a better understanding of these
pathways, it is important to identify novel genes that may participate in regulating
osteoblast functions. Determination of the relative contribution of these genes will
advance our understanding of the regulatory mechanisms and pathways involved in
osteoblast formation and function.

Osteoclasts
Osteoclasts are the effector cells for bone resorption. Osteoclast precursors are
hematopoietic cells derived from the monocyte/macrophage lineage. Because osteoclasts
are formed by the fusion of osteoclast precursors, they are distinctly large and
multinucleated (Boyle, Simonet, & Lacey, 2003). A principle function of osteoclasts is
to remove mineralized bone. Reorganization of the actin cytoskeleton enables osteoclasts
to attach to bone surface via integrin binding to RGD sites in bone matrix proteins
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(Negishi-Koga & Takayanagi, 2009). The formation of a ruffled border generates a
specific sealing zone. Within this zone, the osteoclast dissolves the hydroxyapatite of
bone by secretion of HCl to create an acidic environment. Bone degradation is further
mediated by the actions of proteolytic enzymes such as cathepsin K and matrix
metalloproteinases (Negishi-Koga & Takayanagi, 2009). Finally, increased extracellular
levels of calcium within the resorption pit triggers osteoclast apoptosis and subsequent
cessation of bone resorption (Negishi-Koga & Takayanagi, 2009). Osteoclast specific
marker genes include tartrate resistant acid phosphatase (TRAP), cathepsin K (Ctsk),
calcitonin receptor, and β3-integrin (Boyle et al., 2003). Serum levels of C-terminal
telopeptides, a degradation product of osteoclast resorption, is commonly used as an
index of bone resorption (Christenson, 1997). Another marker used for the assessment of
bone resorption and osteoclast differentiation is TRAP (Halleen et al., 2000). Thus, these
regulatory molecules enable the osteoclast to carry out bone resorption.

MCSF/RANKL/OPG Regulatory Axis
Intercellular interaction and signaling between osteoblasts and osteoclasts is an
important mechanism that regulates bone resorption (Figure 2). The finding that
generation of osteoclasts using co-cultures of bone marrow or spleen cells and stromal
cells indicated that cell-cell contact was essential for osteoclastogenesis and that factors
secreted by the stromal cell facilitated this process (Takahashi et al., 1988). MCSF and
RANKL are critical cytokines that are essential for osteoclastogenesis. These cytokines
are produced by osteoblasts. MCSF secreted by osteoblasts binds to its cognate receptor,
c-FMS, expressed on osteoclast precursors to regulate the proliferation and survival of
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osteoclast precursors cells. MCSF also induces RANK expression on osteoclast
precursors to enable them to respond to RANKL (Arai et al., 1990). RANKL is a
membrane bound ligand found on osteoblasts. RANKL binds to its cognate receptor,
RANK, expressed on osteoclast precursors and osteoclasts to mediate osteoclast
differentiation. The importance of MCSF and RANKL are demonstrated in genetic
mouse models. Osteopetrosis (a condition characterized by abnormally high bone density
due to a lack of functional osteoclasts) is observed in mice lacking MCSF or RANKL
genes due to defective osteoclast formation (Kong et al., 1999; Yoshida et al., 1990).
These findings demonstrate that MCSF and RANKL are both necessary and sufficient for
osteoclastic bone resorption. OPG, a factor produced by osteoblasts, is a negative
regulator of bone resorption because it inhibits RANKL. Mice deficient in OPG exhibit a
severe osteoporotic phenotype due to excessive osteoclastogenesis (Bucay et al., 1998).
In contrast, transgenic overexpression of OPG in mice leads to osteopetrosis (Simonet et
al., 1997). Thus, the MCSF/RANKL/OPG ratio is an important regulatory axis for
determining bone resorption.

Transcriptional Regulation of Osteoclast Differentiation
Several transcription factors are involved in mediating the proliferation, survival,
and differentiation of osteoclasts (Figure 3). PU.1 and MITF play a significant role in
regulating the formation and survival of osteoclast precursors. Therefore it is not
surprising that they are associated with MCSF signaling. PU.1 stimulates the expression
of c-fms and disruption of PU.1 in mice results in defective macrophage and osteoclast
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Figure 3. Regulation of osteoclast differentiation. Based on osteoclast formation in
vitro, the process has been divided into proliferation, differentiation, survival and fusion.
Characteristic gene expression changes at each stage are regulated by different signaling
molecules and transcription factors. Selected stage-specific markers of osteoclast
differentiation are shown.
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development, leading to osteopetrosis (Tondravi et al., 1997). Subsequent studies
revealed that in vitro osteoclast differentiation positively correlated with increased PU.1
expression. MITF is activated by MCSF signaling and regulates the expression of the
anti-apoptotic protein, Bcl-2 by binding to its promoter (McGill et al., 2002).
Furthermore, osteopetrosis is observed in mice lacking MITF (Weilbaecher et al., 2001).
RANKL stimulation results in the downstream activation of NF-κB and AP-1. Targeted
mutagenesis of the p50/p52 component of NF-κB leads to the development of
osteopetrosis (Franzoso et al., 1997; L. Xing et al., 2002). Similarly, mice lacking the
cFos component of AP-1 also suffer from osteopetrosis due to a blockade in osteoclast
differentiation (Grigoriadis et al., 1994).
NFATc1 is a master regulator of osteoclast differentiation. Transcription of
NFATc1 is regulated by intracelluar calcium. NFATc1 is dephosphorylated by
calcineurin and transclocated to the nucleus to regulate gene transcription. Inhibitors of
calcium signaling and calcineurin suppress RANKL induced osteoclastogenesis by
inhibiting translocation of NFATc1, suggesting this pathway is critical for osteoclast
differentiation (Takayanagi et al., 2002). The findings that embryonic stem cells derived
from NFATc1 KO mice fail to differentiate into osteoclasts and that forced expression of
NFATc1 induces osteoclastogenesis even in the absence of RANKL, established the
necessary and sufficient role of NFATc1(Takayanagi et al., 2002). Osteoclast specific
deletion of NFATc1 in mice results in osteopetrosis (Aliprantis et al., 2008). NFATc1
regulates the expression of many osteoclast specific genes including: TRAP, cathepsin K,
calcitonin receptor, and integrin (Crotti et al., 2006; Matsumoto et al., 2004; Takayanagi
et al., 2002), thus highlighting the importance of this transcription factor in regards to
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osteoclast function. NFATc1 regulates osteoclast cell fusion and acidification by
modulating expression of DC-STAMP and d2 isoform of vacuolar ATPase VO domain,
respectively, through co-activation with MEF2 and MITF (Q. Zhao, Wang, Liu, He, &
Jia, 2010). Despite their importance in the survival of osteoclast precursors, PU.1 and
MITF can also interact with NFATc1 to regulate gene expression (Matsumoto et al.,
2004). Overall, these data establish NFATc1 as a master regulator of osteoclast
differentiation and function.

Factors that Modulate Osteoclastogenesis
In general, factors that regulate osteoclastogenesis can exert their effects via an
indirect mechanism by stimulating MCSF/RANKL production in osteoblasts (Figure 2)
or by acting directly on osteoclasts to modulate RANKL signaling. TNF-α promotes
osteoclastogenesis by acting on both osteoblasts and osteoclast precursors. TNF-α also
synergizes with RANKL signaling by activating NF-κB (Lam et al., 2000). Like TNF-α,
IL-1 also activates osteoclastogenesis by acting on osteoblasts and osteoclasts.
Furthermore, IL-1 also activates NF-κB (Jimi et al., 1998). Vitamin D promotes
osteoclast differentiation by stimulating RANKL expression on osteoblasts (Ramasamy,
2006). Another study showed that vitamin D can act directly on osteoclast precursors via
a vitamin D receptor to negatively regulate osteoclast differentiation (Takasu et al.,
2006). PTH can induce osteoclast differentiation by binding to osteoblasts to stimulate
MCSF and RANKL production (Ramasamy, 2006). Although osteoclasts express PTH
receptor, in vitro cell culture experiments reveal that PTH does not exert a direct effect on
osteoclasts, suggesting that PTH receptor is not needed or sufficient for directly
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activating osteoclast differentiation (Brown, 2006). Consistent with these findings, is the
demonstration that TNF-α, vitamin D, and PTH do not stimulate bone resorption in
RANK KO mice (J. Li et al., 2000). Prostaglandins act on stromal cells and osteoblasts
to stimulate bone resorption via stimulation of RANKL and suppression of OPG
(Kobayashi & Narumiya, 2002). Prostaglandins may also directly stimulate osteoclasts,
however this notion is controversial and the subject of ongoing investigation (Sarrazin,
Hackett, Fortier, Gallant, & de Brum-Fernandes, 2004). Chemokines such as SDF-1,
MCP-1, MIP-1α, and RANTES that are derived from hematopoietic cells can directly
regulate osteoclasts by promoting osteoclast precursor recruitment and/or RANKL
induced osteoclastogenesis (Lapidot & Petit, 2002; Silva, Garlet, Fukada, Silva, &
Cunha, 2007; Thomas, Liu, & Link, 2002; L. Xing, Schwarz, & Boyce, 2005). Levels of
sex hormones can also influence osteoclast differentiation. Sex hormones such as
estrogens and androgens suppress RANKL induced osteoclastogenesis and also regulate
OPG production (Syed & Khosla, 2005). Therefore, pathological bone loss is likely to
occur following disruption of sex hormone actions since these hormones are negative
regulators of osteoclast differentiation and functions.
In summary, much progress has been made in identifying the factors that regulate
osteoclast differentiation. However, the role of other molecular components that regulate
osteoclast differentiation remains to be determined. Therefore, it is critical to identify
novel genes and their pathways that regulate osteoclast differentiation and their function.
Such genes may interact with important regulatory pathways such as MCSF, RANKL, or
TNF-α signaling. Thus, the identification of other genes and their relative contribution to
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osteoclast regulation will advance our understanding of the key regulatory molecular
pathways involved in osteoclast formation and function.

Osteocytes
Osteocytes are terminally differentiated osteoblasts which become embedded in
the bone matrix. They are the most abundant cell type of the bone comprising 90% of the
population (Knothe Tate, Adamson, Tami, & Bauer, 2004). Osteocytes form a dense
network within the bone matrix and via long dendritic-like processes, interact with other
osteocytes, osteoblasts, and osteoclasts. A means by which osteocytes communicate with
these cell types is through gap junctions (Doty, 1981). Osteocytes respond to mechanical
stimulation and may initiate and direct signals which trigger the bone remodeling process
(Bonewald, 2011). They are also critical in the maintenance of bone structure (Datta, Ng,
Walker, Tuck, & Varanasi, 2008). Osteocytes play a central role in the regulation of
bone formation. Osteocytes promote mineralization by expression of Dmp1 and Phex,
and inhibit bone formation by production of sclerostin, an antagonist of the Wnt pathway
(Winkler et al., 2003). Osteocytes can also activate and inhibit osteoclast resorption
(Bonewald, 2011). Therefore the ability of the ostecyte to communicate with multiple
cell types and regulate diverse functions, renders the osteocytes uniquely suited to
regulate all phases of bone remodeling.

Bone Remodeling
The skeleton is a complex organ composed of 213 bones (Dempster, 2006).
Important functions of bone include the maintenance of the structural integrity of the
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skeleton, protection of vital organs, and regulation of mineral homeostasis (Dempster,
2006). Contrary to popular belief, bone is a dynamic organ which constantly undergoes
remodeling to repair damaged bone and to maintain a constant bone mass (Boyle et al.,
2003). It is not surprising that bone remodeling is a tightly regulated and coordinated
process orchestrated by osteoblasts that are the bone-forming cells and osteoclasts that
are the bone-resorbing cells. Dysregulation of the coupling between bone formation and
bone resorption results in aberrant loss of bone (Rodan & Martin, 2000). Therefore an
understanding of the molecular mechanisms and signaling pathways which regulate
osteoblast and osteoclast functions are of fundamental importance.
The two principal functions of bone remodeling is to repair stressed or damaged
bone with new bone and to provide access to important minerals such as calcium and
phosphorous. The remodeling phase is divided into five phases: activation, resorption,
reversal, formation, and termination.

Activation
The activation phase is characterized by the initiation of a bone remodeling
signal. Stimuli which can intiate bone remodeling include mechanical strain, changes in
hormone levels (e.g. estrogen), low blood calcium, and microfractures of the bone
(Raggatt & Partridge, 2010). Osteocytes detect these remodeling signals and these
changes initiate osteocyte apoptosis. Because osteocytes produce TGF-β, an inhibitor of
osteoclasts, the loss of osteocytes via apoptosis removes the inhibitory signal thereby
increasing osteoclastogenesis (Heino, Hentunen, & Väänänen, 2002). The findings that
osteocytes regulate osteoclasts is supported by a study which showed that ablation of

24

osteocytes using osteocyte specific DMP-1 promoter increased osteoclast number and
bone resorption (Tatsumi et al., 2007).

Resorption
The resorption phase is characterized by the recruitment of osteoclast precursors
and active resorption accomplished by mature osteoclasts. In response to remodeling
signals, osteoblasts secrete numerous factors to facilitate bone resorption. They release a
number of cytokines including monoctye chemoattractant protein-1 (MCP-1) and serum
derived factor -1 (SDF-1), that stimulate the recruitment of osteoclast precursors (Graves,
Jiang, & Valente, 1999; X. Li et al., 2007; Yu, Collin-Osdoby, & Osdoby, 2003).
Osteoblasts also release signals to modulate the expression of osteoclastogenic cytokines
(Matsuo & Irie, 2008). The production of MCSF and RANKL are increased to promote
the proliferation of osteoclast precursors and differentiation of osteoclasts respectively
(Boyle et al., 2003). The expression of OPG, an inhibitor of RANKL, is also decreased.
Osteoblasts also secrete matrix metalloproteinases (MMPs) to degrade the unmineralized
osteoid of the bone surface (Partridge et al., 1987; C. M. Yang et al., 2004). This process
exposes the RGD adhesion sites and facilitates the attachment of mature osteoclasts to the
bone surface (Ross et al., 1993). Once attached to the bone surface, the osteoclasts
actively resorb bone by creating an acidic environment via production of hydrogen ions
to dissolve the bone and form a trench (Teitelbaum, 2000).
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Reversal
The reversal phase is characterized by the transition from bone resorption to bone
formation. In essence transition signals halt bone resorption and osteoclasts undergo
apoptosis (Parfitt, 1982; Wakeyama et al., 2007). The exact nature of the cells
responsible for the reversal phase is still being investigated however some studies have
suggested that macrophages or mesenchymal stem cells may be responsible for preparing
the bone surface for osteoblast mediated bone formation (Raggatt & Partridge, 2010).

Formation
The formation phase is characterized by bone formation via osteoblasts. The
exact nature of the coupling factors that initiate bone formation remains to be elucidated.
However, evidence supports the hypothesis that bone matrix and/or osteoclasts are
involved. One explanation is that the degradation of the bone matrix by functionally
active osteoclasts results in the liberation of coupling factors. The liberation of growth
factors such as IGF-I, IGF-II, BMPs, and TGF-β from the bone matrix induces osteoblast
differentiation (Martin & Sims, 2005; Pfeilschifter, D'Souza, & Mundy, 1987; Wozney et
al., 1988). However, studies in mice and humans showed that osteoblast bone formation
still occurs in the presence of functionally defective osteoclasts (bone matrix is not
degraded) suggesting that not the bone matrix but osteoclasts produce the secreted
coupling factors (Raggatt & Partridge, 2010). Sphingosine-1-phosphate is secreted by
osteoclasts and promotes recruitment of osteoblast precursors and osteoblast
differentiation (Pederson, Ruan, Westendorf, Khosla, & Oursler, 2008). Another report
described that EphB4ephrin-B2 bidirectional signaling activates bone formation and
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inhibits bone resorption (C. Zhao et al., 2006). Regardless of the source of coupling
factors the objective is to induce differentiation of osteoblasts. These mature osteoblasts
produce collagen type I, proteoglycans, ALP, osteocalcin, and osteopontin which forms
replacement bone (Marie, 2008).

Termination
The termination phase is characterized by mineralization and entry into
quiescence. The precise mechanism by which termination occurs remains unknown,
however a role for the osteocytes is emerging. Osteocytes produce sclerostin, a negative
regulator of bone formation (Winkler et al., 2003). Increased sclerostin expression
corresponds with decreased bone formation. Mature osteoblasts undergo apoptosis or
become embedded in the mineralized matrix and differentiate into osteocytes (Bonewald,
2011). Mineralization is completed and the bone remodeling cycle ends.

Novel Molecules that Regulate Bone Formation and Bone
Resorption
Bone remodeling is a complex process that is affected by the mutual activity and
communication between osteocytes, osteoblasts, and osteoclasts. Evidently, a multitude
of transcription factors, growth factors, hormones, and cytokines are critical factors
involved in regulating the formation and differentiation of osteoblasts and osteoclasts.
Skeletal diseases such as osteoporosis stem from a disruption in bone formation and/or
bone resorption processes. Therefore, a thorough understanding of the cellular and
molecular mechanisms that regulate these processes are of paramount importance in
determining therapeutic strategies to prevent low bone mass. In this regard, we have
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sought to examine three novel molecules involved in the regulation of bone formation
and bone resorption. The work presented in this dissertation, will focus on the role of
Glutaredoxin 5 (Grx5), Diabetes and Obesity Related protein (DOR), and Claudin 18
(Cldn-18).

Oxidative Stress and Bone
Oxidative stress has recently been shown to be involved in a variety of
pathological situations including aging, cancer, type II diabetes, ischemia/reperfusion
injury, and neurodegenerative disorders (Chandra, Samali, & Orrenius, 2000). There is
now increasing evidence which suggest an important role for reactive oxygen species
(ROS) in osteoporosis. For example, increased oxidative stress results in decreased bone
mineral density in aged men and women (Basu et al., 2001) and elderly osteoporotic
women displayed lower plasma levels of antioxidants compared to age-matched controls
(Maggio et al., 2003). Postmenopausal osteoporotic women displayed higher levels of
lipid peroxidation and decreased activity of antioxidant enzymes including catalase,
superoxide dismutase, and glutathione peroxidase (Ozgocmen et al., 2007; Sontakke &
Tare, 2002). In addition, one study showed that postmenopausal women displayed lower
alkaline phosphatase activity suggesting decreased osteoblastic function (Sontakke &
Tare, 2002). Varanasi et al., proposed that a mitochondrial DNA deletion may be
associated with oxidative stress and male osteoporosis (Varanasi, Francis, Berger, Papiha,
& Datta, 1999). Although most of these studies have been conducted in individuals who
are predominantly middle-aged or elderly, the detrimental effects of oxidative stress are
not limited to an aging population. Recently Heilman et al. described an association
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between oxidative stress and lower bone mineral density in children with type 1 diabetes
(Heilman, Zilmer, Zilmer, & Tillmann, 2009). Finally, it was reported that the
antioxidant enzyme, catalase, may be a genetic determinant of osteoporosis in
postmenopausal women (Oh et al., 2007). In vitro studies have shown that ROS had
different effects on osteoclasts versus osteoblasts. For instance, ROS stimulates the
differentiation and activation of osteoclasts in vitro (Bax et al., 1992; Garrett et al., 1990;
T. Hall, Schaeublin, Jeker, Fuller, & Chambers, 1995; J. Lean et al., 2003; J. M. Lean,
Jagger, Kirstein, Fuller, & Chambers, 2005; Steinbeck, Appel, Verhoeven, & Karnovsky,
1994; Suda, Morita, Kuroda, & Murota, 1993). Osteoclast stimulation can be harmful
during oxidative stress since these cells are involved in bone resorption, and increased
osteoclast formation and activity have been linked to osteoporosis. In contrast to
osteoclast stimulation, ROS was shown to inhibit cell differentiation, and induce
apoptosis in osteoblasts (Bai et al., 2004; Liu, Zhang, Zhu, Liao, & Liu, 2004; Mody,
Parhami, Sarafian, & Demer, 2001; Park, Yoo, Kim, Kwon, & Kim, 2005).
Consequently, these accumulating data provides strong evidence implicating the harmful
effects of oxidative stress in bone, thus warranting further investigation to fully
understand the mechanism.

Protection against Oxidative Stress
The formation of ROS is an inevitable consequence of being an aerobic organism.
Normal byproducts of respiration includes hydrogen peroxide (H2O2), superoxide anion
(O2-), hydroxyl radical (OH.), nitric oxide (NO), and peroxynitrite (ONOO-) (Cabiscol,
Piulats, Echave, Herrero, & Ros, 2000; Haliwell B, 2007). These ROS can also derive
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from external environmental factors such as redox active drugs, radiation, and heavy
metals (Cabiscol et al., 2000). However, the majority of the ROS produced by cells can
be attributed to the mitochondrial respiratory chain (Cabiscol et al., 2000). Cells use
oxygen as the terminal electron acceptor in the electron transport chain and ATP is
produced via oxidative phosphorylation. In addition, physiological processes such as
growth factor stimulation can generate ROS which can function as second messengers in
a variety of signal transduction cascades under normal conditions in the cell. However,
oxidative stress occurs when the levels of oxidants are higher than the levels of reductants
overwhelming the system (Ott, Gogvadze, Orrenius, & Zhivotovsky, 2007). This
imbalance in the redox state can occur during the natural aging process or during certain
disease states. Fortunately, cells have developed both non-enzymatic and enzymatic
defense mechanisms to counteract the deleterious effects of oxidative stress by either
detoxifying ROS or repairing ROS induced damage. Some non-enzymatic examples
include vitamin C, vitamin E, ubiquinone, flavenoids, and glutathione (GSH) and some
examples of enzymatic scavengers include catalase, glutathione peroxidase, thioredoxin,
glutaredoxin, and Cu/Zn superoxide dismutase (Cu/Zn SOD) and Mn/superoxide
dismutase (MnSOD) (Martindale & Holbrook, 2002). Without these defensive
mechanisms, the production of ROS in the cell would be unabated and the overall
viability of the cell and cellular macromolecules would be compromised. For example
DNA, lipids, and proteins, the primary targets of ROS can undergo redox modifications
that alter their normal cellular function. Excessive oxidative damage can lead to altered
proliferation, differentiation, and apoptosis in the absence of adequate antioxidant

30

defense systems. Therefore, understanding the components of defense mechanisms to
combat oxidative stress could provide drug targets for osteoporosis therapy.

Glutaredoxins
Glutaredoxins (Grx) are glutathione dependent oxidoreductases that help maintain
cellular redox homeostasis in the cell (Holmgren, 1989). The glutaredoxin system
consists of GSH, NADPH, and GSH reductase (Fernandes & Holmgren, 2004; Holmgren
et al., 2005). Sulfydryl or thiol (-SH) groups and available cysteine residues of proteins
are very sensitive to ROS and thus oxidative modification. Cysteine residues play a key
role in protein folding, metal coordination, and enzyme catalysis (Frand, Cuozzo, &
Kaiser, 2000; Giles et al., 2003; Johnson, Dean, Smith, & Johnson, 2005). The redox
status of sulfhydryl groups in proteins is important because these groups play an
important role in the regulation of cellular functions including the synthesis and folding
of proteins and the regulation of the structure and activity of enzymes, receptors, and
transcription factors (Kanda et al., 2006). Depending upon the severity of the oxidative
stress, protein thiol groups can be reversibly oxidized to sulfenic acid (SOH) or
irreversibly oxidized to sulfinic (SO2H) or sulfonic (SO3H) acid (Herrero & de la TorreRuiz, 2007). The sulfenic moiety is very unstable and can react with other thiols to form
intra- or intermolecular disulfides. The modification of critical groups on proteins, lipids,
or DNA can be deleterious to the cell leading to inactivation and perturbing redox
homeostasis. Proteins can be post-translationally modified by glutathione (known as
glutathionylation) which helps protect them from irreversible oxidation (Biswas, Chida,
& Rahman, 2006). Although the protection is temporarily beneficial, prolonged or
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chronic glutathionylation can alter the function of proteins by activating or deactivating
them. For example, glutathionylation alters the biological functions of important proteins
such as actin, creatine kinase, protein tyrosine phophatase 1B, c-Jun, and glyceraldehyde
3-phosphate dehydrogenase (Berndt, Lillig, & Holmgren, 2007). Protein
glutathionlyation can be reversed by glutaredoxins which reduce glutathionlylated
proteins by either a dithiol mechanism involving two cysteines at their active site or a
monothiol mechanism involving only one cysteine located at the amino terminal region.
Therefore, glutaredoxins play a critical role in redox regulation and signaling.
In yeast, Grx1 and Grx2 are dithiol glutaredoxins which contain the active site
Cys-Pro-Tyr-Cys. Grx1 is localized mainly in the cytosol while Grx2 is localized in both
the cytosol and mitochondria (Herrero & de la Torre-Ruiz, 2007). In addition to dithiol
glutaredoxins, yeast also contain three monothiol glutaredoxins including Grx3, Grx4,
and Grx5. These monothiol Grxs are different from the classical dithiol glutaredoxin
because their active site contains only one cysteine— Cys-Gly-Phe-Ser (Herrero & de la
Torre-Ruiz, 2007). Grx3 and Grx4 are localized to the nucleus while Grx5 is localized in
the mitochondria. Although Grx3, Grx4, and Grx5 are monothiol glutaredoxins, there are
differences in their structure. For example, Grx3 and Grx4 have an additional
thioredoxin-like domain as an N-terminal extension (Bellí et al., 2002; Molina, Bellí, de
la Torre, Rodríguez-Manzaneque, & Herrero, 2004; Vilella et al., 2004), whereas Grx5
lacks such a domain. Certainly, these differences in structure, active sites, and
subcellular localization of glutaredoxin family members provide credence to the notion
that the biological roles of glutaredoxins may be highly diversified and specialized.
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In contrast to yeast, the mammalian system contains three known members of the
glutaredoxin family Grx1, Grx2, and Grx5. Grx1 (12 kDa), a dithiol glutaredoxin, is
localized mainly in the cytosol and contains the active site Cys-Pro-Tyr-Cys. It is
involved in general disulfide-dithiol exchanges, donation of electrons to ribonucleotide
reductase, dehydroascorbate reduction, regulation of transcription factors, differentiation,
and apoptosis (Bandyopadhyay, Starke, Mieyal, & Gronostajski, 1998; Chrestensen,
Starke, & Mieyal, 2000; Daily et al., 2001; Hirota et al., 2000; Holmgren, 1989;
Nakamura et al., 1999; Takashima et al., 1999; Wells, Xu, Yang, & Rocque, 1990).
Recently, Leonberg et al. (Leonberg & Chai, 2007), showed that enzymatic activity of cAbl kinase was inhibited by S-glutathionylation of its cysteine residues and that the
inhibition was reversed by glutaredoxin. Grx2 (16 kDa), a dithiol glutaredoxin, contains
two splice variants of Exon I which localize to either the mitochondria or the nucleus. In
contrast to Grx1, the active site of Grx2 is Cys-Ser-Tyr-Cys. Grx2 involved in protein
deglutathionylation of mitochondrial complex I, prevention of cardiolipin oxidation and
cytochrome c release, contains an iron sulfur cluster bridging two Grx2 monomers, and
reduction of low molecular weight compounds such as GSSG and CoA disulphide
(Holmgren et al., 2005). In contrast to Grx1, Grx2 is not inhibited by oxidation of
structural cysteine residues. In addition, while Grx1 and Grx2 are both reduced by
glutathione, Grx2 can also be reduced by thioredoxin reductase (Johansson, Lillig, &
Holmgren, 2004).
The recently discovered Grx5, a monothiol glutaredoxin is hypothetically
localized to the mitochondria and contains the active site Cys-Gly-Phe-Ser. Most of what
is known on Grx5 has come from studies in yeast. The loss of Grx5 in yeast leads to
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constitutive oxidative damage, sensitization to ROS, iron accumulation, and inactivation
of iron-sulfur (Fe-S) cluster containing enzymes (Alves, Herrero, & Sorribas, 2004; H.
Kim, Park, & Lim, 2005; Rodríguez-Manzaneque, Ros, Cabiscol, Sorribas, & Herrero,
1999; Rodríguez-Manzaneque, Tamarit, Bellí, Ros, & Herrero, 2002). Interestingly, the
loss of Grx3 or Grx4 did not exert the same dramatic effect compared to the loss of Grx5.
A recent study by Wingert et al. in zebrafish showed that loss of Grx5 causes
hypochromic anemia and severely inhibits the formation of Fe-S clusters (Wingert et al.,
2005). Since only one study on Grx5 has been performed in mammals (zebrafish), our
proposed studies will advance our understanding of the role of Grx5 in mammals.

Glutaredoxins and Apoptosis
Several studies have demonstrated the importance of glutaredoxins in protecting
against apoptosis. For example, Song et al. showed that overexpression of Grx1
protected cells from glucose deprivation induced metabolic stress (Song & Lee, 2003;
Song et al., 2002). This group showed that Grx1 plays a role in regulating the redox state
of apoptosis signaling kinase 1 (ASK1) by directly binding to it. Through this binding,
Grx1 supresses ASK1 activation and its downstream targets SEK1 and JNK1, thus
effectively abolishing the apoptotic cascade (Song & Lee, 2003). Studies by Murata et
al. also provided evidence that Grx1 is a key player in protecting against oxidative stress
(Murata et al., 2003). The overexpression of glutaredoxin protected cardiac myocytes
from hydrogen peroxide induced oxidative stress (Urata et al., 2006). Specifically, Grx1
protected the redox state of AKT, a survival kinase that inactivates pro-apoptotic
proteins, from inactivation by hydrogen peroxide. Similar to Grx1, Grx2 has also been
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shown to protect against apoptosis. Enoksson et al. showed that the overexpression of
Grx2 decreased the susceptibility of HeLa cells to apoptosis induced by doxorubicin or 2deoxy-D-glucose (Enoksson et al., 2005). This was accomplished by the prevention of
cardiolipin oxidation, inhibition of cytochrome c release and caspase activation. Another
study showed that the knockdown of Grx2 using siRNA, sensitized HeLa cells to cell
death induced by oxidative stress inducing compounds such as doxorubicin and
phenylarsine oxide (Lillig, Lönn, Enoksson, Fernandes, & Holmgren, 2004). Taken
together these findings indicate that glutaredoxins play a crucial role in protection against
apoptosis.

Rationale and Hypothesis
Based on the findings that oxidative stress is harmful to bone and that Grx family
members (Grx1 and Grx2) play a critical role in protecting against the damaging effects
of oxidative stress induced apoptosis in various cell types, the following hypothesis has
been proposed,
Grx5 is an important mediator of osteoblast cell functions which acts as a
scavenger of ROS and protects osteoblasts from oxidative stress induced apoptosis.
To test this hypothesis the specific aims are the following:
a. Examine whether modulation of Grx5 expression sensitizes osteoblasts to
oxidative stress induced apoptosis.
b. Determine the molecular mechanism by which Grx5 protects osteoblasts
against oxidative stress induced apoptosis.
These findings are summarized in Chapter 2.
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Thyroid Hormone
Hypothalamic-Pituitary Thyroid Axis
Thyroid hormone (TH) is important in growth, metabolism, and differentiation
(Yen et al., 2006). Given the importance of this hormone in regulating activities in
multiple tissues it is not surprising that TH levels are tightly regulated. Thyroid releasing
hormone (TRH) is produced in the hypothalamus and acts on the thyrotroph cells of the
anterior pituitary to stimulate the synthesis and secretion of thyroid stimulating hormone
(TSH) (J. H. Bassett & G. R. Williams, 2008). TSH then acts via Thyroid stimulating
hormone receptor (TSHR) to simulate the growth of the follicular cells of the thyroid and
the synthesis and release of thyroid hormones thyroxine (T4) and a small amount of
3,5,5΄-L-triiodothyronine (T3) (J. H. Bassett & G. R. Williams, 2008). TH can then act
via TH receptors (TR) located on the hypothalamus and pituitary to inhibit the synthesis
and secretion of TRH and TSH, respectively (J. H. Bassett & G. R. Williams, 2008).
Thus, circulating levels of TH are maintained by a classical negative feedback loop.

TH Effects on Bone
TH is particularly important for the development and establishment of peak bone
mass. Clinical observations and genetic manipulation in mice have highlighted the
importance of TH in the growth and maintenance of bone. Perturbations in the levels of
TH in juveniles and adults have different effects on the skeleton. TH deficiency
(hypothyroidism) in children causes growth failure, delayed bone age, and short stature
(Boersma, Otten, Stoelinga, & Wit, 1996; Rivkees, Bode, & Crawford, 1988). TH
deficiency in adults results in high bone turnover and increased fracture risk (Eriksen,
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Mosekilde, & Melsen, 1986). TH excess or thyrotoxicosis in juveniles leads to advanced
bone age, accelerated skeletal growth, and premature fusion of growth plates and cranial
sutures which ultimately result in short stature (Segni, Leonardi, Mazzoncini, Pucarelli,
& Pasquino, 1999). Thyrotoxicosis in adults results in accelerated bone loss which leads
to osteoporosis and increased fracture risk (Mosekilde, Eriksen, & Charles, 1990).
Ablation of TR in mice results in growth retardation and epiphyseal dysgenesis
(Williams, 2009). Taken together, these observations demonstrate the importance of TH
signaling in regulating skeletal development.
T3 regulates differentiation, proliferation, and apoptosis of osteoblasts both
directly and indirectly via complex signaling pathways involving numerous growth
factors and cytokines. T3 induces the synthesis of IGF-I and its regulatory binding
proteins (IGFBP-2 and -4), and regulates FGF signaling (Gogakos, Duncan Bassett, &
Williams, 2010; Milne, Quail, Rosen, & Baran, 2001; Stevens et al., 2003; Varga,
Rumpler, & Klaushofer, 1994). T3 also induces the expression of osteocalcin,
osteopontin, type I collagen, ALP, MMP-13, MMP-9 and the tissue inhibitor of MMP in
osteoblasts (Beber et al., 2009; Milne et al., 2001; Varga, Spitzer, & Klaushofer, 2004).
Whereas TRs are expressed in osteoblasts, these receptors are not expressed in
osteoclasts (Bassett & Williams, 2003). Therefore it seems unlikely that T3 exerts direct
effects on osteoclasts. In osteoblasts, T3 induces the synthesis of prostaglandin E2, IL-6,
and RANKL, which promote osteoclastogenesis (Bassett & Williams, 2003; Miura et al.,
2002). Furthermore, in vitro studies have demonstrated that osteoclasts will only resorb
bone when cultured in the presence of osteoblasts (Bassett & Williams, 2003). These
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data suggest that T3 effects on osteoclasts are mediated indirectly in part by
osteoclastogenic factors produced by osteoblasts.

TH Action
The entry of TH into cells is mediated by cell membrane transporters including
monocarboxylate transporter-8 (MCT8), MCT10, and organic acid transporter protein1c1 (OATP1c1) (van der Deure, Peeters, & Visser, 2010). MCT8 is expressed in all bone
cells regardless of differentiation status (Williams, 2009) while OATP1c1 may not be
expressed in mouse skeleton or osteoblasts (Capelo, Beber, Fonseca, & Gouveia, 2009).
It remains to be determined whether MCT10 is expressed in bone. Circulating levels of
T4, the pro-hormone form of TH are 3-4 fold higher than T3 (Williams, 2009). The
generation of the biologically active form T3 is accomplished by the activities of type 1,
2 and 3 deiodinase enzymes (D1, D2, D3) in a process called prereceptor ligand
metabolism (Bassett & Williams, 2003). However, D1 is not expressed in bone cells
(Gogakos et al., 2010). T4 gets converted to the active ligand T3 by removal of an iodine
atom (5΄ monodeiodination) via D2 (J. Bassett & G. Williams, 2008). In contrast, D3
inactivates T4 by 5΄ monodeiodination by forming reverse T3 and T2 (J. H. Bassett & G.
R. Williams, 2008). Therefore, the relative intracellular levels of T3 is determined by the
actions of D2 and D3.

Thyroid Hormone Receptors (TRs)
The biological actions of TH are mediated by TRα and TRβ receptors. Thyroid
hormone receptor alpha (THRA) and thyroid hormone receptor beta (THRB) genes
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encode three functional receptors: TRα1, TRβ1, and TRβ2. TRα1 and TRβ1 are widely
expressed in many tissues (Bassett, Harvey, & Williams, 2003). However, TRβ2
expression is limited to the hypothalamus, pituitary, cochlea, and the retina (Abel,
Ahima, Boers, Elmquist, & Wondisford, 2001; Abel et al., 1999). Although TRα1 and
TRβ1 are both expressed in bone, RT-PCR studies revealed that TRα1 is expressed 10fold higher relative to TRβ1 (Bookout et al., 2006; P. J. O'Shea et al., 2003). These
findings suggest that TRα1 that is the predominant receptor in bone since it is expressed
at a substantially higher level.

Non-genomic and Genomic Actions of TH
Nongenomic Mechanisms
Besides classical genomic regulation of gene transcription, recent studies have
shown that TH may exert it effects via nongenomic mechanisms. Nongenomic
mechanisms are not initiated by ligand binding to TR complex in the nucleus. Instead,
these mechanisms begin at the plasma membrane or cytoplasm and are associated with
secondary messenger cascades (Bassett et al., 2003). Independent of TR, TH can
modulate the activity of Ca2+ ATPase enzyme via PKC, the plasma membrane Na+/H+
exchanger via PKC and MAPK, and inward rectifying potassium channel (P. Davis,
Davis, & Cody, 2005; P. J. Davis, Tillmann, Davis, & Wehling, 2002). A putative Gcoupled TH protein receptor has also been proposed to act via MAPK (Lin, Davis,
Gordinier, Martino, & Davis, 1999). T3 also activates the PI3K-Akt pathway in human
fibroblasts (Cao, Kambe, Moeller, Refetoff, & Seo, 2005). In regards to bone, Scarlett et
al. (A. Scarlett et al., 2008) demonstrated that integrin αvβ3 is a cell surface receptor for
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T4 and is involved in mediating osteoblast proliferation. T3 suppresses the kinase
activity of Src in osteoblasts (Asai et al., 2009). However, it remains to be determined
whether nongenomic actions are involved in mediating TH effects.

Genomic Mechanisms
TRs are ligand inducible transcription factors that belong to a nuclear receptor
superfamily that include retinoic acid, peroxisomal proliferators receptors, vitamin D, and
steroid hormone. TRs contain three functional domains: an N-terminal activation
domain, conserved DNA binding domain, and a carboxy terminal ligand binding domain.
The amino-terminal activation domain interacts with basal transcription factors such as
IIB (Hadzic et al., 1995). Modulation of key amino acid residues within the activation
domain decreased T3 dependent transcriptional activation and inhibited binding to TRE.
These data suggest that the activation domain is important for full transcriptional
activation (Hadzic, Habeos, Raaka, & Samuels, 1998). The DNA binding domain is
highly conserved and contains two zinc fingers motifs that bind to distinct DNA
sequences known as TH response elements (TRE) in the promoter of T3 target genes.
Besides facilitating TH binding, the ligand binding domain has other functions that
include binding to coregulatory proteins (corepressors and coactivators) and mediating
homodimerization (e.g. TR/TR) as well as heterodimerization (e.g. TR/RXR) with other
members of the nuclear receptor superfamily (Bassett et al., 2003). Evidently, the
distinct functional domains of TR play a central role in regulating transcriptional activity.

40

Thyroid Hormone Response Elements (TRE)
TRs bind to thyroid hormone response elements (TRE) in the promoters of T3
target genes. TREs contain a consensus sequence consisting of (A/G)GGT(C/A/G)A
which is known as a hexamer half site (S. Y. Cheng, Leonard, & Davis, 2010).
Functional binding and activation requires two of the half sites with different
configurations as direct repeats, palindrome, or as inverted repeats. The spacing between
the half sites varies depending on the configuration. In general, a spacing of four, zero,
and six nucleotides is observed, respectively, in direct repeats, palindrome, and inverted
repeats (S. Y. Cheng et al., 2010). Although TRE direct repeats are more common than
inverted repeats, mixed configurations (e.g. direct repeat and palindrome) also occur at
the promoters of T3 target genes (Yen, 2001). Thus, TRE diversity may function as a
regulatory mechanism in mediating the multiple biological actions of TH.
Although TRs bind as homodimers at TRE, TRs can also bind as a heterodimer
with other members of the nuclear receptor superfamily including vitamin D receptor,
RXR, and retinoic acid receptor subtypes (S. Y. Cheng et al., 2010). The formation of a
heterodimer with RXR helps to enhance the binding of TRs to TREs, the responsiveness
of TR to T3, and transcriptional activation (Zhang & Kahl, 1993; Zhang & Pfahl, 1993).
Therefore, heterodimerization is beneficial in modulating TR functions since it enables
TR to mediate complex actions within the cell and participate in crosstalk signaling with
other pathways.
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Mechanisms of Transcriptional Regulation
Unlike steroid hormone receptors, TRs bind to TRE in both the absence and
presence of ligand or TH. In the absence of TH, TR functions as a silencer of
transcription. Chromatin remodeling plays an important role in facilitating transcription
(J. Zhang & M. A. Lazar, 2000). The basal transcription machinery is repressed due to
closed chromatin. Highly condensed chromatin is associated with histone deacetylation
which inhibits transcription by restricting access to transcription machinery. In the
presence of TH, TR activates transcription. Open configuration of chromatin facilitates
the assembly of the basal transcription machinery and therefore increases the
transcription rate. Histone acetylation, a marker of transcriptionally active chromatin
structure, alleviates the restriction and enables access to transcription machinery.
Therefore, remodeling of chromatin structure is a crucial component of transcriptional
regulation.

Nuclear Receptor Coregulators
Nuclear coregulatory proteins can modulate the transcription of T3 target genes
via interaction with TR (Figure 4). Structural changes facilitate the dissociation of
corepressors and association of activators (Feng et al., 1998; Wagner et al., 1995). In the
absence of ligand, corepressors are recruited to TR. Corepressors such as nuclear
receptor corepressor (NCoR) and SMRT (silencing mediator of RAR and TAR) bind to
TR. These corepressors also recruit histone deacetylases and can form large complexes
with other proteins such as Sin3 and transducin-like protein to repress transcription (Yen
et al., 2006). Other corepressors for TR include Hairless, Alien, RIP-140, and SUN-CoR
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Figure 4. Model for transcriptional activation of TH receptor regulated genes. Thyroid
hormone receptors or (TR) interact with distinct DNA sequences called TRE or thyroid
hormone response element in the promoters of T3 target genes. They function as
transcriptional repressors or activators depending on the hormonal status of the receptor.
In the absence of T3, TR interacts with a co-repressor and represses gene transcription.
In the presence of T3, TR undergoes a conformational change thereby releasing the corepressor. Co-activators are recruited to the complex and facilitate gene transcription.
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(S. Y. Cheng et al., 2010). In the presence of ligand, TR undergoes a conformational
change resulting in dissociation of the corepressors and recruitment of coactivators.
Coactivators such as steroid hormone receptor (SRC) and CBP/p300 are recruited to the
complex. SRC-1 and CBP posess histone acetyltransferase (HAT) activity and can
modify the chromatin to increase transcription. Another group of proteins that do not
possess HAT activity are the TR asscociated proteins (TRAPs) and vitamin D receptor
interacting proteins (DRIPs) (Rosenfeld & Glass, 2001). Recruitment of TRAP220
mediates the binding and stabilization of RNA polymerase II binding to promote gene
transcription. These studies indicate that corepressors and coactivators are critical
regulators of TR transcriptional activation.

Diabetes and Obesity Related Protein (DOR)
The importance of TH on bone is well established. However, the molecular
mechanisms of TH action in osteoblasts have not been fully characterized.
Although many nuclear coregulatory proteins have been identified in regulating gene
transcription of T3 target genes, it is evident that TR is associated with multiple protein
complexes. Therefore, the identification of other coregulatory proteins that interact with
the TR complex could advance our fundamental understanding of TH action.
In this regard, Baumgartner et al. recently identified DOR as a key mediator of
TH action in myoblasts (Baumgartner et al., 2007). DOR was identified in a subtractive
hybridization screening to identify potential risk facors associated with Type II diabetes.
By screening genes in Zucker diabetic rats and non-diabetic rats, they found that DOR
was significantly repressed in diabetic rats. Because DOR was highly expressed in
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tissues (skeletal muscle and heart) with high metabolic rate, the authors speculated about
the role of this protein in modulating TH action. Furthermore, since DOR was localized
to the nucleus and homologous to a protein involved in transcriptional activation, the
authors investigated the role of DOR in regulating transcriptional activity of TR. They
found that DOR physically interacts with TRα, enhanced the transcriptional activity of
TRα, and was recruited to T3 responsive promoters. The authors concluded that DOR
plays a critical role in modulating TH action and myoblast differentiation.

Rationale and Hypothesis
As described previously, TH plays an important role in regulating bone formation.
However, because the molecular mechanisms of TH signaling in osteoblasts is not well
understood, the identification of potential signaling molecules involved in regulating
thyroid hormone action is essential for elucidating molecular pathways. Based on the
findings that DOR is a key determinant of myoblast differentiation and modulates TH
function in myoblasts, the following hypothesis has been proposed,
DOR is differentially expressed during osteoblast differentiation and acts as a
modulator of TH action in osteoblasts.
To test this hypothesis the specific aims are the following:
a. Evaluate the expression of DOR in response to known inducers of osteoblast
differentiation.
b. Determine whether modulation of DOR expression alters TH action on
osteoblast differentiation.
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c. Examine DOR gene for the presence of single nucleotide polymorphisms
(SNPs) in humans and assess whether genotype-phenotype correlations exist.
These findings are summarized in Chapter 3.

Tight Junctions (TJs)
Specialized cell junctions occur at points of cell-cell and cell-matrix contact in
many organs (Alberts et al., 2002). These junctions are important for maintaining
biological compartments and for keeping external and internal environments separate.
Tight Junctions (TJs) are sites of cell-cell contact which are important in regulating the
paracelluar transport of molecules and forming a tight seal between neighboring or
adjacent cells. TJs consist of a branching network of multiple sealing strands that
surrounds the apical region of the cells. Within a cell, TJs function as a fence in
establishing cell polarity and restricting the lateral diffusion of membrane proteins
between the apical and basolateral regions of the plasma membrane (Gupta & Ryan,
2010). Between adjacent cells, TJs function as a gate in regulating the paracellular
transport of water, solutes, ions, and small molecules (Gupta & Ryan, 2010). It was
originally thought that barrier function was related to density of the TJ strands. However,
it the nature of the strands rather than the density that determines the barrier function
(Stevenson, Anderson, Goodenough, & Mooseker, 1988). Transepithelial resistance
(TER) is a measure of the actual barrier capacity of TJs.
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Claudins (Cldns) are Essential for TJ Formation
The major components of TJs include occludin, junctional adhesion molecule
(JAM), Claudins (Cldns), and tricellulin. Occludin was the first tight junction protein to
be identified and was assumed to be a key component of TJ strands (Furuse et al., 1993).
However, Saitou et al. unexpectedly observed that TJs were still formed and functioned
normally in occludin KO mice, suggesting that another unidentified component was
critical for TJ formation (Saitou et al., 2000). This discovery led to the identification of
Cldn family members (Tsukita & Furuse, 2000). By sucrose step gradient and peptide
sequencing of the same liver fraction used to identify occludin, the authors identified 2
putative TJ proteins named Cldn-1 and -2. Claudin is derived from a Latin name which
means “to close.” Introduction of a single Cldn species (Cldn-1 or Cldn-2) into mouse L
fibroblasts that lack TJs, resulted in the formation of well developed networks of TJs
(Furuse, Sasaki, Fujimoto, & Tsukita, 1998). Neither JAM nor tricellulin can induce the
formation of TJs. Taken together, these findings provided experimental proof of concept
that Cldns are directly involved in the formation of TJs and are the primary components
of TJ strands.

Claudin Protein Structure
The Cldn family is comprised of 24 members. Clnds range in size from 20-34
kDa. As shown in figure 5, Cldns have 4 transmembrane helices, two extracellular
(ECL) loops, a short intracellular loop, and cytoplasmic N- and C-termini. The first ECL
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Figure 5.
Schematic representation of Claudin (Cldn) structure.
Cldns are
transmembrane proteins which contain four domains, two extracellular (ECL) loops, and
a C-terminal cytoplasmic tail. ECL1 regulates paracellular ion selectivity and contains
two cysteines involved in disulfide bone formation. ECL2 participates in binding
interactions with other Cldn members. The cytoplasmic tail at the C-terminus contains
phosphorylation sites and a PDZ binding domain. Palmitoylation sites have been
identified in the cytoplasmic domains following the second and fourth transmembrane
domains.
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is approximately 52 amino acid residues and shows high sequence variation (Van Itallie
& Anderson, 2006) and exhibits ion selectivity via electrostatic charges from amino acid
residues. The diversity of amino acids in the first ECL probably explains why this part of
the molecule regulates paracellular ion selectivity of the TJ barrier. For instance, Cldns-2
and-7 are highly permeable to sodium while Cldn-8 is permeable to bicarbonate
(Angelow, Kim, & Yu, 2006; Colegio, Van Itallie, Rahner, & Anderson, 2003; Colegio,
Van Itallie, McCrea, Rahner, & Anderson, 2002). The first ECL also contains two highly
conserved cysteines which are believed to provide protein stability by the formation of an
intramolecular disulfide bond. The second ECL consists of approximately 16-33 residues
and participates in binding to other Cldn family members.
The cytoplasmic C-termini exhibits the most heterogeneity with respect to length
(21-63 residues) and sequence (Findley & Koval, 2009). It contains a signature PDZ
binding motif which enables direct interaction with other PDZ domain containing
proteins such as zonula occludens (ZO)-1, ZO-2, ZO-3, MUPP1, PATJ, and possibly
other proteins (Hamazaki, Itoh, Sasaki, Furuse, & Tsukita, 2002; Itoh et al., 1999; Roh et
al., 2002). The ZO proteins interact with Cldns by binding to the YV sequence located in
the C-terminus of Cldn proteins. These interactions are important because it stabilizes
TJs by indirectly anchoring Cldns to the actin cytoskeleton via the ZO proteins (Umeda et
al., 2006). Disruption of this interaction may lead to misolcalization, as in the case of
Cldn-16 where it accumulates in the lysosomes (Müller et al., 2003). Furthermore, these
bridging interactions may link Cldns to intracellular signaling which affects cell
proliferation, differentiation, and gene expression (Gupta & Ryan, 2010). The
cytoplasmic C-termini is also a site for post-translational modifications such as
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serine/threonine and tyrosine phosphorylation (González-Mariscal, Tapia, & Chamorro,
2008) and palmitoylation (Van Itallie, Gambling, Carson, & Anderson, 2005). These
modifications can affect Cldn localization and function. Overall, Cldn action and function
is regulated by its distinct functional domains.

Cldn Expression and Interaction
Cldns exhibit distinct tissue and cell type expression patterns (Morita, Furuse,
Fujimoto, & Tsukita, 1999). Several Cldns may be expressed within the same tissue/cell
or Cldn expression may be tissue/cell specific. For example, Cldn-1 is ubiquitously
expressed whereas Sertoli cells only express Cldn-11 (Van Itallie & Anderson, 2006).
Cldn expression can vary even within the same organ. Different expression patterns of
Cldns are observed in different segments of the kidney (Kiuchi-Saishin et al., 2002).
Since several Cldn members may be expressed within a given tissue, the issue of whether
these members are functionally redundant arises. Cldn-15 KO mice do not exhibit a
compensatory change in Cldn expression at mRNA and protein level in the small
intestine (Tamura et al., 2008). In contrast, disruption of Cldn-11 revealed increased
Cldn-3 mRNA expression (5-fold higher than WT) and diminished Cldn-1 mRNA
expression in the cochlea (Gow et al., 2004). These findings suggest that some Cldn
members have distinct functions while others may serve a redundant role for each other.
Because multiple Cldns are often expressed in the same cell, there is a potential
for interaction between these Cldns. Cldns may interact in the paracellular space via a
homotypic, heterotypic, or heteromeric manner (Gupta & Ryan, 2010). In homotypic
interactions, strands of the same Cldn family member interact in the paracellular space.
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In heterotypic interactions, two different Cldns in adjacent cells interact via head-to-head
binding. In heteromeric interactions, different Cldns can form mixed oligomers within
the same cells and can interact via lateral interactions. The combination and
stoichiometry of Cldns determine the paracellular permeablity. For example, cytoplasmic
tail swapping of Cldns-2 and -4 did not affect localization, but instead affected protein
stability and TER (Van Itallie, Colegio, & Anderson, 2004). Since several members
comprise the Cldn family, the variation of Cldns within and between TJs increases the
structural and functional diversity of TJs and therefore enhances the complexity of ion
selectivity (Balkovetz, Chumley, & Amlal, 2009; Furuse, Sasaki, & Tsukita, 1999).

Mechanisms of Regulation for Cldn Levels and Actions
Cldn function is regulated at multiple levels and by diverse mechanisms. As
described earlier, Cldns contain potential serine and/or threonine phosphorylation sites in
their cytoplasmic C-terminal domains. Phosphorylation can lead to changes in
paracellular permeability. For example, increased paracellular permeability is observed
following phosphorylation of Cldn-3 and Cldn-4 by PKA and PKC respectively
(D'Souza, Agarwal, & Morin, 2005; D'Souza, Indig, & Morin, 2007). WNK4
phosphorylates multiple claudins and increases paracellular permeability (Yamauchi et
al., 2004). Other studies have shown that phosphorylation of Cldn-4 is enhanced by
EphA1 (Tanaka, Kamata, & Sakai, 2005). Therefore post-translational modification, in
particular phosphorylation, is an important mechanism for modulating Cldn function.
Claudins are also regulated at the transcriptional level. Snail is a transcription
factor that has been shown to bind directly to the promoters of various claudin genes to
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affect their expression. Snail binds directly to the E-boxes in the promoter region of
Cldn-7 (Ikenouchi, Matsuda, Furuse, & Tsukita, 2003) and thereby represses
transcription. They also demonstrated that overexpression of Snail decreases Cldn-3, -4,
and -7 expression. GATA-4 binds to the promoter of Cldn-2 and when co-expressed with
CDX or HNF-1 increases Cldn-2 expression (Escaffit, Boudreau, & Beaulieu, 2005).
Cldn-2 expression decreases with time as Caco-2 cells are cultured in vitro. Forced
expression of GATA-4 rescues declining levels of Cldn-2 in Caco-2 cells. Therefore,
transcriptional regulation of Cldns represents a key regulatory mechanism for modulating
Cldn expression.
Endocytic recycling is another mechanism for Cldn regulation. Plasma
membrane transporters such as aquaporin and CFTR are regulated by this mechanism
(Van Itallie & Anderson, 2006). Cldns are continually removed and replaced at the
apical junctional complex via clathrin mediated endocytosis. This process occurs in
normal cells and also during calcium withdrawal (Van Itallie & Anderson, 2006).
Endocytic recycling functions as a physiological mechanism to regulate barrier function
by remodeling TJs (Koval, 2006). This feature is not unique to TJs since gap junctions
also undergo internalization. Palmitoylation represents another mechanism for regulation
of Cldn function. Signature di-cysteine palmitoylation motifs are conserved throughout
the Cldn family. Palmitoylated Cldn-14 partitioned more efficiently into detergent
resistant membranes compared to non-palmitoylated mutants (Nusrat et al., 2000). This
finding suggests that palmitoylation enhances Cldn incorporation into TJs and that the
increased Cldn protein stability may be mediated by lipid rafts.
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Growth factors and cytokines also play a role in regulating Cldn expression and
function. Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) regulate
Cldn expression via signaling through MAP Kinase pathway. Stimulation of MDCK II
cells with EGF, was associated with decreased Cldn-2 expression with an increase in
Cldn-1, -3, and -4 expression leading to an increase in TER (Singh & Harris, 2004).
HGF treatment of MDCK II cells also increases TER via a mechanism that involves
decreased Cldn-2 expression (Lipschutz, Li, Arisco, & Balkovetz, 2005). Interferon-γ
increases Cldn endocytosis and tight junction permeability (Chiba, Kojima, Osanai, &
Sawada, 2006). In addition, another report demonstrated that other inflammatory
cytokines such as TNF-α and IL-13 increase paracellular permeability (Prasad et al.,
2005; Tedelind, Ericson, Karlsson, & Nilsson, 2003). Therefore, growth factor activation
and inflammation are key stimuli which regulate paracellular permeability by modulating
Cldn expression and/or function. However, the role of Cldn in mediating the actions of
growth factors and inflammatory cytokines remains to be established.

Phenotypic Effects of Cldn Loss of Function
Mutations or deletion of Cldns demonstrate the importance of Cldns in
modulating biological functions in a variety of systems. Table 2 lists some of the
phenotypes associated with Cldn gene deletion. Cldn deficient mice exhibit multifaceted
phenotypic changes in several physiological systems. Ablation of Cldn-14, Cldn-1, and
Cldn-5 affect cochlear hair cell function, and the skin and blood-brain barrier respectively
(Ben-Yosef et al., 2003; Furuse et al., 2002; Nitta et al., 2003). A severe renal phenotype
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Table 2. Claudin loss of function mutations in the mouse
Gene
Phenotype
Cldn-1 KO
Neonatal death due to skin barrier defect with water loss
Cldn-5 KO
Neonatal death from blood brain barrier defect
Cldn-11 KO
Central nervous system myelin defect; Infertile males due to blood-testis barier defect
Cldn-14 KO
Deaf due to cochlear hair cell degeneration
Cldn-15 KO
Megaintestine due to increased proliferation
Cldn-16 KD
Reduced body weight; hypomagnesemia, hypermagnesuria, hypercalciuria, nephrocalcinosis
Cldn-18 KO
Decreased bone mineral density
Cldn-19 KO
Peripheral nervous system defect; Schwann cell barrier defect
Cldn-19 KD
Reduced body weight; hypomagnesemia, hypermagnesuria, hypercalciuria, nephrocalcinosis

is observed in mice lacking Cldn-7, Cldn-16, or Cldn-19, while Cldn-15 deficient mice
exhibit megaintestine (Kausalya et al., 2006; Miyamoto et al., 2005; Tamura et al., 2008;
Tatum et al., 2010). Deletion of Cldn-11 hampers CNS nerve conduction and induces
male sterility (Gow et al., 1999). Thus, the findings from loss of function studies clearly
demonstrate that Cldns are crucial proteins in various biological systems.

Cldn-18
Discrete phenotypes seen in mice with targeted disruption of different Cldns
suggest that Cldns have highly specialized roles in particular cell types. In this regard,
we recently found in collaboration with Lexicon Pharmaceuticals Inc that deletion of
Cldn-18 results in decreased bone mineral density (BMD). These findings indicate that
Cldn-18 may play an important role in regulating bone. Cldn-18 was identified as a
downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor in the
lung (Niimi et al., 2001). These investigators found that alternative splicing resulted in
two tissue-specific isoforms, Cldn-18a1 (lung isoform) and Cldn-18a2 (stomach isoform)
driven by alternate promoters (Niimi et al., 2001). Cldn-18 is also known to be expressed
in a variety of other tissues and cell types including the inner ear, hair follicles, and radial
glia (Yano, Imaeda, & Niimi, 2008). Jovov et al. demonstrated that Cldn-18 may play a
role in contributing to acid resistance in Barrett’s esophagus (Jovov et al., 2007). Cldn18 overexpression increased TER and reduced paracellular permeability to sodium and
hydrogen ions. They also found that Cldn-18 colocalized with ZO-1. Cldn-18 may also
be involved in the regulation of tumorigenesis. Cldn-18 expression was downregulated
in patients with gastric cancer and correlated with poor survival (Sanada et al., 2006).
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Although the biological role of Cldns in cancer is currently being investigated, it is
reasonable to speculate that disruption of Cldn-18 function and therefore TJ function
could alter permeability properties and cell polarity thereby contributing to epithelial
tumorigenesis (Sanada et al., 2006). Collectively, these findings demonstrate a
physiological role for Cldn-18.

Rationale and Hypothesis
Recent studies have demonstrated that various Cldn members are expressed in
bone (Prêle, Horton, Caterina, & Stenbeck, 2003; Wongdee et al., 2008). However, the
biological role of any Cldn member in bone remains to be elucidated. Furthermore
relatively little is known about the biological functions of Cldn-18 in other tissues. Cldns
are important components of TJs that aid in forming tight adhesions between cells and
may participate in signal transduction pathways. Therefore it may be possible that
disruption of Cldn-18 alters cell-to-cell adhesion at the bone surface and/or signaling
mechanisms, thereby leading to abnormal bone physiology. Based on the findings that
disruption of Cldn-18 in mice decreases BMD and Cldn-18 is expressed in bone cells, the
following hypothesis has been proposed,
Cldn-18 is a negative regulator of bone resorption.
To test this hypothesis the specific aims are the following:
a. Determine if Cldn-18 is expressed in osteoclasts.
b. Evaluate whether Cldn-18 regulates osteoclast resorption and thereby BMD.
These findings are summarized in Chapter 4.
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Abstract
There is now increasing evidence which suggest an important role for reactive
oxygen species (ROS) in the pathogenesis of osteoporosis. However, little is known on
the molecular components of the oxidative stress pathway or their functions in bone. In
this study, we evaluated the role and mechanism of action of glutaredoxin (Grx) 5, a
protein that is highly expressed in bone. Osteoblasts were transfected with Grx5 siRNA
and treated with hydrogen peroxide (H2O2). Grx5 siRNA treatment increased apoptosis
while Grx5 overexpression protected MC3T3-E1 cells against H2O2 induced apoptosis
and ROS formation. Grx5 deficiency results in impaired biogenesis of Fe-S cluster in
yeast. Accordingly, activity of mitochondrial aconitase, whose activity is dependent on
Fe-S cluster, decreased in Grx5 siRNA treated cells. Since reduced formation of Fe-S
cluster would lead to increased level of free iron, a competitive inhibitor of manganese
superoxide dismutase (MnSOD), we measured MnSOD activity in Grx5 deficient
osteoblasts and found MnSOD activity was significantly reduced. The consequence of
long term inhibition of Grx5 on osteoblast apoptosis was evaluated using lentiviral
shRNA technology. Grx5 shRNA cells exhibited higher caspase activity and cardiolipin
oxidation in the presence of H2O2. MnSOD activity was rescued by addition of MnCl2 to
Grx5 shRNA osteoblasts in the presence of H2O2. Our findings are consistent with the
hypothesis that Grx5 is an important determinant of osteoblast apoptosis and acts via a
molecular pathway that involves regulation of ROS production, cardiolipin oxidation,
caspase activity, Fe-S cluster formation, and MnSOD activity.
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Introduction
The formation of reactive oxygen species (ROS) is an inevitable consequence of
being an aerobic organism. Normal byproducts of respiration includes hydrogen
peroxide (H2O2), superoxide anion (O2-), and hydroxyl radical (OH.) [1, 2]. These ROS
can also derive from external environmental factors such as redox active drugs, radiation,
and heavy metals [1]. However, the majority of the ROS produced by cells can be
attributed to the mitochondrial respiratory chain [1]. Oxidative stress occurs when the
levels of oxidants are higher than the levels of reductants, thus overwhelming the system
[3]. Cells have developed both non-enzymatic and enzymatic defense mechanisms to
counteract the deleterious effects of oxidative stress by either detoxifying ROS or
repairing ROS induced damage. Some non-enzymatic examples include vitamin C,
vitamin E, ubiquinone, flavenoids, and glutathione (GSH), and some examples of
enzymatic scavengers include catalase, glutathione peroxidase, thioredoxin, Cu/Zn
superoxide dismutase (Cu/Zn SOD), Mn/superoxide dismutase (MnSOD), and
glutaredoxins [4]. Without these defensive mechanisms, the production of ROS in the
cell would be unabated and the overall viability of the cell and cellular macromolecules
would be compromised.
Recently there is mounting evidence that oxidative stress poses detrimental effects
on bone by depleting antioxidants, activating osteoclasts, inhibiting bone formation, and
increasing the incidence of apoptosis [5-11]. For example, increased oxidative stress
results in decreased bone mineral density in aged men and women [12] and elderly
osteoporotic women displayed lower plasma levels of antioxidants compared to agematched controls [5]. Postmenopausal osteoporotic women displayed higher levels of
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lipid peroxidation and decreased activity of antioxidant enzymes including catalase,
superoxide dismutase, and glutathione peroxidase [13, 14]. These accumulating data
provide strong evidence implicating the harmful effects of oxidative stress in bone, thus
warranting further investigation to fully understand the mechanisms.
Glutaredoxins (Grx) are glutathione dependent oxidoreductases that help maintain
cellular redox homeostasis in the cell [15]. The glutaredoxin system consists of GSH,
NADPH, and GSH reductase [16]. The mammalian system contains three known
members of the glutaredoxin family Grx1, Grx2, and Grx5. Grx1 (12 kDa), a dithiol
glutaredoxin, is localized mainly in the cytosol and is involved in general disulfidedithiol exchanges, donation of electrons to ribonucleotide reductase, dehydroascorbate
reduction, regulation of transcription factors, differentiation, and apoptosis [15, 17-21].
Grx2 (16 kDa), a dithiol glutaredoxin, localizes to either the mitochondria or the nucleus.
Grx2 is involved in protein deglutathionylation of mitochondrial complex I, prevention of
cardiolipin oxidation and cytochrome c release, and reduction of low molecular weight
compounds such as GSSG and CoA disulphide [16]. The recently discovered Grx5, a
monothiol glutaredoxin, is hypothetically localized to the mitochondria. Most of what is
known on Grx5 has come from studies in yeast. The loss of Grx5 in yeast leads to
constitutive oxidative damage, sensitization to ROS, iron accumulation, and inactivation
of iron-sulfur (Fe-S) cluster containing enzymes [22-24]. A recent study by Wingert et
al. [25] in zebrafish showed that loss of Grx5 causes hypochromic anemia and severely
inhibits the formation of Fe-S clusters.
Several studies have demonstrated the importance of glutaredoxins in protecting
against apoptosis. For example, overexpression of Grx1 protected cells from glucose
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deprivation induced metabolic stress by regulating the redox state of apoptosis signaling
kinase 1 (ASK1) [26]. Studies by Murata et al. [27] also provided evidence that Grx1 is a
key player in protecting against oxidative stress. The overexpression of glutaredoxin
protected cardiac myocytes from hydrogen peroxide induced oxidative stress [28].
Specifically, Grx1 protected the redox state of AKT, a survival kinase that inactivates
pro-apoptotic proteins, from inactivation by hydrogen peroxide. Similar to Grx1, Grx2
has also been shown to protect against apoptosis. Overexpression of Grx2 decreased the
susceptibility of HeLa cells to apoptosis induced by doxorubicin or 2-deoxy-D-glucose
[29]. Another study showed that the knockdown of Grx2 using siRNA, sensitized HeLa
cells to cell death triggered by oxidative stress inducing compounds such as doxorubicin
and phenylarsine oxide [30]. Together these findings indicate that glutaredoxins play a
crucial role in protection against apoptosis. Since Grx5 is highly expressed in osteoblasts
and little is known about the role of Grx5 in mammalian cells, we investigated the
biological role of Grx5 in osteoblasts. Based on what is known about Grx1 and Grx2
actions in other systems, we hypothesized that Grx5 protects osteoblasts from oxidative
stress. The purpose of this study is to evaluate the cause and effect relationship between
Grx5 expression and osteoblast apoptosis and determine the molecular pathway for Grx5
action in osteoblasts.

Materials and Methods
Cell Culture
MC3T3-E1 cells were grown in standard growth media consisting of α-MEM
(Invitrogen, Carlsbad, CA) containing 10% calf serum (Atlanta Biologicals, Norcross,
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GA) + 1% penicillin/streptomycin (Cambrex Biosicence, Walkersville, MD). Serum free
media consisted of α-MEM + 1% penicillin/streptomycin and cell culture treatments with
cadmium chloride (CdCl2), hydrogen peroxide (H2O2), tumor necrosis factor-α (TNF-α),
and manganese chloride (MnCl2) were made in α-MEM + 0.1% BSA + 1%
penicillin/streptomycin. Murine bone marrow stromal cells (BMSCs) were isolated and
differentiation was induced as previously described [31]. Osteoblasts were isolated from
the calvaria of 6 day old C57BL-6J mice as previously described [52]. Osteocalcin
expression was used to confirm in vitro differentiation of BMSCs into osteoblasts. H2O2,
CdCl2, and MnCl2 were purchased from Sigma-Aldrich (St. Louis, MO). TNF-α was
obtained from PeproTech Incorporated (Rocky Hill, NJ).

RNA Isolation and Extraction
RNA was extracted from C57BL-6J mice, MC3T3-E1 cells, and BMSCs using a
RNeasy Mini kit (Qiagen, Valencia, CA) as previously described [31].

Gene Expression Analysis
Real time RT-PCR was conducted according to the protocol previously described
[31] using a Stratagene Brilliant SYBRGreen master mix (Stratagene, La Jolla, CA) and
an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA).
Gene specific primers (Integrated DNA Technologies, San Diego, CA) were used to
amplify Grx1 (forward: 5΄--AACAACACCAGTGCGATTCA--3΄, reverse: 5΄-ATCTGCTTCAGCCGAGTCAT--3΄), Grx2 (forward: 5΄--GCTGGAATATGG
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CAACCAGT--3΄, reverse: 5΄--GATGAA CCAGAGGCAGCAAT--3΄), and Grx5
(coding region—forward: 5΄--CGCTGGTGAAGAAGGACAA--3΄, reverse: 5΄-TGGTTGGCCAGTTGGAGTA--3΄ and 3΄ untranslated region—forward: 5΄-ATGTCGCGATCCTGTATTGC--3΄, reverse: 5΄-- TCCTCT GTCCATCATTTCCC -3΄). Peptidylprolyl isomerase A (PPIA) was used as the endogenous control. Fold
change was calculated according to the formula 2-ΔΔCT.

Gene Transfection
MC3T3-E1 cells were transiently transfected by electroporation using 1
µg negative control siRNA (Qiagen, Valencia, CA) or 1 µg Grx5 siRNA (Santa
Cruz Biotechnology, Santa Cruz, CA) with siPORT siRNA electroporation
buffer (Ambion, Austin, TX). Electroporation was performed as previously
described [32]. MC3T3-E1 cells were also transduced with lentiviral shRNA to
evaluate the long term effect of gene silencing. MC3T3-E1 cells were
transduced with Mission® non-target shRNA control (Sigma-Aldrich, St. Louis,
MO) transduction particles or four different Mission® Grx5 transduction
particles (Grx5 shRNA 86-89) (Sigma-Aldrich, St. Louis, MO). The efficiency
of the four Grx5 shRNAs was evaluated to determine which one provided the
highest inhibition of Grx5. Cells were seeded at a density of 5,000 cells/well in
a 24-well plate (BD Biosciences, San Jose, CA) in α-MEM + 10% calf serum +
1% penicillin/streptomycin. The following day the media was changed and 8
μg/ml hexadimethrine bromide was added to the media to enhance infection
efficiency. Cells were transduced four times (morning and evening) using a
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MOI of 10 over the course of two days. After the last transduction, cells were
replenished with fresh standard growth media for 1 day. Cells were then replated in a 6-well plate (Falcon) and the antibiotic puromycin (10 μg/ml)
(Sigma-Aldrich, St. Louis, MO) was used in cell culture media for three days to
perform selection. Following selection with 10 μg/ml puromycin, cells were
expanded in standard growth media.

Cloning of Grx5 into MLV Vector
Grx5 was amplified by PCR using Mus musculus liver cDNA (50 ng) as a
template. Cloning was accomplished using PCR selection kit—high fidelity (Invitrogen,
Carlsbad, CA). The reaction mixture consisted of 5 μl of 10X Pfx50 PCR mix, 1 μl each
of forward and reverse primers, 2.5 μl of 10 mM dNTPs, 32.5 μl of DNA water, 2.5 μl
DMSO, and 0.5 μl Pfx50 DNA polymerase. The 5´ end of the forward primer contains a
Kozak consensus sequence that initiates protein translation and the 3´ end of the reverse
primer contains a synthetic FLAG epitope (underlined) at the C-terminus that allows for
identification of the protein. The primer sequences are (5´ to 3´): Grx5 forward: 5’-GGG
TCG AC GCC ACC ATG AGC GCG TCC CTG AGC CGG GCG GC -3’ and Grx5
reverse: 5’-CGC GGA TCC TCA CTT GTC GTC ATC GTC TTT GTA GTC CTT GGA
GTC TTG GTC CTT CTC ATC TA -3’. Amplification was carried out at 95oC for 10
min, 40 cycles at 95oC for 15 s, 60oC for 1 min, and 72oC for 3 min using Pfx50 DNA
polymerase (Invitrogen, Carlsbad, CA) for PCR cloning due to its high specificity and
high fidelity. The PCR product was purified with GeneClean spin kit (Qbiogene,
Carlsbad, CA) according to manufacturer’s instructions and was then digested overnight
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at 37oC with Bam HI and Sal I. The digested product was purified from a gel using
GeneClean spin kit. Finally the PCR product was subcloned into the corresponding
restriction sites of the MLV expression vector [33]. All plasmids were transformed into
E. coli XL1 BLUE cells and the plasmids were isolated using EndoFree® Plasmid Maxi
(Qiagen, Valencia, CA). The Grx5 PCR product sequence was confirmed by DNA Lab
at Arizona State University (Tempe, AZ).

MLV-Based Vector Production and MLV Transduction
VSV-G protein was used as the envelope for our MLV-based vector and the
vectors were generated by transient transfection in 293T cells as previously described
[33]. Briefly, a 10-cm plate of 293T cells was transfected with a mixture of 20 μg of
retroviral expression vector (Grx5 or β-gal control vectors), 10 μg of MLV-GP
expression vector, and 1 μg of VSV-G expression vector by CaPO4 precipitation. The
conditioned medium containing the viral vectors was collected 48 hours after the
transfection. The viral titer was determined by the end-point dilution assay for the
marker gene (β-Gal) expression in HT1080 cells. MC3T3-E1 cells were transduced as
previously described [33].

Western Blot Analysis
Equal amounts of protein (20 μg) were resolved on a 15% SDS polyacrylamide
gel. Proteins were transferred to a 0.2 μM nitrocellulose membrane (BioRad, Hercules,
CA) at 300 mA for 20 minutes at 4oC. The membrane was blocked in 5% milk in TBST
overnight with rotation at 4oC. The following day, the membrane was probed with
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specific antibody to anti-Flag (1:5000) (Sigma-Aldrich, St. Louis, MO) for 1 hour. After
washing, the membrane was incubated with horseradish peroxidase conjugated antimouse anitbody (1:10,000) (Sigma-Aldrich, St. Louis, MO) for 1 hour and then washed.
Detection of Grx5 was visualized using Super Signal West Pico Chemiluminescent
Substrate (Pierce, Rockford, IL). After exposure to chemiluminescene, the same
membrane was stripped and reprobed with anti-β-actin (Sigma-Aldrich, St. Louis, MO).

Determination of Apoptosis
Trypan blue exclusion was performed on MC3T3-E1 cells in the presence of
CdCl2 or H2O2. Cells were seeded at a density of 800 cells/well in a 96-well dish (BD
Biosciences, San Jose, CA). The media was changed to serum free for 24 hours and cells
were treated with different doses of CdCl2 or H2O2 for 48 hours. The media was removed
and cells were incubated with 0.4% Trypan blue (ICN Biomedicals, Inc, Irvine, CA) in
PBS for 45 minutes at 37oC with 5% CO2. The percentage of dead cells was calculated
by dividing the number of dead (blue) cells by the number of live (clear) cells in a given
field. Data are representative of four random fields per well. DNA fragmentation was
quanitated in MC3T3-E1 cells transfected with negative control siRNA or Grx5 siRNA.
Cells were seeded at a density of 200,000 cells/well in a 6-well dish (BD Biosciences,
San Jose, CA) and were harvested according to the manufacturer’s protocol (Calbiochem,
San Diego, CA). Briefly, samples were diluted 1:20 and the number of nucleosomes was
determined by measuring the absorbance at dual wavelengths of 450/595 nm. The
amount of protein was determined according to the method of Bradford [34]. Annexin V
stain was performed on β-Gal control, Grx5 overexpressing cells, and MC3T3-E1 cells
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transfected with negative control siRNA or Grx5 siRNA. Cells were seeded at a density
of 20,000 cells/well in a 24-well dish (BD Biosciences, San Jose, CA) and were treated
with 200 μM H2O2 for six hours. The cells were washed 2 times with PBS and incubated
with 5 μl Alexa Fluor 488 annexin V (Molecular Probes Invitrogen, Carlsbad, CA) in 1X
binding buffer to detect phosphatidlyserine (PS). Plates were covered with foil and
gently rotated for 15 minutes on an orbital shaker. After incubation, the media was
removed and cells were washed with PBS. Images were immediately taken using an
Olympus IX70 and fluorescence was observed using the appropriate filters. Caspase 3,7
activity was measured using Caspase-Glo 3,7 assay (Promega, Madison, WI). Non-target
shRNA control or Grx5 shRNA cells were plated at a density of 2,000 cells/well in a 96well dish. The following day the media was replaced with serum free media. Twentyfour hours later cells were treated with either 200 μM H2O2 or 20 ng/ml TNF-α. Caspase
3,7 activity was determined after a 30 minute incubation by measuring luminescence with
Synergy 2 (Biotek Instruments Incorporated, Winooski, VT) according to the
manufacturer’s protocol.

MultiTox-Fluor Multiplex Cytotoxicity Assay
Non-target shRNA control or Grx5 shRNA cells were plated at a density of 2,000
cells/well in a 96-well dish (BD Biosciences, San Jose, CA). The following day the
media was replaced with serum free media. Twenty-four hours later cells were treated
with 20 ng/ml TNF-α for 24 hours. Cytotoxicity (Promega, Madison, WI) was
determined as per the manufacturer’s instructions.
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ROS Assay
β-Gal control or Grx5 overexpressing cells were plated at a density of 2,000
cells/well in a 96-well dish. The following day the cells were rinsed with serum free
media and 24 hours later cells were incubated with 20 µM 2′,7′-dichlorofluorescin
diacetate (DCF) (Sigma-Aldrich, St. Louis, MO) for 45 minutes at 37oC with 5% CO2.
Following incubation, cells were treated with 500 µM H2O2 for 2 hours. ROS levels
were determined by measuring the fluorescent intensity in Synergy 2 at excitation
wavelength 485 nm and emission wavelength 530 nm.

Enzymatic Activities
The activity of aconitase and manganese superoxide dismutase (MnSOD) were
measured in MC3T3-E1 cells transfected with negative control siRNA or Grx5 siRNA.
Briefly, the aconitase reaction mixture consisted of 90 mM Tris-HCl pH 7.5, 20 mM DLisocitrate, 1 mM sodium citrate, dH2O, and protein in a final volume of 1 ml. The
formation of cis-aconitate was recorded for 6 minutes at 25oC in a spectrophotometer at
240 nm. MnSOD activity (Cayman Chemical, Ann Arbor, MI) was measured according
to the manufacturer’s protocol. Protein concentrations were determined using the BioRad
protein assay reagent .

10-N-nonyl acridine orange (NAO)
Cardiolipin oxidation was assessed by staining with NAO (Invitrogen, Carlsbad,
CA), a probe for mitochondrial cardiolipin. Non-target shRNA control or Grx5 shRNA
cells were plated at a density of 2,000 cells/well in a 96-well dish. The following day the
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media was replaced with serum free media. Twenty-four hours later cells were treated
with 200 μM H2O2 or 400 μM H2O2. Following treatment for 12 hours, cells were rinsed
twice with PBS and incubated in 5 μM NAO for 30 minutes in the dark at room
temperature. Samples were rinsed twice with PBS and fluorescence was measured at
excitation wavelength 495 nm and emission wavelength 519 nm using Synergy 2 (Biotek
Instruments Incorporated, Winooski, VT).

Statistical Analysis
Data are presented as mean ± SEM (standard error of the mean) and were
analyzed using Student’s T-test, one-way, or two-way ANOVA (Statistica 6, Tulsa, OK).
Post-hoc analysis was performed using Duncan’s test.

Results
Characterization of Glutaredoxin Expression in Mouse Tissues and
Cells
Although Grx5 is expressed in multiple tissues, its expression is greatest in bone
(Fig 6A). Furthermore, Grx5 is expressed at a 7-fold and 25-fold higher level than Grx1
and Grx2 respectively in bone (Fig. 6B). Grx5 expression was examined during in vitro
differentiation of bone marrow stromal cells into osteoblasts. As shown in Figure 6C,
Grx5 was upregulated 2.8-fold at day 12. Basal expression of Grx5 was also examined in
MC3T3-E1 cells and undifferentiated bone marrow stromal cells, and there was no
difference in Grx5 expression between these two cell types (data not shown). These
results indicate that Grx5 is highly expressed in bone and cells of osteoblast lineage.

71

Figure 6. Glutaredoxin expression in mouse tissues and cells. (A) Grx5 expression in
tissues of 8 week old C57BL-6J mice as determined by real time RT-PCR. Values are
presented as mean ± SEM of 3 replicates. A,B: data with different letters indicate
significant difference at P < 0.05. Tissues with same letters are not statistically different.
(B) Grx 1, 2, and 5 expression in the bones of 8 week old C57BL-6J mice as determined
by real time RT-PCR. Values are presented as mean ± SEM of 3 replicates. A,B: data
with different letters indicate significant difference at P < 0.05. Genes with same letters
are not statistically different. (C) Grx5 expression during in vitro differentiation of bone
marrow stromal cells into osteoblasts. RNA was extracted at day 0, 6, 12, 18, and 24.
Differentiation of bone marrow stromal cells into osteoblasts was confirmed by
osteocalcin expression. Values are presented as mean ± SEM of 6 replicates. A=P <
0.01 vs. day 0 (Grx5) and B=P < 0.05 vs. day 0 (osteocalcin).
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Grx5 Deficient Cells are Sensitized to H2O2 Induced Apoptosis
To determine if Grx function is important in osteoblasts, MC3T3-E1 cells were
treated with different doses of CdCl2, a known inhibitor of Grx activity [20, 27, 28, 30],
and the effect on cell death was examined by trypan blue exclusion. Treatment with
CdCl2 resulted in a dose dependent increase in death of MC3T3-E1 cells (2.5-fold
increase at the 1 µM dose) (Fig. 7A). In addition, treatment with H2O2 resulted in a dose
dependent increase in death of MC3T3-E1 cells (Fig 7B). To verify that the observed
biological effects of CdCl2 on osteoblasts is caused by inhibition of Grx activity, Grx5
was specifically knocked down by transfecting MC3T3-E1 cells with Grx5 siRNA using
electroporation [32]. Grx5 expression decreased by 80% (P<0.05) and 40% (P<0.05) at
24 and 72 hours, respectively, following transfection with Grx5 siRNA compared to
negative control siRNA (data not shown). Grx5 knockdown did not alter the expression
of other Grx family members (data not shown), thus suggesting that Grx5 siRNA effect is
target specific.
To test the hypothesis that Grx5 protects osteoblasts against oxidative stress
induced apoptosis, Grx5 siRNA transfected cells were treated with H2O2, a known
inducer of oxidative stress. The dose of H2O2, 200 μM, used in our experiments was
selected based on published reports [12, 51]. Grx5 siRNA transfected cells treated with
H2O2 exhibited 2.7-fold higher number of annexin V positive cells in comparison to
control siRNA cells treated with H2O2 (Fig. 7C). One of the hallmark features of
apoptosis is DNA fragmentation. DNA fragmentation induced by H2O2 was 2.2-fold
higher in Grx5 siRNA transfected cells compared to control siRNA transfected cells (Fig.
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Figure 7. Inhibition of Grx5 augments cell death. Trypan blue exclusion of MC3T3-E1
cells treated with different doses of either CdCl2 (A) or H2O2 (B) for 48 hours. Values
are presented as % increase from BSA treated control ± SEM (n=8). A=P < 0.05 vs.
control. (C) Annexin V stain of MC3T3-E1 cells transfected with either control siRNA
or Grx5 siRNA for twenty-four hours. Cells were treated with 200 µM H2O2 for six
hours. Panels are representative of I) Grx5 siRNA-control, II) Grx5 siRNA-H2O2, III)
control siRNA-control, and IV) control siRNA-H2O2. Annexin V positive cells (green)
were visualized by fluorescent microscopy using an Olympus IX70. Images were taken
at 40X magnification and arrowheads indicate apoptotic cells. (D) DNA fragmentation
assay of MC3T3-E1 cells transfected with either control siRNA or Grx5 siRNA for
twenty-four hours and then treated with 200 µM H2O2 for six hours. Values are
expressed as % increase from corresponding BSA treated control ± SEM (n=5). A=P <
0.05 vs. control siRNA.
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7D). These results suggest that Grx5 may function to protect osteoblasts from oxidative
stress induced apoptosis.

TNF-α Treatment Sensitizes Grx5 shRNA Osteoblasts to Apoptosis
Since Grx5 siRNA that was used for functional studies only blocked Grx5
expression transiently, we used lentiviral vector based shRNA strategy to evaluate the
consequence of long term inhibition of Grx5 on osteoblast apoptosis. MC3T3-E1 cells
were transduced with either Grx5 shRNA clones or non-target shRNA control. Grx5
expression decreased by 70% in Grx5 shRNA 86 in comparison to control shRNA (Fig.
8A). Therefore, long term and stable knockdown of Grx5 was established in MC3T3-E1
cells.
Prompted by evidence that Grx5 deficient cells treated with H2O2 are sensitized to
apoptosis, we proceeded to evaluate the effects of TNF-α, a known inducer of cell death
[35, 36] on Grx5 shRNA cells. We found that 24 hour treatment with 20 ng/ml TNF-α
increased cytotoxicity in shRNA control cells, but cytoxicity was induced by more than
3.5-fold in Grx5 shRNA 86 treated cultures in comparison to shRNA control (Fig. 8B).
These results demonstrate that TNF-α treatment increases cell death and that loss of Grx5
sensitizes osteoblasts to TNF-α induced cell death.

Grx5 Overexpression Protects Against H2O2 Induced Apoptosis
Because Grx5 inhibition in the presence of oxidative stress resulted in heightened
sensitivity to apoptosis, we sought to determine if the overexpression of Grx5 offered
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Figure 8. Lentiviral Grx5 shRNA transduction in MC3T3-E1 cells induces cytotoxicity
in the presence of TNF-α. (A) Grx5 expression in MC3T3-E1 cells transduced with
either non-target shRNA control or Grx5 shRNA 86 as determined by real time RT-PCR.
Values are presented as mean ± SEM of 4 replicates. A=P < 0.01 vs. Non-target shRNA
control. (B) TNF-α induced cytotoxicity in non-target shRNA control or Grx5 shRNA
86. Cells were treated with either vehicle or 20 ng/ml TNF-α for twenty-four hours. The
number of dead cells was determined using MultiTox-Fluor multiplex cytotoxicity assay.
Values are expressed as % increase from corresponding BSA treated control ± SEM
(n=6). Basal values (relative fluorescent units) of non-target shRNA control (98.0 RFU ±
8.17) and Grx5 shRNA 86 (148.50 RFU ± 19.44). A=P < 0.05 vs. Non-target shRNA
control.
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protection against apoptosis. Grx5 expression was 54-fold higher in MC3T3-E1 cells
transduced with MLV-Grx5 compared to MLV β-Gal control (Fig. 9A) and Grx5 protein
was detected at 16 kDa using Flag antibody in Grx5 overexpressing cells but not β-Gal
control cells (Fig. 9B). Grx5 overexpressing and β-Gal control cells were treated with
200 µM H2O2 for 6 hours and annexin V staining was performed. As expected, Grx5
overexpression decreased the H2O2 effect as evidenced by fewer (38% less) annexin V
positive cells in comparison to control (Fig. 9C). We also evaluated the effect of Grx5
overexpression on DNA fragmentation in the presence of H2O2 and found that Grx5
overexpression decreased DNA fragmentation by 50% in comparison to β-Gal control
(Fig. 9D).

Grx5 Mediates H2O2 Induced ROS Generation
It is well known that stressors such as H2O2 can induce ROS production and that
ROS is a key mediator of apoptosis [3, 37]. To determine the molecular pathway by
which Grx5 protects against oxidative stress induced apoptosis, we determined the
amount of ROS generated in response to H2O2 treatment in Grx5 overexpressing cells
and β-Gal control cells. ROS levels increased 65% in β-Gal control cells following 2
hour treatment with 500 μM H2O2. Moreover, Grx5 overexpression decreased H2O2
induced ROS production by 57% (Fig. 10A). These data demonstrate that H2O2
treatment increases oxidative stress and that Grx5 may act by regulating the levels of
ROS in osteoblasts. Based on the finding that Grx5 overexpression decreased ROS
production, we next evaluated the effect of ROS on cardiolipin oxidation. Cardiolipin is
a mitochondrial lipid and previous studies have shown that cardiolipin oxidation is
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Figure 9. Grx5 overexpression attenuates H2O2 induced apoptosis in MC3T3-E1 cells.
(A) Grx5 expression in β-Gal control and Grx5 overexpressing cells as determined by
real time RT-PCR. Values are presented as mean ± SEM of 3 replicates. A=P < 0.01 vs.
β-Gal control. (B) Detection of Grx5 protein (16 kDa). (C) Annexin V stain of β-Gal
control and Grx5 overexpressing cells following treatment with 200 μM H2O2 for 6
hours.
Panels are representative of I) Grx5 overexpression-control, II) Grx5
overexpression-H2O2, III) β-Gal control-control, and IV) β-Gal control-H2O2. Images
were taken at 40X magnification and arrowheads indicate apoptotic cells. (D) DNA
fragmentation assay of β-Gal control and Grx5 overexpressing cells treated with 200 µM
H2O2 for six hours. Values are presented as % increase from corresponding BSA treated
control ± SEM (n=4). A=P < 0.05 vs. β-Gal control.
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Figure 10. Effect of Grx5 overexpression or inhibition on H2O2 induced ROS generation
in MC3T3-E1 cells. (A) ROS generation in β-Gal control or Grx5 overexpressing cells
treated with 500 µM H2O2 for two hours. Values are presented as % increase from
corresponding BSA treated control ± SEM (n=5). A=P < 0.05 vs. β-Gal control. (B)
Cardiolipin oxidation of Grx5 shRNA and non-target shRNA control cells following
treatment with 200 μM H2O2 and 400 μM H2O2 for 12 hours. Cardiolipin oxidation was
measured using 5 μM NAO. Values are presented as % increase from corresponding
BSA treated control ± SEM (n=6-8). Basal values (relative fluorescent units) of nontarget shRNA control (370.83 RFU ± 15.99) and Grx5 shRNA 86 (328.13 RFU ± 15.56).
A,B,C: data with different letters indicate significant difference at P < 0.001. Treatment
groups with same letters are not statistically different.
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associated with apoptosis [29, 38]. Non-target shRNA control and Grx5 shRNA cells
were treated with H2O2 for 12 hours and the effect on cardiolipin oxidation was
examined. Cardiolipin oxidation was significantly higher in Grx5 deficient cells in
comparison to non-target shRNA control cells at two different doses of H2O2 (Fig. 10B).

Grx5 Deficient Cells Exhibit Increased Caspase 3,7 Activation in the
Presence of H2O2 and TNF-α
To further investigate the molecular mechanism of Grx5 during oxidative stress
induced apoptosis, we measured caspase 3,7 activity in non-target control shRNA and
Grx5 shRNA cells since caspase dependent apoptosis is a major mechanism by which
TNF-α and H2O2 induce apoptosis [39]. Cells were treated with H2O2 and TNF-α, and
caspase activity was measured at different timepoints. Maximal caspase activity was
observed at 12 hours in the H2O2 treated cells and the caspase activity of Grx5 shRNA
cells was 3.6-fold higher in comparison to non-target shRNA cells (Fig. 11A). In cells
treated with TNF-α, maximal caspase activity was observed at 48 hours and Grx5 shRNA
cells displayed a 2.3-fold higher caspase activity than non-target control shRNA cells
(Fig. 11B). To confirm our results in MC3T3-E1 cells, caspase activity was also
evaluated in primary calvaria osteoblasts transfected with Grx5 siRNA in the presence or
absence of TNF-α for 48 hours. As shown in Figure 11C, Grx5 deficient calvaria
osteoblasts exhibited higher caspase activity in comparison to control siRNA cells with or
without TNF-α. Therefore, these data provide further evidence that Grx5 is important in
regulating osteoblast apoptosis.
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Figure 11. Grx5 deficient cells exhibit increased caspase 3,7 activity. Caspase 3,7
activity in non-target shRNA control or Grx5 shRNA following treatment with either (A)
200 μM H2O2 or (B) 20 ng/ml TNF-α. Caspase 3,7 activity was measured at the times
indicated on the graph. Values are presented as % increase from corresponding BSA
treated control ± SEM (n=5-6). A,B,C: data with different letters indicate significant
difference at P < 0.05. Treatment groups with same letters are not statistically different.
(C) Caspase 3,7 activity in primary calvaria osteoblasts transfected with control siRNA
or Grx5 siRNA following treatment with TNF-α for 48 hours. Values are presented as
mean ± SEM (n=5-6). A,B,C: data with different letters indicate significant difference at
P < 0.01. Treatment groups with same letters are not statistically different.
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Grx5 siRNA Treatment Decreases Aconitase and MnSOD Activity
Previous studies in yeast have shown that Grx5 deficiency results in impaired
biogenesis of Fe-S cluster, a critical cofactor for a large number of regulatory proteins
[22, 24, 40-42]. The activity of aconitase, an Fe-S cluster dependent enzyme, was
evaluated in Grx5 deficient cells. Aconitase activity decreased by 37% in Grx5 siRNA
treated cells (Fig. 12A). Since reduced formation of Fe-S cluster would lead to increased
level of free iron, a competitive inhibitor of MnSOD, MnSOD activity was measured in
Grx5 deficient and control osteoblasts. As shown in Figure 12B, Grx5 deficiency led to a
56% reduction in MnSOD activity. Inhibition of Grx5 did not alter aconitase or MnSOD
gene expression (data not shown). These results suggest that Grx5 is a regulator of Fe-S
cluster formation and may be involved in regulating the activities of aconitase and
MnSOD in osteoblasts.
Previous studies have demonstrated that MnCl2 increases SOD activity by
competing with free iron in the active site [43-45]. To test our proposed model that Grx5
regulates SOD activity in osteoblasts by decreasing free iron levels, non-target shRNA
control and Grx5 shRNA cells were treated with H2O2 in the presence of MnCl2, and the
effect on caspase activity was measured. We predicted that if loss of Grx5 decreased
MnSOD activity by iron replacing Mn in the active site, then addition of excess Mn
should rescue MnSOD activity. As expected, treatment with H2O2 alone increased
caspase activity in both non-target shRNA control and Grx5 shRNA cells. Furthermore,
H2O2 induced increase of caspase activity was significantly attenuated in the presence of
MnCl2 and Grx5 deficient cells were rescued from apoptosis (Fig. 12C). Therefore, these
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Figure 12. Grx5 siRNA treatment reduces the activities of aconitase and MnSOD.
MC3T3-E1 cells were transfected with either control siRNA or Grx5 siRNA for seventytwo hours. (A) Aconitase activity was measured following a six minute incubation. A=P
< 0.01 vs. control siRNA. Values are presented as mean ± SEM (n=3). (B) MnSOD
activity was detected following a twenty minute incubation. A=P < 0.001 vs. control
siRNA. Values are presented as mean ± SEM (n=3). (C) Caspase 3,7 activity in nontarget shRNA control and Grx5 shRNA cells following 12 hours treatment with 200 μM
H2O2 in the presence or absence of 200 μM MnCl2. Cells were pretreated with MnCl2 for
45 minutes prior to the addition of H2O2. Values are presented as mean ± SEM (n=6).
A,B,C,D,E: data with different letters indicate significant difference at P < 0.01.
Treatment groups with same letters are not statistically different.
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data provide evidence that Grx5 modulation of H2O2 induced apoptosis in osteoblasts is
mediated in part by SOD activity.

Discussion
Although previous studies have shown that Grx1 and Grx2 regulate apoptosis [21,
27, 30, 46], nothing was known about Grx5 function in any mammalian cell type. In this
study we have provided the first direct evidence that Grx5 is important in regulating
apoptosis in mammalian cells. Overexpression of Grx5 protected osteoblasts from
apoptosis as evidenced by fewer annexin V positive cells and decreased DNA
fragmentation. Inhibition of Grx5 augmented apoptosis as demonstrated by increased
annexin V staining, DNA fragmentation, and caspase activity. Thus, all three members
of Grx family seem to be involved in protecting cells against oxidative stress induced
apoptosis.
Increased ROS production is an important mechanism for regulating apoptosis.
For instance, the oxidation of cardiolipin, a mitochondrial lipid, results in cytochrome c
release and activation of the apoptotic cascade [29]. Cardiolipin oxidation was higher in
Grx5 deficient cells in the presence of H2O2 and this finding was consistent with
increased markers for apoptosis in Grx5 deficient cells. Therefore elaborate antioxidant
defense systems are in place to combat ROS. In MC3T3-E1 cells, we determined that
Grx5 overexpression attenuated ROS production in the presence of H2O2. The regulation
of ROS production in osteoblasts by Grx5 is in agreement with findings in yeast and
plants [23, 47], thus suggesting that the role of Grx5 in protecting against oxidative stress
is conserved across multiple species. If Grx5 is the major antioxidant defense system in
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osteoblasts, we would then expect that loss of Grx5 to cause a large increase in ROS
production and apoptosis. However, our data demonstrates that differences in ROS
production and caspase activity in Grx5 deficient cells become manifested only in the
presence of ROS inducers but not under basal conditions. One potential explanation for
this observation is that multiple defense mechanisms may operate to protect cells during
oxidative stress, since several antioxidant and enzymatic antioxidant systems are located
in different parts of the cell. When one of these components is disrupted, redundancy
enables another component to compensate. As a result, knockdown of Grx5 alone does
not produce a drastic effect due to redundancy unless cells are exposed to higher
oxidative stress.
In terms of mechanism by which Grx5 acts, studies by Rodrigues-Manzaneque et
al. [24] have shown that Grx5 deficiency in yeast impairs the biogenesis of Fe-S cluster
formation. Fe-S clusters are involved in electron transfer in oxidative phosphorylation of
respiratory chain, stabilization of protein structure, citric acid cycle, and redox regulation
[40, 48]. Since the formation of Fe-S clusters is involved in a variety of complex cellular
functions, disruption of Fe-S clusters can affect many components of the cell. Aconitase
is a Fe-S cluster enzyme which plays an important role in the Krebs cycle. Inhibition of
aconitase can have adverse affects on the Krebs cycle leading to impairment in energy
production. Since Grx5 deficiency in yeast resulted in decreased aconitase activity, we
examined the activity in osteoblasts and found that aconitase activity decreased in Grx5
siRNA transfected cells. This is in line with other studies that also reported decreased
aconitase activity in the absence of Grx5 [25, 42].
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Inactivation of Fe-S clusters results in the release of free iron and an increase in
free iron can be harmful to cells. It is well known that ROS is a normal byproduct of
respiration, in particular H2O2. Free Fe2+ can react with H2O2 to produce hydroxyl radical
which is known as the Fenton reaction. The hydroxyl radical is highly reactive and can
cause extensive oxidative damage to protein, lipids, and DNA. We hypothesized that
inhibition of Grx5 would lead to decreased formation of Fe-S clusters and therefore
intracellular levels of iron would be increased. Although we did not directly measure
levels of iron in this study, it is known that increased levels of free iron inhibits MnSOD
activity. Accordingly we observed that MnSOD activity was reduced in Grx5 siRNA
cells. This is in agreement with the published results from Yang et al. [44] who observed
that Δgrx5 mutants (Saccharomyces cerevisiae) accumulated iron and exhibited
decreased SOD activity and by Camaschella et al., [42] who noted that Grx5 deficient
patients exhibited iron overload and anemia. MnSOD is a key mitochondrial enzyme in
scavenging ROS. Mice expressing mutant SOD exhibited high ROS production and
subsequent damage to mitochondria lipid and proteins [49]. MnSOD knockout mice
exhibit increased lipid peroxidation [50]. Reduced activity of MnSOD would further
exacerbate ROS production and apoptosis. We further tested this notion by treating cells
simultaneously with MnCl2 and H2O2 to determine if Grx5 deficient cells could be
rescued from apoptosis. Consequently, MnCl2 (an inducer of SOD activity) was able to
rescue cells from apoptosis. Consistent with these results is the observation that Grx5
inhibition reduces MnSOD activity which cripples antioxidant defenses. Therefore it is
important to maintain the integrity of Fe-S clusters because Grx5 acts to sequester free
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iron, thus alleviating stress and decreasing the opportunity for Fe2+ to react with H2O2
and form highly reactive superoxide radical.
In conclusion, we have demonstrated that Grx5 protects osteoblasts from
oxidative stress induced apoptosis. The protective ability of Grx5 on apoptosis appears to
be due to its ability to regulate ROS production, cardiolipin oxidation, caspase activity,
Fe-S cluster formation, and MnSOD activity (Fig 13). Therefore, our findings support
the contention that Grx5 is an important mediator of osteoblast cell functions which acts
as a scavenger of ROS and thereby attenuates its harmful effects by protecting against
oxidative stress induced apoptosis. Our future studies will examine the relative
contribution of Grx5 deficiency in the pathogenesis of bone loss under conditions of
oxidative stress.

Acknowledgments
The authors would like to thank Thien Nguyen, Catrina Alarcon, Qianwei Tan,
and Joe Rung-Aroon for their expert technical assistance. This work was supported by
NIH grants R01AR31062, 1F31AR056204, and 5R25GM060507 (Loma Linda
University-NIH Initiative for Minority Students Program). All work was performed with
the facilities provided by the Department of Veterans Affairs.

94

Figure 13. Proposed model for mechanism of Grx5 action. Grx5 protects osteoblasts
against oxidative stress induced apoptosis by scavenging ROS and decreasing DNA
fragmentation. Since Grx5 plays a role in Fe-S cluster formation, it regulates the activity
of MnSOD (ROS scavenger).
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Abstract
Although thyroid hormone (TH) is known to exert important effects on the
skeleton, the nuclear factors constituting the TH receptor co-activator complex and the
molecular pathways by which TH mediates its effects on target gene expression in
osteoblasts remain poorly understood. A recent study demonstrated that the actions of
TH on myoblast differentiation are dependent on diabetes and obesity related protein
(DOR). However, the role of DOR in osteoblast differentiation is unknown. We found
DOR expression increased during in vitro differentiation of bone marrow stromal cells
into osteoblasts and also in MC3T3-E1 cells treated with TH. However, DOR expression
decreased during cellular proliferation. To determine if DOR acts as a modulator of TH
action during osteoblast differentiation, we examined whether overexpression or
knockdown of DOR in MC3T3-E1 cells affects the ability of TH to induce osteoblast
differentiation by evaluating alkaline phosphatase (ALP) activity. ALP activity was
markedly increased in DOR overexpressing cells treated with TH. In contrast, loss of
DOR dramatically reduced TH stimulation of ALP activity in MC3T3-E1 cells and
primary calvaria osteoblasts transduced with lentiviral DOR shRNA. Consistent with
reduced ALP activity, mRNA levels of osteocalcin, ALP, and Runx2 were significantly
decreased in DOR shRNA cells. In addition, a common single nucleotide polymorphism
(SNP), DOR1 found on the promoter of human DOR gene, associated with circulating
osteocalcin levels in non-diabetic subjects. Based on these data, we conclude that DOR
plays an important role in TH-mediated osteoblast differentiation, and a DOR SNP
associates with plasma osteocalcin in men.
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Introduction
Osteoporosis poses a major public health threat with six million fractures
occurring annually in the United States (8). Two defining features of osteoporosis
include low bone mineral density and microarchitectural deterioration. Individuals with
osteoporosis exhibit increased bone fragility and are therefore at an increased risk for
osteoporotic fracture. Therefore, studies that focus on the mechanisms regulating bone
accretion and peak bone mass during active growth periods are of considerable
importance in the prevention and treatment of osteoporosis. Several studies have
implicated a role for thyroid hormone (TH) in skeletal development and maturation. For
example, TH deficiency results in delayed bone age, disruption of epiphyseal growth
plate formation, and short stature (4, 16). TH excess causes advanced bone age and
premature fusion of growth plates and cranial sutures (35). Although there is
considerable evidence regarding the importance of TH in skeletal development, the
molecular mechanisms of TH action in bone are poorly understood.
It is known that TH regulates gene expression by interacting with a family of
nuclear receptors known as thyroid hormone receptors (TR) that bind to TH response
elements (TRE) as either a homodimer (TR/TR) or as a heterodimer (TR/RXR) in the
promoters of T3 target genes to facilitate activation of gene transcription (3). In the
absence of TH ligand, corepressors such as Nuclear receptor corepressor protein (NCoR)
and the silencing mediator of retinoid and thyroid hormone receptors (SMRT) are
recruited to TR and basal transcription is repressed (2, 35). However, in the presence of
TH, ligand bound TR undergoes a conformational change thereby releasing the
corepressors and recruiting coactivators such as CBP/p300, pCAF, and SRC-1 to the
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transcriptional complex to facilitate gene transcription (21, 47). Although TH action is
mediated in part by nuclear receptors, chromatin remodeling, and known corepressors
and coactivators, it remains unknown whether additional nuclear cofactors are recruited
to the TH receptor coactivator complex during osteoblast differentiation and bone
formation. Therefore, the identification of potential signaling molecules involved in
regulating TH action is essential for elucidating molecular pathways.
Recently, Baumgartner et al. (5) found that diabetes and obesity related protein
(DOR) also known as tumor/transformation related protein p53 inducible protein 2
(Tp53inp2), is a key determinant of myoblast differentiation and modulates TH function
in muscle cells. Based on the important role of DOR in mediating TH action and
differentiation in myoblasts, we hypothesized DOR is differentially expressed during
osteoblast differentiation and modulates TH action in osteoblasts. To address this
hypothesis, we evaluated the expression of DOR in response to known inducers of
osteoblast differentiation and also examined whether DOR gain of function or loss of
function alters TH action on osteoblast differentiation by evaluating the effect on alkaline
phosphatase (ALP) activity. The gene expression of osteoblast specific markers was also
assessed in DOR deficient cells stimulated by TH. This study provides experimental
evidence that DOR acts as a stimulatory mediator of TH effects in osteoblasts and may be
involved in regulating osteoblast differentiation. In addition, we provide preliminary
evidence that a common DOR polymorphism associates with plasma osteocalcin levels.
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Material and Methods
Reagents
3,3′,5-Triiodo-L-thyronine (T3), L-Thyroxine (T4), cycloheximide, ascorbic acid
(AA), and β-glycerophosphate were purchased from Sigma Aldrich (St. Louis, MO).
Fibroblast growth factor (FGF) was obtained from R&D systems (Minneapolis, MN) and
calf serum (CS) was from Atlanta Biologicals Inc (Lawrenceville, GA). Lentiviral
expression vectors of pCMVDR8.7, pMD2G, PLMVTHMScr (scramble control),
PLMVTHMSi6 (DOR shRNA) and rabbit polyclonal antibody against DOR were
produced as described (5). Antibodies to β–actin, β–tubulin, and histone H3 were
purchased from Sigma Aldrich (St. Louis, MO).

Cell Culture
Bone marrow stromal cells (BMSCs) were isolated from the femur and tibia of
mice and plated at 20 X 106 cells/90-mm petri dish. To induce differentiation into
osteoblasts, BMSCs were treated with AA as described (14). Primary osteoblasts were
isolated from the calvaria of 4-day old C57BL/6J mice as previously reported (30). All
mice were housed at the Jerry L. Pettis Memorial VA Medical Center Veterinary Medical
Unit (Loma Linda, CA) under standard approved laboratory conditions. Animal use
protocols were approved by the Institutional Animal Care and Use Committee of the
Jerry L. Pettis Memorial VA Medical Center. MC3T3-E1 mouse pre-osteoblasts from
American Type Culture Collection (Manassas, VA) were grown in standard α-MEM
growth media containing 10% calf serum (CS), penicillin (100 units/ml), and
streptomycin (100 µg/ml) (1% PS). Twenty-four hours prior to factor treatment, cells
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were incubated in the presence of serum free media consisting of α-MEM + 1% PS. Cell
culture treatments with appropriate factors (T3, T4, cycloheximide, FGF, and CS) were
made in α-MEM + 0.1% bovine serum albumin (BSA) + 1% PS. For differentiation
experiments, the media was also supplemented with AA and β-glycerophosphate.

RNA Isolation and Gene Expression Analysis
RNA was extracted using Trizol and chloroform, and isolation was completed
using RNeasy mini kit (Qiagen, Valencia, CA). Reverse transcription was accomplished
using Superscript (Invitrogen, Carlsbad, CA) and the cDNA was used for real-time RTPCR. Real-time RT-PCR was performed to assess the gene expression of osteocalcin,
alkaline phosphatase (ALP), and Runx2 as previously described (13). Gene specific
primers were used to amplify DOR (forward: 5′-CCAGCCTTTTCTTCAACACC-3′,
reverse: 5′ GCCCCTCTGCAGTAAAACAG-3′). The housekeeping gene peptidylprolyl
isomerase A (PPIA) was used as an internal control in the PCR reaction and the fold
change compared to control was calculated according to the formula 2-ΔΔCt.

Cloning of DOR
Full length coding sequence of DOR was amplified by PCR with high fidelity
enzyme Pfx50 (Invitrogen, Carlsbad, CA) using Mus Musculus bone cDNA as a template
as previously described (26). The primer sequences are DOR forward: 5′-GGGTCGA
CGCCACCATGCATCATCACCATCACCATTTCCAGCGCTTCACCAGCCTTTTC-3′
and DOR reverse: 5′-CGCGGATCCTCAGTAGTTGAACTGGCGCTGGCACGG-3′.
The PCR product was purified with GeneClean Spin kit (Qbiogene, Carlsbad, CA) and
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digested with Bam HI and Sal I (New England Biolabs, Ipswich, MA). The digested
product was purified and then cloned into corresponding restriction sites of pY
expression vector. DOR coding sequence was confirmed by DNA sequencing at Arizona
State University (Tempe, AZ).

Murine Leukemia Virus-based Viral Vectors (MLV-based vector) and
Lentivirus-Based Vectors (HIV-based vectors) Production and
Transduction
To generate MLV-based vectors, in a 10 cm plate, 293T cells were transduced
with a mixture of 20 μg of MLV-based expression vector (β-gal or DOR), 10 μg of MLVGP expression vector, and 1 μg of VSV-G expression vector by CaPO4 precipitation.
The conditioned medium containing the viral vectors was collected 48 hours after the
transduction (38). To generate lentiviral vectors, 293T cells were transduced with a
mixture of 10 µg of lentiviral expression vector (scramble control or DOR shRNA), 7 µg
of HIV-GP expression vector, pCMVD8.7, and 1 µg of VSV-G expression vector (5).
MC3T3-E1 cells or primary murine calvaria osteoblasts were transduced as previously
described (26, 38).

Alkaline Phosphatase (ALP) Activity Assay
ALP assay was performed to determine osteoblast differentiation. Cells were
seeded at 8,000 cells/well in a 96-well plate containing α-MEM + 10% CS + 1% PS. The
following day the media was changed to serum free α-MEM for 24 hours. The cells were
incubated with T3 (0.1 ng/ml, 1 ng/ml, 3 ng/ml, and 10 ng/ml) or T4 (10 ng/ml, 100
ng/ml, and 1000 ng/ml) for 72 hours. All treatments contained AA (100 µg/ml) and β-
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glycerophosphate (10 mM). Cell were then rinsed with PBS and lysed with 0.1% Triton
X-100 in 250 mM NaHCO3. Protein concentration was determined by BCA method
(Thermo Fisher Scientific Inc., Rockford, IL) and ALP activity was assayed as previously
described (15).

Western Blot
Cytoplasmic and nuclear extracts of MC3T3-E1 cells were prepared as previously
described (46). Equivalent amounts of protein were resolved on an SDS polyacrylamide
gel (12%) and transferred to a PVDF membrane (Millipore, Billerica, MA). Membranes
were blocked with 10% non-fat dry milk in Tris buffered saline with 0.1 % Tween-20
overnight with rotation at 4oC. The following day, the membranes were probed with
specific antibody to DOR (1:1000), β-actin (1:10,000), β-tubulin (1:10,000), or antihistone H3 (1:10,000) for 1 hour at room temperature. The membranes were washed and
incubated with appropriate horseradish peroxidase conjugated antibody (1:10,000)
(Sigma-Aldrich, St. Louis, MO). Detection was performed with Super Signal West Pico
Chemiluminescent Substrate (Thermo Fisher Scientific Inc., Rockford, IL).

Subjects
For the analysis of polymorphisms, 306 Spanish non-diabetic men from the
general population were recruited at Hospital Trueta (Girona, Spain) and subjected to
phenotyping. All subjects had fasting plasma glucose < 7.0 mM and two-hour post-load
plasma glucose < 11.1 mM in a 75g oral glucose tolerance test. Inclusion criteria were 1)
BMI < 40 kg/m2, 2) absence of systemic disease, and 3) absence of infection within the
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previous month. None of the control subjects were under medication or had evidence of
metabolic disease other than obesity. All studies were approved by the ethics committees
of the participating centers. All subjects provided written informed consent prior to
participation.

Genotyping
DOR1 (rs2378256) was genotyped in the samples by restriction digestion with Dde1
(Invitrogen) following PCR amplification with 5’-AGGAGCCGGTAGGAGGGA
GTGGAG-3’ (forward) and 5’- CGCCGGCGGAGACAGACAAAG-3’ (reverse). All
analyses were performed by ANOVA using appropriately-transformed variables within SPSS
for Windows v11.5.

Statistical Analysis
Data are expressed as mean ± SEM (standard error of the mean) and were
analyzed using Student’s T-test or ANOVA (one-way or two-way) (Statistica 6, Tulsa,
OK) as appropriate. Post-hoc analysis was performed using Duncan's test. Values were
considered statistically significant when P< 0.05.

Results
DOR Expression Increases During Osteoblast Differentiation
Treatment with FGF and CS that are known to promote proliferation and inhibit
differentiation caused a drastic 75% and 90% reduction in DOR expression in MC3T3-E1
osteoblasts respectively (Fig. 14A). To determine if DOR expression is regulated during
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Figure 14. DOR expression during osteoblast proliferation and differentiation. A, DOR
expression decreases during osteoblast proliferation. MC3T3-E1 cells were treated with
or without FGF (1 ng/ml) or 10% calf serum (CS) for 24 hours. DOR expression was
determined by real-time RT-PCR analysis. DOR expression in vehicle treated control
(ΔCt =9.74 ± 0.07). Values are presented as % of vehicle treated control ± SEM (n=3).
A= P < 0.01 vs. vehicle. B, DOR expression increases during BMSC differentiation as
measured by real time RT-PCR. BMSCs were cultured with α-MEM containing 10%
calf serum in the presence or absence of AA (100 µg/mL) and β-glycerophosphate (10
mM) for 24 days to induce osteoblast differentiation. ALP gene expression was also
assessed to confirm BMSC differentiation. DOR expression in undifferentiated BMSCs
(ΔCt =11.24 ± 0.27). Values are presented as fold change relative to day 0 ± SEM
(n=6). A= P < 0.001 vs. undifferentiated BMSCs. C, TH stimulates DOR gene
expression. MC3T3-E1 cells were incubated in the presence or absence of T3 (10 ng/ml)
or T4 (100 ng/ml) for 6 hours or 24 hours. DOR expression was determined by real-time
RT-PCR analysis. Values are presented as fold change from corresponding vehicle
control ± SEM (n=3-5). A,B,C: data with different letters indicate significant difference
at P < 0.05. Treatment groups with same letters are not statistically different. D,E TH
induction of DOR is acute and is minimally affected by de novo protein synthesis.
MC3T3-E1 cells were pretreated with cycloheximide (1 µM) for 1 hour prior to the
addition of T3 (10 ng/ml) or T4 (100 ng/ml) for 6 hours (D) or 24 hours (E). DOR
expression was determined by real-time RT-PCR analysis. DOR expression was 60%
lower in cycloheximide vehicle group compared to vehicle alone at 24 hours. DOR
expression in vehicle treated control (ΔCt=9.39 ± 0.11). Values are presented as fold
change from corresponding vehicle control ± SEM (n=3-5). A= P < 0.05 vs. vehicle
control and B=P < 0.05 vs. T3 alone.
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osteoblast differentiation, as in the case of myoblast differentiation, we examined the
effects of agents known to modulate osteoblast differentiation on DOR expression. DOR
expression increased by 3.8-fold during in vitro differentiation of BMSCs into osteoblasts
(Fig. 14B). Differentiation was confirmed by increased ALP gene expression.
To examine if TH regulates DOR expression and whether the effect is acute, DOR
mRNA expression levels were measured at 6 hours and 24 hours. Treatment with T3 or
T4 increased DOR expression at 6 hours (2.4-fold and 2.6-fold) and 24 hours (4.6-fold
and 3.8-fold) respectively (Fig 14C). To examine if TH induction occurs in the absence
of de novo protein synthesis, MC3T3-E1 cells were treated with T3 or T4 in the presence
of cycloheximide (1 µM inhibits >80% protein synthesis) for 6 hours or 24 hours.
Pretreatment with cycloheximide did not affect TH induction of DOR expression at 6 hrs
(Fig. 14D). DOR expression was also induced at 24 hours by T3 and T4 in the presence
of cycloheximide, however it was slightly reduced suggesting a minor effect on protein
synthesis (Fig. 14E).

DOR Modulates TH-Induced Osteoblast Differentiation
To determine the consequence of increased DOR expression during osteoblast
differentiation in modulating TH biological effects, we overexpressed DOR or β-Gal in
MC3T3-E1 cells and examined TH effects on ALP activity. Figure 15A shows increased
DOR expression as determined by western blot in MC3T3-E1 cells transduced with a
retroviral vector expressing DOR compared to cells expressing β-Gal. As expected, TH
increased ALP activity compared to vehicle control in both β-Gal and DOR

113

overexpressing cells. However, DOR overexpressing cells exhibited 2-5-fold higher ALP
activity than β-Gal in response to T3 (Fig. 15B).
We next evaluated the consequence of DOR inhibition on TH-induced osteoblast
differentiation, by utilizing lentiviral particles expressing shRNA against DOR. DOR
expression decreased by 75% at the mRNA level and 70% at the protein level (Fig. 16A
and 16B) in cells expressing DOR shRNA compared to scramble control. Basal ALP
activity was reduced by 34% in DOR shRNA cells (Fig. 16C and 16D). T3 treatment
increased ALP activity in scramble control MC3T3-E1 cells by 2-fold. However, ALP
activity was markedly reduced by 96% at 10 ng/ml of T3 in DOR shRNA cells compared
to control shRNA cells (Fig. 16C). Because we found that T3, the biologically active
form of TH, increased ALP activity, we next examined the effect of pro-hormone, T4, in
DOR shRNA cells. T4 treatment increased ALP activity in MC3T3-E1 cells in a dose
dependent manner, but at a much higher dose compared to T3. However, DOR shRNA
cells exhibited 95% less ALP activity than scramble control at 100 ng/ml of T4 (Fig.
16D).
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Figure 15. DOR overexpression exacerbates T3-induced increase in ALP activity. A,
Expression of DOR in MC3T3-E1 cells transduced with MLV-β-Gal or MLV-DOR as
determined by western blot using whole cell lysates. B, MLV-β-Gal and MLV-DOR
overexpressing MC3T3-E1 cells were treated with T3 (0.1 ng/ml, 1 ng/ml, 3 ng/ml, and
10 ng/ml) and ALP activity was determined 72 hours after treatment. Values are
presented as % of vehicle treated MLV-β-Gal ± SEM (n=5-8). Basal ALP activity values
of MLV-β-Gal (1.48 mU/mg protein ± 0.11) and DOR overexpressing cells (2.52
mU/mg protein ± 0.18). Data were analyzed by two-way ANOVA and a significant
interaction was observed between gene and treatment. A= P < 0.05 vs. vehicle treated
control and B= P < 0.05 vs. MLV-β-Gal at corresponding dose.
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Figure 16. Inhibition of DOR reduces TH stimulation of ALP activity in MC3T3-E1
cells. A, Expression of DOR in MC3T3-E1 cells transduced with scramble control
shRNA or DOR shRNA as determined by real time RT-PCR analysis. Values are
presented as mean ± SEM (n=4). A= P < 0.01 vs. scramble control. B, DOR protein
level as determined by western blot using whole cell lysates. Scramble control and DOR
shRNA MC3T3-E1 cells were treated with (C) T3 (0.1 ng/ml, 1 ng/ml, 3 ng/ml, and 10
ng/ml) or (D) T4 (10 ng/ml, 100 ng/ml, and 1000 ng/ml), and ALP activity was
determined 72 hours after treatment. Values are presented as % of vehicle treated
scramble control ± SEM (n=6-8). Basal ALP activity values of scramble control (0.35
mU/mg protein ± 0.01) and DOR shRNA (0.23 mU/mg protein ± 0.01). Data were
analyzed by two-way ANOVA and a significant interaction was observed between gene
and treatment. A= P < 0.05 vs. vehicle treated control and B= P < 0.05 vs. scramble
control at corresponding dose.
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To confirm our results in MC3T3-E1 cells, ALP activity was also evaluated in
primary mouse calvaria osteoblasts transduced with DOR shRNA. The transduction
efficiency was determined by examining GFP fluorescence since scramble and DOR
lentiviral constructs also express GFP reporter gene. As shown in figure 17A, the
transduction efficiency was greater than 90% in primary calvaria osteoblasts transduced
with scramble control shRNA and DOR shRNA. These results were also confirmed by
sorting GFP-positive cells using FACS analysis (data not shown). Basal ALP activity
was dramatically suppressed by 50% in DOR shRNA cells. As expected, ALP activity
increased in a dose dependent manner in scramble control shRNA osteoblasts with a
maximal increase of 71% at 10 ng/ml of T3. In contrast, treatment with T3 or T4 failed
to elicit a substantial increase in ALP activity in DOR shRNA cells (Fig. 17B).
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Figure 17. TH-induced increase in ALP activity is severely reduced in primary calvaria
osteoblasts transduced with DOR shRNA. A, Transduction efficiency of primary
calvaria osteoblasts transduced with scramble control or DOR shRNA. Panels are
representative of I) scramble control-bright field II) scramble control-GFP fluorescence
III) DOR shRNA-bright field and IV) DOR shRNA-GFP fluorescence. Images were
taken at 40X magnification using an Olympus IX70. B, Scramble control and DOR
shRNA primary calvaria osteoblasts were treated with T3 (0.1 ng/ml, 1 ng/ml, and 10
ng/ml) or T4 (100 ng/ml), and ALP activity was determined 72 hours after treatment.
Values are presented as % of vehicle treated scramble control ± SEM (n=6). Basal ALP
activity values of scramble control (43.1 mU/mg protein ± 0.67) and DOR shRNA (21.2
mU/mg protein ± 1.5). Data were analyzed by two-way ANOVA and a significant
interaction was observed between gene and treatment. A= P < 0.05 vs. vehicle treated
control and B= P < 0.001 vs. scramble control at corresponding dose.
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Inhibition of DOR Impairs TH-Induced Expression of Osteogenic
Markers
Based on our finding that DOR shRNA cells exhibited reduced ALP activity, we
next examined the gene expression of osteoblast specific differentiation markers
stimulated by T4 in scramble control and DOR shRNA MC3T3-E1 cells. Expression of
osteocalcin, an osteoblast differentiation marker protein, increased 16-fold. However,
osteocalcin expression decreased by 60% in DOR shRNA cells compared to scramble
control shRNA (Fig. 18A). Expression of ALP, another osteoblast differentiation marker
protein, increased 3-fold in scramble control but T4 failed to stimulate ALP gene
expression in DOR shRNA cells (Fig. 18B). We also evaluated the effect on Runx2, a
major transcription factor involved in osteoblast differentiation. T4 treatment increased
Runx2 gene expression nearly 2-fold in scramble control but failed to stimulate Runx2
gene expression in DOR shRNA cells (Fig. 18C). Basal gene expression was similar
between untreated scramble control and untreated DOR shRNA cells. Based on our
findings we would expect DOR to be a nuclear factor. Cell fractionation of the
cytoplasm and nucleus from MC3T3-E1 cells revealed DOR protein expression was only
present in the nuclear extract in both vehicle and TH treated cultures (Fig. 18D).
Furthermore, acute treatment with T3 or T4 did not alter nuclear localization of DOR, a
finding consistent with an earlier report (B. Baumgartner et al., 2007).
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Figure 18. DOR deficiency decreases the gene expression of osteoblast specific markers.
Scramble control and DOR shRNA MC3T3-E1 cells were incubated in the presence or
absence of T4 (100 ng/ml) for 24 hours (osteocalcin) or 72 hours (ALP and Runx2). All
treatments contained AA (100 µg/mL) and β-glycerophosphate (10 mM). Expression of
(A) osteocalcin, (B) ALP, and (C) Runx2 was determined by real time RT-PCR. Values
are presented as fold change ± SEM (n=4). A=P < 0.05 vs. vehicle control and B= P <
0.05 vs. scramble control. D, DOR is localized to the nucleus. DOR expression was
evaluated by western blot in MC3T3-E1 cells incubated in the presence or absence of T3
(10 ng/ml) or T4 (100 ng/ml) for 1 hour. Cell lysates from cytosolic and nuclear
fractions were analyzed and histone H3, β-actin, and β-tubulin served as internal controls.
Data are representative of four independent experiments (n=4).
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A SNP in DOR Promoter Associates with Circulating Osteocalcin in
Healthy Subjects
The human DOR gene (current HUGO ID: c20orf110, LocusLink ID 58476)
contains 5 exons, though alternative splicing leads to at least 5 transcript variants. In the
longest transcript (Ensembl ID OTTHUMT00020002515), the protein coding region
starts at exon 3. DOR maps to chromosome 20q11.22. Resequencing of exonic
sequence in 20 non-diabetic Spanish subjects, together with inspection of CELERA and
public databases failed to identify any common variants within DOR coding sequence but
did reveal a common variant (DOR1, rs2378256) located 23 bp upstream of transcription
start site (predicted, and as confirmed by 5’RACE) (data not shown). Based on these
data, we looked for possible genotype-phenotype correlations in a cohort of healthy
individuals. Of 306 non-diabetic middle-aged Spanish men, those with the CC genotype
(n=55) showed lower osteocalcin levels in plasma compared to G carriers (Figure 19).
CC and G carrier subjects did not show any differences in age, body mass index, and
fasting glycemia (Table 3).
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Figure 19. Ninety-five percent confidence interval (95% CI) of circulating osteocalcin
levels according to DOR / Tp53inp2 gene polymorphism. Osteocalcin levels in G/G vs.
C/C carriers were significantly different.
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Table 3:Clinical characteristics of subjects
Clinical characteristics
G / (-) carriers
251

C / C subjects
55

p
-

Age (years)

49.1 12.4

50.6 14.6

0.4

BMI (Kg/m2)

31.2

8.1

30.6

7.7

0.6

100.9

22.9

102.7 20.4

0.6

6.13

0.01

n

Fasting Glucose (mg/dl)
Osteocalcin(ng/ml)

7.31 3.7
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2.8

Discussion
In this study, we provide the first experimental evidence that DOR is involved in
mediating the effects of TH on osteoblast differentiation. Specifically, DOR
overexpression potentiated the effect of TH on ALP activity. In contrast, inhibition of
DOR attenuated the stimulatory effect of TH on ALP activity and also reduced THinduced gene expression of osteoblast specific markers. DOR expression was
upregulated during osteoblast differentiation, and DOR was differentially regulated by
TH. We also demonstrate that DOR was localized to the nucleus. In addition, a SNP,
DOR1, found on the promoter of the human DOR gene associated with plasma
osteocalcin levels. Therefore, our data support an important role for DOR in mediating
TH-induced osteoblast differentiation and associating with plasma osteocalcin levels in
men.
To determine a role for DOR in osteoblasts, we first evaluated expression levels
of DOR in response to agents that regulate proliferation and/or differentiation of
osteoblasts. We found that DOR expression increased robustly during in vitro
differentiation of bone marrow stromal cells into osteoblasts and also in the presence of
T3 and T4, known inducers of osteoblast differentiation. This finding is consistent with a
report by Baumgartner et al. (5) who described increased DOR expression during
myoblast differentiation and by Malik et al. (28) who found T3 treatment of rat
hepatocytes increased DOR expression. In contrast, DOR expression was significantly
downregulated in the presence of FGF and CS, agents which stimulate proliferation.
During the switch to cellular proliferation, the expression and/or activity of signaling
molecules involved in cellular differentiation decreases. While proliferation specific
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genes such as c-fos/c-jun and histone are upregulated during proliferation, the expression
of these genes is downregulated during the transition from cell cycle growth to
differentiation. Others have demonstrated the inverse relationship that exists between the
expression of proliferation and differentiation specific genes (22, 27, 41). T3 inhibits cell
proliferation by downregulating histone and cell-cycle specific gene expression, but it
increases the expression of ALP and osteocalcin markers of differentiated osteoblasts (12,
43, 45). Therefore, DOR downregulation observed during cell proliferation is consistent
for a role of this protein in osteoblast differentiation.
In regards to the potential mechanisms regulating DOR expression during
differentiation in osteoblasts, it is possible that the increased expression of DOR may be
mediated by exogenously added ascorbic acid and/or local growth factors produced by
differentiating osteoblasts. It is well established that BMP-2 and IGF-I increase during
osteoblast differentiation. Therefore, it is feasible that the endogenous production of
these factors may act as local growth factors in mediating DOR expression. In this
regard, we found that ascorbic acid and/or BMP-2 increased the expression of DOR in
C3H10T1/2 cells (data not shown). TH effects on DOR expression may be direct or
indirect via growth factors. Using UMR-106 rat osteoblastic cells and fetal rat limb bone
cultures, Lakatos et al. (24) observed that T3 and T4 increased the secretion of IGF-1 into
the conditioned medium. T3 and T4 treatment increases IGF-I expression, and IGF-I is
important for mediating the anabolic effects of TH (18, 44). TH also influences the
IGF/IGFBP system in vivo in hyperthyroid patients (25).
It is also possible that T3 and T4 directly regulate DOR expression. DOR
expression was acutely regulated by T3 and T4 at 6 hours suggesting it may be an early
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response gene. Moreover, we found that TH effect on DOR is independent of new
protein synthesis. These data are consistent with a recent study by Malik et al. (28) who
observed early gene expression of DOR in hepatocytes stimulated with T3. Sequence
analyses of DOR promoter revealed 4 putative sites containing TH response element
(TRE) consensus sequence (AGGTCA) located within the promoter region 5kb upstream
of the transcription start site. Further studies are needed to determine if TH regulates
transcription of DOR gene via its TRE.
If DOR is involved in mediating TH biological effects, then modulating DOR
expression should influence TH effects on osteoblast differentiation. It is well
established that TH plays a role in stimulating osteoblast differentiation. Accordingly, in
our study ALP activity significantly increased following treatment with T3 and T4.
These findings are consistent with previous studies in MC3T3-E1, ROS 17/2.8, and
primary calvarial osteoblasts that have demonstrated stimulation of ALP activity in the
presence of T3 and T4 (1, 20, 39, 45). The overexpression of DOR enhanced the effects
of TH on ALP activity. In contrast, ALP activity was substantially decreased in DOR
shRNA MC3T3E-1 cells and primary osteoblasts stimulated with TH. Therefore, these
data demonstrate that DOR plays an important role in mediating TH signaling in
osteoblasts during differentiation, and these findings are consistent with the role of DOR
in myoblasts (5). However, ALP activity was not completely abolished in DOR deficient
cells. This observation raises the possibility that DOR may not be the sole mediator of
TH signaling in osteoblasts and suggests that other factors are involved. Recently,
several studies have described non-genomic effects of T3 and T4 (1, 7, 9, 19, 40).
Therefore, additional mechanisms regulating TH action besides the genomic pathway
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may potentially be involved. However, in our experiments it seems unlikely that DOR is
a cytoplasmic factor which nongenomically modulates TH signaling since DOR was not
found in the cytoplasm of MC3T3-E1 cells. Instead, our data demonstrated that DOR
was predominantly detected in the nuclear fraction suggesting that it may act via a
genomic mechanism. Further studies are needed to examine this possibility.
It is well known that the biological actions of TH are mediated via TH receptor,
namely TRα and TRβ. Although both TR isoforms are expressed in bone, the major
isoform in bone is TRα (3). The receptor binds as either a homodimer (TR/TR) or as a
heterodimer (TR/RXR) at the TRE in promoter of TH target genes to modulate gene
transcription. However, it remains to be determined whether DOR interacts with the
homodimer or heterodimer in osteoblasts.
We found DOR loss of function in MC3T3-E1 cells and primary calvaria
osteoblasts decreased basal ALP activity in the absence of exogenously added TH.
Osteoblasts produce a number of growth factors including BMP-2 and IGF-I during
differentiation. It remains to be determined if the effect is due to DOR mediating the
effects of other factors besides TH. This observation was evident in primary osteoblasts
derived from calvaria of 4-day old C57BL/6J mice and in the pre-osteoblast cell line
MC3T3-E1. The loss of DOR alone decreased myoblast gene expression in the absence
of T3 (5) while we did not observe an effect on osteoblast gene expression in the present
study. Potential explanations for these differences can be due to the cell type, anatomical
origin, passage number, and differentiation status (11, 17).
Consistent with our findings, other studies have shown that T4 regulates gene
expression of ALP and osteocalcin in osteoblasts (23, 42). Moreover, the suppression of
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DOR impaired T4 induced expression of osteoblast specific markers. These findings
suggest that loss of DOR reduces the osteogenic effect of TH in bone. These data are in
agreement with a previous report showing that loss of DOR decreased TH-induced
myoblast gene expression (5). Asai et al. (1) found that Runx2 expression was
unchanged after stimulation with T3. In contrast, we observed a modest increase in
Runx2 expression following treatment with T4. Potential explanations for these
differences could be due to the length of treatment with TH (36 hours vs. 72 hours)
and/or the form of TH used in the experiments (T3 vs. T4). In our study, treatment with
T3 and T4 induced DOR gene expression and increased ALP activity in both MC3T3-E1
cells and primary calvarial osteoblasts. T4 was used at a much higher dose since T3 is
the biologically active form of TH and because TR has a higher affinity for T3 ligand
(36). Consistent with a previous report (44), we did not observe a significant difference
in the responsiveness of the cells between T4 (prohormone) and T3 (active form).
Presently this is the first published study to demonstrate that a DOR SNP in
humans associates with plasma levels of the bone formation marker osteocalcin. In
agreement with this finding in humans, our in vitro studies demonstrated that inhibition
of DOR decreased gene expression of osteocalcin and other bone formation markers. It
is possible that DOR gene expression plays a significant role in modulating the
expression of bone formation markers. This finding in humans further strengthens our
contention that DOR is an important mediator of osteoblast functions and differentiation.
Analysis of putative transcription factor binding sites using Transcription Element Search
Software (37) revealed a potential binding site for RXR and T3Rα in the region
containing the DOR1 SNP. The binding site for RXR and T3Rα was conserved across
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the promoters of human, mouse, and rat. Further studies are needed to determine the
functional significance of the polymorphism in mediating changes in DOR transcription
and expression levels.
Besides its role in modulating TH action and cellular differentiation, other
biological functions of DOR have been described in mammalian and drosophila systems.
Bennetts et al. (6) demonstrated that DOR is involved in mouse embryonic development.
It is expressed in the developing heart and nervous system as well as during limb and
craniofacial development. DOR also plays a role in mammalian cell autophagy by
recruiting specific proteins required for autophagosome development (29, 33, 34).
Alterations in the processing or expression of DOR may also lead to tumorigenesis.
Alternative splicing of DOR by heterogenous ribonucleoprotein A2 promotes ovarian
cancer cell migration and invasion (31). A 700-kb deletion of chromosome 20
encompassing DOR was detected in hairy cell leukemia patients (32). In Drosophila
melanogaster, DOR acts as a coactivator for ecdysone receptor (10). Collectively, these
findings provide evidence that DOR has broad effects beyond modulation of TH action
and is significant in various biological processes.
In conclusion, we have demonstrated that DOR is differentially regulated by TH
and acts as a stimulatory mediator of TH effects in osteoblasts. DOR may also play a
role in regulating osteoblast differentiation; however, other factors besides DOR may also
be important in mediating TH effects on osteoblast differentiation. Further studies
identifying such molecules will advance our understanding of the molecular mechanisms
responsible for TH signaling in osteoblasts.
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CHAPTER FOUR
CLAUDIN 18 (CLDN-18) IS A NOVEL NEGATIVE REGULATOR OF BONE
RESORPTION AND OSTEOCLAST DIFFERENTIATION
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Summary
Claudin 18 (Cldn-18) belongs to a large family of transmembrane proteins that are
important components of tight junction strands. Although several claudin members are
expressed in bone1-4, the functional role for any claudin member in bone is unknown.
Here we demonstrate that disruption of Cldn-18 in mice markedly decreased total body
bone mineral density, trabecular bone volume, and cortical thickness in Cldn-18 -/- mice.
Histomorphometry revealed that bone resorption parameters were increased significantly
in Cldn-18 -/- mice without changes in bone formation. Serum levels of TRAP5b and
mRNA expression levels of osteoclast markers were also increased. In vitro studies with
bone marrow macrophages revealed Cldn-18 disruption markedly enhanced RANKLinduced osteoclast differentiation but not MCSF-induced BMM proliferation.
Furthermore, Cldn-18 effects on RANKL-induced osteoclast differentiation were
mediated in part by Zonula occludens 2 (ZO-2). In conclusion, we demonstrate that
Cldn-18 is a novel negative regulator of bone resorption and osteoclast differentiation.

Introduction
Tight junctions are important in the development and maintenance of multicellular organisms because they aid in the assembly of cellular sheets. Located at the
apical region of the plasma membrane, tight junctions establish cell polarity by
maintaining the polarized distribution of proteins and lipids. Besides their canonical
function as a selective barrier, recent evidence demonstrates that tight junctions also
participate in intracellular signaling pathways affecting cell proliferation, differentiation,
and gene expression5.

142

A major structural component of tight junction strands is the Claudin (Cldn)
family which consists of 24 members. Cldns encode 20-27 kDa proteins with four
transmembrane domains, two extracellular loops, and a cytoplasmic C-tail. Certain Cldns
are widely expressed at high levels suggesting a housekeeping function while others are
expressed at low levels suggesting specialized or regulatory functions6. While recent
studies have shown that several Cldn family members are expressed in bone1-4, their role
in bone biology remains unknown.

Results
To investigate the functional role of Cldn-18 in the development of peak bone
mass, Cldn-18 -/- mice were generated using conventional gene targeting7. Cldn-18 was
inactivated by replacing exons 2-4 with LacZ/neomycin selection cassette (Fig 20a).
Southern blotting confirmed disruption of Cldn-18 gene (Fig 20b). Genotyping of
genomic DNA from heterozygous (+/-), Cldn-18-null homozygous (-/-), and wild type
(+/+) reveal the presence of a 453-bp and 551-bp product from WT and mutant alleles
respectively (Fig 20c). Cldn-18 deficiency was confirmed in stomach (positive control)
and bone marrow macrophages (BMMs) from Cldn-18 -/- mice by immunoblot (Fig.
20d). Mating of Cldn-18 heterozygous mice generated pups of three possible genotypes
(+/+, +/-, and -/-) at the expected Mendelian frequency and all were viable. Homozygous
Cldn-18 -/- mice exhibited no obvious differences compared to control littermates in a
battery of tests designed to detect developmental, neurological, cardiac, endocrinological,
and hematological abnormalities.
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Figure 20. Generation of Cldn-18 -/- mice. (a) Schematic diagram of the targeting
strategy used to disrupt exons 2-4 of Cldn-18 gene by homologous recombination. The
positions of the 5′ and 3′ external probes used for Southern blot analyses and of the
restriction endonuclease sites are indicated. The position of the primers (1, 19, Neo3a,
and 4) used for genotyping is shown on the target vector. (b) Southern blot analysis of
HindIII and BamHI digested genomic DNA reveals the targeted deletion of Cldn-18 in
129SvEvBrd-derived embryonic stem cells. (c) Genotyping of genomic DNA from
heterozygous (+/-), Cldn-18-null homozygous (-/-), and wild type (+/+) mice. (d)
Immunoblot analysis of Cldn-18 expression in stomach (positive control) and bone
marrow macrophages (BMMs) derived from WT and Cldn 18 -/- mice. β-actin was used
as an internal loading control.
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Body length and femur length were unaffected between Cldn-18 -/- mice and
littermate controls (Fig. 21a-b). Whole body DXA revealed reductions of 20%-25% in
total body bone mineral content (BMC), total body bone mineral density (BMD), vertebra
BMD, and femur BMD in Cldn-18 -/- mice compared to control mice at 26 weeks of age
(Figure 21c-f). Phenotypic differences due to gender-genotype interaction were not
observed and therefore data from both genders were pooled for analysis. µCT analysis
revealed that Cldn-18 -/- mice had decreased (20%) cortical thickness resulting in
increased bone marrow volume relative to littermate control mice at 26 weeks of age
(Fig. 21g,i). Cross-sectional area was not significantly different between the two groups
(Fig. 21h). Trabecular bone volume, trabecular thickness, and trabecular number were
dramatically reduced by 50% in Cldn-18 -/-mice (Fig. 21j-m,o) while trabecular
separation was increased by 50% compared to control mice at 26 weeks of age (Fig.
21n). Connectivity density was reduced 50% in Cldn-18 -/- mice (Fig. 21p) and this
group also displayed a higher ratio of rods to plates as indicated by structure model index
(SMI) (Fig. 21q). Similar deficits were also observed in mice at 4 weeks (Fig. 22).
Significant perturbations in levels of calcium, phosphate, glucose, albumin,
creatinine, and cholesterol were not observed in Cldn-18 -/- mice compared to wild type
mice (Fig. 23). This finding indicates that a systemic deficiency of ions or nutrients is
not the cause for decreased BMD in Cldn-18 -/- mice.
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Figure 21. Cldn-18 -/- mice exhibit reduced bone mineral density. (a) Body length and
(b) femur length in WT and Cldn-18 -/- mice at 26 weeks of age (genders combined).
(n=8/group). (c) Total body BMC, (d) total body BMD, (e) vertebra BMD, and (f) femur
BMD as determined by DXA in WT and Cldn-18 -/- mice at 26 weeks of age (genders
combined). (n=8/group); A=P < 0.01 vs. WT littermates. (g) Cross sections of femur
mid diaphysis analyzed by µCT in WT and Cldn-18 -/- mice at 26 weeks of age. (h)
Cross sectional area (CSA) and (i) cortical thickness at femur mid diaphysis in WT (open
bars) and Cldn-18 -/- mice (filled bars). (n=3-5/group); A=P < 0.05 vs. WT littermates.
µCT image of (j) L5 vertebra and (k) distal femur metaphysis from 26 week old WT and
Cldn-18 -/- mice. (l-q) Quantitative measurements of trabecular bone structure of L5
vertebra and distal femur metaphysis (genders combined). (l) % Trabecular bone volume
(BV/TV %) (m) Trabecular thickness (TbTh) (n) Trabecular spacing (TbSp) (o)
Trabecular number (TbN)
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Figure 21. (p) Connectivity density (ConnD) (q) Structure model index (SMI).
(n=8/group); A=P < 0.05 vs. WT littermates.
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Figure 22. Cldn-18 -/- mice exhibit reduced bone mineral density. (a) Body weight, (b)
body length, and (c) femur length in WT mice and Cldn-18 -/- mice at 4 weeks of age
(genders combined). (n=14/group). (d) Total body BMC, (e) total body BMD, (f)
vertebra BMD, and (g) femur BMD as determined by DXA in WT mice and Cldn-18 -/mice at 4 weeks of age (genders combined). (n=14/group); A=P < 0.01 vs. WT
littermates. (h-m) Quantitative measurements of trabecular bone structure of L5 vertebra
and distal femur metaphysis in WT (open bars) and Cldn-18 -/- mice (filled bars) at 4
weeks of age (genders combined). (h) % Trabecular bone volume (BV/TV %) (i)
Trabecular thickness (TbTh) (j) Trabecular spacing (TbSp) (k) Trabecular number (TbN)
(l) Connectivity density (ConnD) (m) Structure model index (SMI). (n=6-14/group);
A=P < 0.05 vs. WT littermates.
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Figure 23. Serum chemistry measurements in Cldn-18 -/- mice and WT mice. Serum
was collected from 14 week old Cldn-18 -/- mice and WT mice. (n=8/group).
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Dynamic histomorphometry revealed that bone formation parameters were not
significantly different between Cldn-18 -/- and control mice at 4 weeks of age (Fig. 24ad). In addition, serum and mRNA levels of osteocalcin, a bone formation marker, were
unaltered between Cldn-18 -/- mice and control mice (Fig. 24e-f). Moreover, in vitro
bone formation assay using bone marrow stromal cells from Cldn-18 -/- and control mice
demonstrated no significant difference in mineralized nodule formation (Fig. 24g-h).
Collectively, these results indicate that Cldn-18 deficiency does not impair bone
formation.
In contrast, TRAP staining revealed that endocortical (EC) TRAP labeled surface
increased by 104% in Cldn-18 -/- mice compared to control mice (Fig. 25a). To adjust for
the increased EC surface in Cldn-18 -/- mice, we determined % EC TRAP labeled surface
and found 87% increase in TRAP labeled surface in Cldn-18 -/- mice relative to control
mice (Fig. 25b) as well as increased osteoclast number (Fig. 25c). Serum levels of
TRAP5b, a bone resorption marker, were elevated (41%) in Cldn-18 -/- mice and
correlated negatively with femur trabecular BV/TV (Fig. 25f-g). Consistent with these
data, mRNA expression of TRAP and cathepsin K (Ctsk) (Fig. 25d-e) were increased
88% and 69% respectively in the femurs of Cldn-18 -/- mice. Osteoclast progenitor cells
derived from Cldn-18 -/- mice and treated with RANKL formed 80% more multinucleated
TRAP positive cells than WT mice in vitro (Fig. 25h,i). Together these findings
demonstrate that increased bone resorption is the major cause for decreased BMD in
Cldn-18 -/- mice.
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Figure 24. Bone formation is unaffected by Cldn-18 deficiency. (a-d) Bone formation
parameters measured at the endocortical surface of tibial metaphysis in wild type and
Cldn-18 -/- mice at 4 weeks of age. (a) Osteoid perimeter (Os.pm) (b) Osteoblast
perimeter (Ob.pm) (c) Osteoblast number (Ob #) (d) Mineral apposition rate (MAR).
(n=10-14/group). (e) Serum osteocalcin levels in WT and Cldn-18 -/- mice. (n=1014/group). (f) Osteocalcin gene expression in the femurs of WT and Cldn-18 -/- mice as
determined by real time RT-PCR. (n=14/group). (g) Mineralized nodule formation in
WT and Cldn-18 -/- mice as determined by Alizarin red staining. (h) Quantitative
mineralization area as measured by Osteomeasure system. (n=5/group).
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Figure 25. Disruption of Cldn-18 increases bone resorption and osteoclast formation.
(a) TRAP staining of osteoclasts at endosteal surface of mid diaphysis of the femur in
WT and Cldn-18 -/- mice at 4 weeks of age. Arrows denote representative osteoclasts.
(b) % Endocortical (EC) TRAP labeled surface and (c) osteoclast number (Oc #) in WT
and Cldn-18 -/- mice at 4 weeks of age. (n=14/group); A=P < 0.05 vs. WT. (d) TRAP
and (e) Cathepsin K gene expression in the femurs of WT and Cldn-18 -/- mice as
determined by real time RT-PCR. (n=14/group); A=P < 0.05 vs. WT. (f) Serum
TRAP5b levels in WT and Cldn-18 -/- mice. (n=10-14/group); A=P < 0.05 vs. WT. (g)
Negative correlation between femur trabecular bone volume and Trap5b in Cldn-18 -/mice. (h) In vitro osteoclast differentiation of BMMs derived from WT and Cldn-18 -/mice cultured in the presence of MCSF (50 ng/ml) and RANKL (100 ng/ml). (i)
Quantification of multinucleated TRAP positive cells. (n=8/group); A=P < 0.01 vs. WT.
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Alternative splicing of Cldn-18 gene results in 4 different isoforms (Cldn-18a1.1,
a1.2, a2.1, and a2.2) (Fig. 26a). Of the various Cldn-18 isoforms, stomach specific
isoform Cldn 18a2.1 was predominantly expressed in bone tissue as well as in isolated
bone cells (Fig. 26b). The consequence of Cldn-18 overexpression (Cldn-18a2.1
isoform) on the formation of multinucleated TRAP positive cells was evaluated using
RAW264.7 cells. Cldn-18 overexpression was confirmed by real time RT-PCR and
western blot (data not shown). RANKL induced osteoclastogenesis was dramatically
inhibited in Cldn-18 overexpressing cells (Fig. 26c-d). Consistent with reduced
osteoclast formation, RANKL stimulation of Ctsk expression was markedly decreased in
Cldn-18 overexpressing cells (Fig. 26e). These results suggest that Cldn-18 may be a
negative regulator of osteoclast differentiation and that increased bone resorption in
Cldn-18 -/- mice is a direct consequence of decreased Cldn-18 action on osteoclast
formation.
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Figure 26. Cldn-18 variant 18a2.1 is expressed in bone and influences osteoclast
formation. (a) Schematic representation of four types of Cldn-18 transcripts.
Organization of exons and introns and predictions for production of four types of
transcripts are shown. The alternatively inserted 12-bp sequence after exon 4 is depicted
with a black box. (b) Expression of Claudin 18a2.1 and Claudin 18a1.1 as measured by
RT-PCR. Cldn 18a1.2 and 18a2.2 transcript was not detected by RT-PCR (data not
shown). (c) In vitro osteoclast differentiation of untransduced RAW264.7 cells, or
RAW264.7 cells containing MLV-β-Gal or MLV-Cldn-18 cultured in the presence of
RANKL (100 ng/ml). (d) Quantification of multinucleated TRAP positive cells. (n=58/group); A=P < 0.01 vs. untransduced or MLV-β–Gal. (e) Real-time RT-PCR analysis
of Cathepsin K expression in MLV-β-Gal and MLV-Cldn-18 RAW264.7 cells treated
with RANKL (30 ng/ml) for 24 hours. (n=4/group); A=P < 0.05 vs. vehicle and B=P <
0.05 vs. MLV-β-Gal.
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MCSF and RANKL are necessary and sufficient for inducing osteoclast
differentiation8,9. To determine if the increased bone resorption in Cldn-18 -/- mice is due
to increased proliferation or differentiation of osteoclast precursors, we examined gene
expression levels of osteoclast progenitors and mature osteoclasts. The mRNA levels of
osteoclast differentiation markers (TRAP, Ctsk, and calcitonin receptor) were
significantly increased in the femurs of Cldn-18 -/- mice (Fig. 27a). In contrast, the
expression of markers for osteoclast progenitors (Cd11b, Csf1r, and PU-1), proliferation
(Cyclin D1), and apoptosis (Bcl2l11) were unchanged. Consistent with these data,
deletion of Cldn-18 did not affect MCSF induced osteoclast precursor cell proliferation
(Fig. 27b), suggesting that increased bone resorption in Cldn-18 -/- mice is not due to
altered proliferation. Furthermore, expression of Cyclin D1, TRAP, and Ctsk in BMMs
was not significantly different in MCSF treated BMMs from Cldn-18 -/- mice and control
mice (Fig. 27c). In contrast, stimulation with RANKL markedly increased TRAP and
Ctsk expression in Cldn-18 -/- osteoclast precursors compared to WT mice (Fig. 27d).
These data indicate that Cldn-18 may differentially regulate osteoclast differentiation via
RANKL signaling pathway.
We next tested whether Cldn-18 effects on RANKL signaling are mediated in part
via interaction of PDZ domain of Cldn-18 with PDZ domain containing protein, zonula
occludens (ZO)-2, since certain Cldns interact with ZO proteins10,11 and ZO-2 is highly
expressed in osteoclasts (data not shown). Accordingly, an interaction between Cldn-18
and ZO-2 was detected by immunoprecipitation (Fig. 27e). Numerous studies have
demonstrated ZO-2 contains NLS and that ZO-2 nuclear translocation is associated with
increased gene expression12-16. Because Cldn-18 interacted with ZO-2, we predicted that
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Cldn-18 overexpression would reduce RANKL induced nuclear translocation of ZO-2.
Accordingly, Cldn-18 overexpression decreased ZO-2 nuclear localization compared to
MLV-β-Gal (Fig. 27f). To assess whether ZO-2 is an important mediator of Cldn-18
effects on osteoclast differentiation, we examined the consequence of ZO-2 inhibition on
osteoclast differentiation by utilizing lentiviral shRNA. RANKL induced osteoclast
formation was dramatically reduced 50% in ZO-2 shRNA cells relative to non-target
shRNA (Fig. 27g,h). Consistent with reduced osteoclast formation, TRAP and Ctsk
expression was significantly reduced in ZO-2 shRNA cells following RANKL
stimulation (Fig. 27i). These findings indicate that Cldn-18 interacts with ZO-2 to
modulate RANKL signaling in osteoclasts.
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Figure 27. Cldn-18 regulates RANKL signaling in osteoclasts. (a) Real time RT-PCR
analysis of osteoclast precursor and differentiation markers in whole femurs (including
bone marrow) of 3 week old WT and Cldn-18 -/- mice. (n=8/group); A=P < 0.05 vs. WT.
(b) Osteoclast precursor proliferation (n=8/group). (c) Real time RT-PCR analysis of
Cyclin D1, TRAP, and Ctsk expression in WT and Cldn-18 -/- BMMs treated with MCSF
(30 ng/ml) for 24 hours. (n=4/group); A=P < 0.05 vs. vehicle. (d) Real-time RT-PCR
analysis of TRAP and Ctsk expression in WT and Cldn-18 -/- BMMs treated with MCSF
(30 ng/ml) and RANKL (100 ng/ml) for 72 hours. (n=4/group); A=P < 0.05 vs. vehicle
and B=P < 0.05 vs. WT. (e) Whole cell lysates from MLV-Cldn-18 RAW264.7 cells
were immunoprecipitated with antibody specific to ZO-2 and immunoblotted with Cldn18. An aliquot from the immunoprecipitation was probed with ZO-2 and served as a
loading control. (f) Immunoblot analysis of ZO-2 levels in nuclear fractions of MLV-β–
Gal and MLV-Cldn-18 RAW264.7 cells cultured with RANKL (30 ng/ml) for 6 hours.
Histone H3 served as an internal control. (g) In vitro osteoclast differentiation of
RAW264.7 cells transduced with non-target shRNA or ZO-2 shRNA cultured with
RANKL (100 ng/ml). (h) Quantification of multinucleated TRAP positive cells.
(n=8/group); A=P < 0.01 vs. non-target shRNA. (i) Real-time RT-PCR analysis of
TRAP and Ctsk expression in non-target shRNA and ZO-2 shRNA cells treated with
RANKL (100 ng/ml) for 24 hours. (n=4/group); A=P < 0.05 vs. vehicle and B=P < 0.05
vs. WT.
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Discussion
Results from the present study defined a new functional role for Cldn-18, a tight
junction protein, in bone. We provide the first experimental evidence for a Cldn family
member in regulating RANKL mediated osteoclast differentiation and thereby bone
resorption. Consistent with an important role for Cldns in bone, a sequence variant in
Cldn-14 was associated with decreased bone mineral density in humans17. These
findings raise the possibility that Cldns may serve an important function in bone biology
and warrants further investigation.
In terms of mechanism for Cldn action in bone, canonical functions of tight
junctions include regulating paracellular transport of ions, small molecules, and water.
We found that serum levels of calcium and phosphate, important ions of bone
metabolism, were unchanged by Cldn-18 disruption. In addition, loss of ZO-2 reduced
the stimulatory effect of RANKL on osteoclast differentiation and gene expression
suggesting an unexpected function of ZO-2 in regulating osteoclast differentiation. Our
data suggests that Cldn-18 modulates RANKL induced osteoclast differentiation via a
mechanism that is independent of its tight junction function. These data are consistent
with others who have reported an emerging role for tight junction proteins as dynamic
regulators of cell functions (proliferation, differentiation, and gene expression)5.
Although Cldns are broadly expressed in multiple tissues, ablation of particular
Cldns in certain tissues can lead to discrete phenotypic changes18-22 suggesting that Cldns
exhibit both redundant and specific physiological functions. Our in vitro data suggests
that Cldn-18 exerts a direct effect on osteoclast differentiation. Because Cldn-18 was
globally disrupted and Cldn-18 is expressed in other tissues besides bone, we cannot
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exclude the possibility that the phenotype of Cldn-18 -/- mice could also be mediated in
part by disruption of Cldn-18 in other tissues. Future studies to determine the role of
local Cldn-18 in bone using conditional KO will elucidate any differences between a total
versus local knockout.
In conclusion, we demonstrate that Cldn-18 is a novel negative regulator of bone
resorption. Our results established a critical role for Cldn-18 in regulating osteoclast
differentiation both in vitro and in bones. Understanding the osteoclast differentiation
process is important because the pathogenesis of bone diseases such as osteoporosis is
characterized by abnormal osteoclastogenesis. Therefore, it is possible that Cldn-18
related disruption in osteoclasts could contribute to development of skeletal disease.
Future studies investigating the molecular mechanisms of Cldn-18 action in bone may
prove useful in developing therapeutic strategies for the prevention and treatment of low
bone mass.

Methods
Mice
Cldn-18 deficient (Cldn-18 -/-) mice were generated via targeted disruption of
coding exons 2-4 of the murine homolog of the Cldn-18 gene (GenBank accession no.
NM_019815) by homologous recombination in 129SvEvBrd-derived embryonic stem
(ES) cells using the λ KO shuttle system as described7. Genotyping of mice was
accomplished using WT and mutant specific primers (Table 4) for PCR. Mice were
housed at Lexicon Pharmaceuticals Inc. (The Woodlands, TX) or Jerry L. Pettis
Memorial VA Medical Center Veterinary Medical Unit (Loma Linda, CA) under
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Table 4: Primer Sequences
GENE
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FORWARD (5′-3′)

REVERSE (5′-3′)

WT-specific genotyping primers (1 and 19)
Mutant-specific genotyping primers (Neo3a and 4)
Osteocalcin
Tartrate Resistant Acid Phosphatase (TRAP)
Cathepsin K (Ctsk)
Claudin 18A1.1
Claudin 18A1.2
Claudin 18A2.2
CD11b
Colony Stimulating Factor 1 Receptor (Csf1R)
PU-1
Cyclin D1 (Ccnd1)

GGGTTACTTGAGTTTCCTGAC
GCAGCGCATCGCCTTCTATC
CTCTCTCTGCTCACTCTGCT
CACTCAGCTGTCCTGGCTCAA
GAACGAGAAAGCCCTGAAGAGA
ACCTTCCCAGCAAGAGGGTG
ACCTTCCCAGCAAGAGGGTG
GTCTGTGTTTGCCAACATGC
ACAGCATCTGCCAAGACGATC
GGCTTGGCTTGGGATGATTCTC
CGCAGCTACAGCAGCTCTAT
AATGTACTCTGCTTTGCTGAA

ATGGACACGAGGATACCGAT
TCCTGTGCATTGCTGGGTGT
TTTGTAGGCGGTCTTCAAGC
CTGCAGGTTGTGGTCATGTCC
TATCGAGTGCTTGCTTCCCTTC
TGATTGCACAGATGCCGGAG
TGATTGCACAGATGCCGGAG
CTTTGAAGGGGAGGACTCAC
TCCTCACCGTCATTTCTCAGA
CCGCAGAAGGATGAGGTTGTGA
GAACTGGTACAGGCGAATCT
ATGAGACCACTAGAGGTCG

Calcitonin receptor (Calcr)
Bcl2-like 11 apoptosis facilitator isoform 1
(Bcl2l11)
Zonula Occludens-2 (ZO-2)

AGGCGAGGAGAGTACTGAAAT
CTCCCTACAGACAGAACCGCAA

TCTGTCTTTCCCCAGGAAATG
AGAAATACCCACTGGAGGACCG

CGGATTCCAGACAAGGTGTT

CCTTCAGAGACCCAGACTGC

standard approved laboratory conditions. Animal use protocols were approved by the
Institutional Animal Care and Use Committee of the participating institutions. The
Claudin 18 -/- mice were produced in collaboration between Genentech, Inc. and Lexicon
Pharmaceuticals, Inc. to analyze the function of about 500 secreted and transmembrane
proteins.

Cell Culture
Bone marrow stromal cells were isolated from the femurs and the tibias of Cldn18 -/- mice and corresponding control mice as reported previously23. Osteoblasts were
obtained by collagenase digestion of newborn mouse calvaria as described24. Primary
osteoclast precursors or bone marrow macrophages (BMMs) were isolated from long
bones (femur and tibia) of Cldn-18 -/- and corresponding control mice25 and maintained in
α-MEM supplemented with 10% fetal bovine serum (FBS), penicillin (100 units/ml),
streptomycin (100 μg/ml), and Macrophage Colony Stimulating Factor (MCSF) (25
ng/ml). MCSF was obtained from R&D Systems (Minneapolis, MN). Twenty-four
hours later, non-adherent cells BMMs were collected and used for subsequent
experiments. Osteoclasts were generated by incubating non-adherent-BMMs with MCSF
(100 ng/ml) and receptor activator of nuclear factor kappa B ligand (RANKL) (100
ng/ml) for 6 days. RANKL was obtained from R&D Systems (Minneapolis, MN).
RAW264.7 cells (American Type Culture Collection, Manassas, VA), an osteoclast
precursor cell line, were cultured in α-MEM containing 10% FBS, penicillin (100
units/ml), and streptomycin (100 μg/ml). All cells were maintained at 37oC in 5% CO2.
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Analysis of Skeletal Morphology
Dual energy x-ray absorption (DXA), Micro-computed tomography (µCT)
analysis, and histomorphometry were carried out as previously reported26.

ELISA
Serum levels of mouse osteocalcin (index of bone formation) and TRAP5b (index
of bone resorption) were measured according to the manufacturer’s instructions
(Immunodiagnostic systems, Fountain Hills, AZ).

Mineralized Nodule Formation
To induce differentiation, BMS cells were incubated with α-MEM containing
10% calf serum (CS), -glycerophosphate (10 mM), and ascorbic acid (50 µg/ml) for 24
days. -glycerophosphate and ascorbic acid were purchased from Sigma Aldrich (St.
Louis, MO). Nodules were stained for mineralized matrix using alizarin red and
mineralized area was quantified as described27.

Gene Expression Analysis
Total RNA was extracted from isolated tissues or cells and synthesized into
cDNA for real time RT-PCR analysis as previously described23. Relative gene
expression levels of osteocalcin, Tartrate resistant acid phosphatase (TRAP), Cathepsin K
(Ctsk), CD11b, Colony stimulating factor 1 receptor (Csf1r), PU-1, Cyclin D1, Calcitonin
receptor (Calcr), Bcl2-like 11 apoptosis facilitator isoform 1 (Bcl2l11), Zonula
occludens-2 (ZO-2), and Claudin 18a1.1, 18a1.2, 18a2.1, and 18a2.2 were examined.
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Primer sequences are listed in table 4. Gene specific primers were used to amplify
Claudin 18a2.1 (forward: 5′-GCTGTACGAGCCCTGATGAT-3′, Reverse: 5′GAGATGATGAACAAGATCCC-3′). The housekeeping gene PPIA was used as an
internal control in the PCR reaction and the fold change compared to control was
calculated according to the formula 2-ΔΔCt.

Cloning of Claudin 18a2.1
Full length coding sequence of Claudin 18a2.1 was amplified by PCR with high
fidelity enzyme Pfx50 (Invitrogen, Carlsbad, CA) using Mus Musculus stomach cDNA as
a template and cloned as described elsewhere28. The primer sequences are (5′ to 3′):
Claudin 18 forward: 5′- GGTCGACGCCACCATGTCGGTGACCGCCTGCCAGG
GCTTGG-3′ and Claudin18 reverse: 5′- CGCGGATCCCTACACATAGTCATACTT
GGTAGGATGAG-3′. Claudin 18a2.1 coding sequence was confirmed by DNA
sequencing at Arizona State University (Tempe, AZ).

Murine leukemia Virus-Based Viral Vectors (MLV-based vector)
Production and Transduction
MLV-based vectors containing (β-gal or Claudin 18a2.1) were generated and
RAW264.7 cells were transduced as previously described29.

Lentivirus Transduction
RAW264.7 cells were transduced with Mission® non-target shRNA control
(Sigma-Aldrich, St. Louis, MO) transduction particles or five different Mission® ZO-2
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transduction particles (ZO-2 shRNA 68-72) (Sigma-Aldrich, St. Louis, MO) as
previously reported28.

In vitro Osteoclast Formation
Tartrate resistant acid phosphatase (TRAP) stain was performed on primary nonadherent BMMs (wild type and Cldn-18 -/- mice) and RAW264.7 cells (untransduced,
MLV-Cldn-18, MLV-β-gal, non-target shRNA control, and ZO-2 shRNA). To induce
osteoclast differentiation, non-adherent BMMs were incubated with MCSF (100 ng/ml)
and RANKL (100 ng/ml) whereas RAW264.7 cells were incubated with only RANKL
(30 ng/ml or 100 ng/ml) for 6 days or the indicated time periods. Osteoclastogenesis was
evaluated by TRAP stain using Fast Garnet GBC sulfate salt (Sigma Aldrich, St. Louis,
MO) as previously described30. The number of multinucleated TRAP positive cells
(defined as 3 or more nuclei per cell) was counted. Data are representative of 4 random
fields per well.

Immunoblotting Analysis
Stomach was obtained from WT and Cldn-18 -/- mice and the gastric contents
were emptied. Tissues were flash-frozen in liquid nitrogen and stored at -80oC until the
extraction was performed. Briefly, the tissue was minced and homogenized in a tightfitting glass homogenizer (using 30 strokes) with lysis buffer containing 50 mM Hepes
(pH 7.4), 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 0.2% sodium deoxycholate,
0.05% SDS, 1% Triton X-100, and protease inhibitor cocktail (Sigma Aldrich, St. Louis,
MO). Using a Sonic Dismembrator Model 100 (Fisher Scientific, Pittsburgh, PA) the
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stomach homogenate was briefly sonicated on ice and centrifuged at 5000 RPM for 5
minutes at 4oC to remove excess debris.
For preparation of whole cell lysates, BMMs derived from WT and Cldn-18 -/mice were washed two times with PBS. Following collection in cold PBS, cells were
centrifuged at 425 x g for 5 minutes at 4oC and the resulting pellets were suspended in
lysis buffer (described above). Samples were lysed under gentle rotation for 30 minutes
at 4oC and were sonicated briefly on ice. The cell lysates were centrifuged at 12,000 x g
for 10 minutes at 4oC to remove excess debris and the resulting supernatant was used for
western blot analysis. Nuclear extracts of RAW264.7 cells expressing MLV-Cldn-18 and
MLV-β-Gal were prepared as reported elsewhere31. Protein concentration was
determined by Bradford method and immunoblotting was carried out as described32.
Membranes were probed with antibodies against Cldn-18 (C-term) (1:250) (Invitrogen,
Carlsbad, CA), ZO-2 (R-19) (1:250) (Santa Cruz Biotechnology Inc, Santa Cruz, CA),
Histone H3 (1:10,000) (Sigma Aldrich, St. Louis, MO), and β-actin (1:10,000) (Sigma
Aldrich, St. Louis, MO).

Immunoprecipitation
MLV-Cldn-18 RAW264.7 cells were cross-linked as previously described26.
Cells were incubated in lysis buffer containing 10 mM HEPES (pH 7.4), 150 mM NaCl,
0.5% sodium deoxycholate, 0.2% SDS, 1% Triton X-100, and 1x protease inhibitor
cocktail for 30 minutes on ice. Immunoprecipitation was performed using 2 µg of ZO-2
(R-19) specific polyclonal antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA) or
control IgG as described elsewhere26. The immunoprecipitated proteins were separated
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by SDS-PAGE under reducing conditions for immunoblot and probed with polyclonal
antibody against Claudin 18 (C-term) (1:250) (Invitrogen, Carlsbad,CA).

Cell Proliferation
CyQUANT assay was used to determine cell proliferation and was performed as
per the manufacturer’s instructions (Invitrogen, Carlsbad, CA). BMMs isolated from WT
and Cldn-18 -/- mice were treated with MCSF (1 ng/ml, 10 ng/ml, and 100 ng/ml) for 48
hours and cell proliferation was determined.

Statistical Analysis
Results are expressed as means ± SD (standard deviation) and were analyzed
using Student’s T-test or ANOVA (one-way or two way) (Statistica 6, Tulsa, OK) as
appropriate. Post-hoc analysis was performed using Duncan's test. Values were
considered statistically significant when P < 0.05.
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CHAPTER FIVE
DISCUSSION
Osteoporosis is a disease characterized by decreased bone mass and
microarchitectural deterioration. It is caused by an increase in bone resorption
accompanied by a corresponding decrease in bone formation resulting in net bone loss.
To date many of the current agents for treating osteoporosis are focused on inhibiting
bone resorption otherwise known as antiresorptive therapy. Some examples of
antiresorptive agents include bisphosphonates, estrogen, SERMS, and calcitonin.
Although antiresorptive therapy is useful in halting bone resorption, a major limitation of
these agents is the inability to replace bone that has already been lost. Therefore, it is
important to identify anabolic agents that can effectively stimulate bone formation.
Currently, parathyroid hormone (PTH) is the only FDA approved anabolic agent
available to treat osteoporosis. However, PTH treatment is limited to a 2 year period
(Bilezikian et al., 2009). This highlights the need to identify other agents which can be
utilized for treatment of this debilitating disease. Understanding the mechanisms which
regulate bone formation and bone resorption may define important control mechanisms
of osteoblasts and osteoclasts. Thus, elucidation of these regulatory mechanisms is
essential for an understanding of the skeletal system both in health and disease states.
Numerous studies have documented the importance of oxidative stress in bone.
In this study we found that a member of the glutaredoxin family, Grx5, protects
osteoblasts from oxidative stress induced apoptosis. Grx1 and Grx2 are also expressed in
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bone but at lower levels than Grx5. We did not observe a compensatory change in the
expression of Grx1 and Grx2 in Grx5 siRNA treated cells. To our surprise, loss of Grx5
alone did not cause a drastic effect in ROS production and apoptosis. Changes between
Grx5 siRNA and control siRNA cells were evident only in the presence of an oxidative
stressor. Therefore, it is possible that another component of the antioxidant system may
counteract the effects of oxidative stress in the absence of Grx5. For example,
inflammatory bowel disorder only was observed in mice that contained a double KO of
glutathione peroxidase 1 and 2 (Esworthy et al., 2001). In this regard, future studies to
systematically identify antioxidant defense mechanisms in bone as well as their relative
contribution will help focus our efforts in developing viable treatment options in
ameliorating the harmful effects of oxidative stress in bone.
Recently an association between diabetes and bone has been described. Reactive
oxygen species is generated by high glucose and other metabolic abnormalities in
diabetics. Since diabetics exhibit increased bone fractures and decreased bone mineral
density it is hypothesized that the effects on bone are due to diabetes induced oxidative
stress (Hamada, Fujii, & Fukagawa, 2009). In support of this hypothesis, overexpression
of thioredoxin, an antioxidant enzyme, prevented the suppression of bone formation in
diabetic mice. These results suggest that oxidative stress associated with diabetes
contributes to bone loss (Hamada, Fujii, Kitazawa, et al., 2009). It would be interesting
to determine whether Grx5 may offer protection against oxidative stress in diabetics.
The importance of Grx is evident in several different biological systems.
Following ischemia-reperfusion injury in mice, deletion of Grx1 increased infarct size
and ROS production (G. Malik, Nagy, Ho, Maulik, & Das, 2008). Overepxression of
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Grx1 reduced ROS levels in the heart following ischemia-reperfusion (G. Malik et al.,
2008). Grx2 overxpression prevented apoptosis and necrosis in myocardial cells (Nagy
et al., 2008). The inhbition of Grx1 results in mitochondrial dysfunction in neural cells
(Saeed et al., 2008). Estrogen treatment stimulates Grx2 expression in cardiac cells
(Urata et al., 2006). Deletion of Grx5 results in disruption of iron sulfur cluster
biogenesis which in turn leads to mitochondrial overload in humans (Ye et al., 2010).
Taken together these findings highlight the functional importance of the Grx family in
maintaining redox status by regulating ROS production and thereby preventing apoptosis.
TH signaling is important in the development and maintenance of bone. In our
study we found that DOR was a critical factor in mediating the actions of TH in
osteoblasts. We found that a DOR single nucleotide polymorphism (SNP) associated
with plasma levels of the bone formation marker osteocalcin. In this regard, studies need
to be performed to determine whether the SNP affects DOR expression via a
transcriptional or post-transcriptional mechanism. Moreover, a correlation with bone
density or osteoblast activity should also be performed in these subjects. As described
earlier, hypothyroidism and hyperthyroidism are associated with increased fracture risk.
Therefore, it would be insightful to evaluate the expression and/or function of DOR in
patients with hypothyroidism and hyperthyroidism to determine if it is abnormally
expressed in these diseases with altered TH signaling.
DOR also plays a role in other biological systems. DOR is involved in regulating
autophagy and protein degradation in mammalian and Drosophila cells (Mauvezin et al.,
2010). In these cells, DOR is localized to the nucleus. However, DOR transclocates
from the nucleus to the autophagasomes after stimulation with rapamycin or with nutrient
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deprivation (Mauvezin et al., 2010; Nowak et al., 2009). In osteoblasts, we determined
that DOR was localized to the nucleus. In contrast, we did not observe nuclear export
into the cytosol following stimulation with TH, indicating that DOR protein localization
is restricted to the nucleus. In light of these results, it is tempting to speculate that DOR
may function as a nuclear coactivator in osteoblasts, however this remains to be
determined.
Although we observed that TH regulates DOR expression, it is conceivable that
other factors may also regulate DOR expression. In our studies we found that DOR was
downregulated in response to FGF suggesting that growth factor signaling may regulate
the expression of DOR. We also examined the effect of known inducers of osteoblast
differentiation on DOR expression. Stimulation of MC3T3-E1 cells (pre-osteoblast cell
line) and C3H10T1/2 cells (mesenchymal stem cell line) with ascorbic acid and/or BMP2 resulted in increased DOR expression. Further studies will examine whether the
increased DOR expression may be mediated by ascorbic acid and/or local growth factors
produced by differentiating osteoblasts. Another mechanism that may regulate DOR
expression is heterodimerization via TRα. TRα forms heterodimers with other nuclear
receptors which include vitamin D receptor (VDR), retinoic acid receptor (RAR),
estrogen receptor (ER), and glucocorticoid receptor (GR) (S. Y. Cheng et al., 2010). A
recent study demonstrated that in Drosophila melanogaster, DOR binds to ecdysone
receptor and acts as a nuclear coactivator (Francis et al., 2010). Heterodimerization
enables TR to interact with other signaling pathways and this crosstalk may serve as
another mechanism in modulating DOR function. Hence, the identification of additional
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signaling pathways that DOR participates in will advance our understanding of the
molecular actions of TH in osteoblasts.
Osteoclast differentiation is a tightly regulated process. The major molecules that
are necessary and sufficient for inducing osteoclast differentiation are MCSF and
RANKL. MCSF is involved in the proliferation and survival of osteoclast precursors
whereas RANKL is responsible for differentiation. In our study we found that Cldn-18, a
TJ protein, regulates osteoclast differentiation. We examined whether the increased bone
resorption in Cldn-18 KO mice was due to increased proliferation or increased
differentiation of osteoclast precursors, and found that deletion of Cldn-18 did not affect
MCSF signaling. In the presence of RANKL we observed a robust increase of osteoclast
specific gene expression, suggesting that Cldn-18 may differentially regulate osteoclast
differentiation via RANKL signaling. It is unknown whether Cldn-18 regulates RANKL
independent actions. Future studies will evaluate the effects of factors that are known to
regulate osteoclast formation (TNF-α, prostaglandins, interleukins) (J. H. Kim et al.,
2009; Yao, Xing, & Boyce, 2009) besides RANKL in order to determine if Cldn-18 can
regulate osteoclast differentiation via a RANKL independent mechanism.
Our findings provide the first evidence that Cldn-18 is expressed in osteoclasts
and affects bone mineral density by regulating bone resorption. Relatively little is known
about the role of TJ proteins in osteoclasts and little is known on the role of any Cldn
family member in bone. There is some evidence to suggest that gap junctions are
important in skeletal biology. Studies by Civitelli’s group have shown that disruption of
connexin 43, a major gap junction protein, leads to decreased bone mineral density in
mice (Lecanda et al., 2000; Watkins et al., 2011). Moreover, connexin 43 participates in
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the fusion of osteoclast precursors into mature osteoclasts (Ilvesaro & Tuukkanen, 2003).
Occludin is a transmembrane protein that is localized at the tight junction. Disruption of
occludin in mice leads to a thinning of cortical bone and postnatal growth retardation
(Saitou et al., 2000). In Cldn-18 KO mice, differences in growth rate were not observed,
thus suggesting that different mechanisms may regulate occludin and Cldn-18 action in
bone.
The unexpected function of Cldn-18 in regulating bone resorption suggests that
Cldn-18 exerts other functions besides regulating paracellular transport. It has been
reported that PDZ domain containing proteins such as ZO-1, ZO-2, and ZO-3 bind to the
YV sequence in the carboxy terminus of Cldn proteins (Itoh et al., 1999). Of these three
proteins we focused on ZO-2 because knockdown of ZO-2 is embryonically lethal (Xu et
al., 2008) and ZO-2 expression was highest in osteoclasts. As transmembrane proteins,
the interaction of Cldns with the actin based cytoskeleton via membrane associated
proteins (such as ZO proteins) is important for maintaining structural organization of the
junctional complex at the plasma membrane and for signal transduction (Umeda et al.,
2006). In terms of the molecular mechanism for Cldn-18 action, we predict that ZO-2
mediates Cldn-18 action by signaling to and from the TJ. TJs have also been shown to
regulate gene expression via interactions with ZO-1-ZO-3, and MUPP1 (Traweger et al.,
2008). For example ZO-2 modulates the transcriptional activity of AP-1 and cyclin D
promoter (Betanzos et al., 2004; Huerta et al., 2007). These findings suggest that ZO-2
may function to regulate the activity of transcription factors. In our study we observed
that RANKL treatment induced the localization of ZO-2 to the nucleus and that
overexpression of Cldn-18 abrogated this effect. Therefore, it is possible that ZO-2 may
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mediate the effects of Cldn-18 in osteoclasts by interacting with transcription factors.
Future studies will need to be performed to examine whether ZO-2 modulates the activity
of NFATc1 and NF-κB, important transcription factors involved in RANKL induced
osteoclast differentiation. Thus, the identification of the molecular pathway by which
Cldn-18 acts will advance our understanding on the regulation of osteoclast
differentiation.

Summary and Conclusions
1)

In the study described in chapter 2, we provide experimental evidence that Grx5

regulates oxidative stress induced apoptosis in osteoblasts. Of the three Grx family
members, Grx5 is more highly expressed than both Grx1 and Grx2 in bone. Grx5
deficiency sensitized osteoblasts to oxidative stress induced apoptosis whereas Grx5
overexpression provided protection. The protective ability of Grx5 appears to be due to
its ability to regulate ROS production, cardiolipin oxidation, caspase activity, Fe-S cluster
formation, and MnSOD activity. In conclusion, Grx5 is an important mediator of
osteoblast cell functions which acts as a scavenger of ROS and thereby attenuates its
harmful effects by protecting against oxidative stress induced apoptosis.
2)

In the study described in chapter 3, we provide experimental evidence that DOR

is involved in mediating the effects of thyroid hormone on osteoblast differentiation.
Specifically we found that DOR expression was markedly upregulated during osteoblast
differentiation. Thyroid hormone induction of DOR expression was acute and
independent of de novo protein synthesis. The modulation of DOR expression affects the
stimulatory effect of thyroid hormone on ALP activity. Specifically, DOR
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overexpression increased ALP activity, whereas DOR inhibition decreased ALP activity.
The loss of DOR reduced the stimulatory effect of thyroid hormone on the gene
expression of osteoblast specific markers (osteocalcin and ALP) and a master osteoblast
transcription factor (Runx2). DOR was detected in the nuclear fraction of osteoblasts and
acute treatment with TH did not alter its nuclear localization. A DOR single nucleotide
polymorphism (SNP) was identified in Spanish non-diabetic men and associated with
plasma levels of osteocalcin, a bone formation marker. In conclusion, DOR acts as a
stimulatory mediator of TH-induced osteoblast differentiation and a DOR SNP associates
with plasma osteocalcin in men.
3)

In the study described in chapter 4, we provide experimental evidence that Cldn-

18 is a negative regulator of bone resorption. Mice lacking Cldn-18 exhibited significant
deficits in bone mineral content, bone mineral density, cortical thickness, and trabecular
bone volume. Bone formation parameters and osteoblast specific gene expression
(osteocalcin) were unchanged by disruption of Cldn-18. In contrast, Cldn-18 deficiency
increased bone resorption parameters and RANKL induced osteoclast differentiation.
Moreover, Cldn-18 overexpression attenuated the stimulatory effect of RANKL on
osteoclast differentiation and cathepsin K mRNA expression. Cldn-18 influences
RANKL signaling and in part mediates the localization of ZO-2 in osteoclasts. Loss of
ZO-2 dramatically reduced the stimulatory effect of RANKL on osteoclast differentiation
and gene expression (TRAP and Ctsk). In conclusion, Cldn-18 is a novel negative
regulator of bone resorption that interacts with ZO-2 to modulate RANKL signaling in
osteoclasts.
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Future Directions
1)

A common approach for determining the function of a gene in vivo is to

manipulate gene expression by either overexpressing or knocking it out. The
overexpression of a particular gene using transgenic mice may not be the best strategy
since the fold changes in gene expression in transgenic mice may not be physiologically
relevant and therefore may confound the interpretation of normal gene function. In this
regard, we would favor generating a knockout (KO) mouse to study the function of a
gene of interest in vivo. In our studies on Grx5, we found that it is an important regulator
of osteoblast functions and protects against oxidative stress induced apoptosis. Since
these studies were performed in vitro, it would be important to evaluate the role of Grx5
in bone in vivo. One strategy to evaluate the role of Grx5 in vivo is to generate a
conditional Grx5 KO mice using osteoblast specific promoter such as Osx-Cre or
Col1α2-Cre. Because total KO of Grx5 in zebrafish is lethal, it is preferable to use a
conditional knockout approach and evaluate the skeletal phenotype of Grx5 KO mice by
examining bone mineral density (DXA and µCT analyses), bone strength, as well as bone
formation and bone resorption parameters (histomorphometry). We predict that deletion
of Grx5 will adversely affect bone leading to increased osteoblast apoptosis and
decreased osteoblast number and bone formation rate. Furthermore, we would expect
increased ROS levels in Grx5 KO mice.
It is well known that sex steroids exert antiapoptotic effects on osteoblasts in vitro
and in vivo (Almeida, Han, Martin-Millan, Plotkin, et al., 2007; J. Chow et al., 1992;
Manolagas, 1995; Syed & Khosla, 2005). Estrogen defciceny can lead to increased
production of ROS which promotes apoptosis. In this regard, it would be interesting to

188

see if ovariectomy induced oxidative stress and bone loss are exacerbated in Grx5 KO
mice relative to control mice. If Grx5 is involved in protecting against oxidative stress in
osteoblasts, then we would predict increased apoptosis and decreased bone mass in Grx5
KO mice relative to control mice.

2)

The major effects of TH are mediated by modulation of gene transcription.

According to the classical genomic model, TRs are bound to TRE both in the presence
and absence of ligand. In the absence of ligand, corepressors are recruited to the TR
receptor complex and basal transcription is repressed. In the presence of ligand, TR
undergoes a conformational change whereby the coactivators are recruited to the
complex. In our studies on DOR, we found that this molecule plays an important role in
mediating the actions of TH on osteoblasts. Because loss of DOR decreases the
stimulatory effect of TH on osteoblasts and was localized to the nucleus, we hypothesize
that DOR may act as a nuclear coactivator. To evaluate this possibility, future studies
can be focused on determining if DOR modulates the transcriptional activation of TRα.
Co-immunoprecipitation experiments could be carried out to determine if DOR
physically interacts with TRα. In addition, co-localization experiments could be
performed to determine if this interaction occurs in the nucleus. A ChIP study using
osteocalcin gene since it contains a known thyroid hormone response element (TRE)
(Varga, Spitzer, Rumpler, & Klaushofer, 2003) will determine if DOR is recruited to the
promoter of osteocalcin in vivo using osteoblasts. Taken together, these findings would
provide strong evidence that DOR may act in part via a genomic mechanism.
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3)

In our studies on Cldn-18, we found that disruption of Cldn-18 resulted in

decreased bone mineral density caused by bone resorption. We found that Cldn-18
interacts with ZO-2 by coimmunoprecipitation and that Cldn-18 effects on osteoclast
differentiation may be mediated in part by ZO-2. Therefore, we plan on determining the
role of the PDZ binding motif (YV) in mediating binding of Cldn-18 to PDZ domain
containing proteins such as ZO-2. Site directed mutagenesis of YV will be carried out
and the effects on ZO-2 localization and Cldn-18 effects on osteoclast differentiation will
be examined. We predict that mutation of the YV site will impair Cldn-18 effect on
osteoclast differentiation. Although we observed an impressive skeletal phenotype in
Cldn-18 KO mice it is possible that this effect was due to Cldn-18 disruption in other
tissues since a global knockout was used. Therefore, a future study to determine the role
of local action of Cldn-18 woud be to generate conditional Cldn-18 KO mice using
osteoclast specific promoter (TRAP-Cre, or Cathepsin K-Cre). Cldn family members are
broadly expressed in different tissues. A future study should evaluate whether the
expression of other Cldn family members were altered in the bones of Cldn-18 KO mice.
In characterizing Cldn-18 expression, we found that Cldn-18 was expressed in
osteoblasts. In this regard it would be interesting to determine if Cldn-18 in osteoblasts
interacts with Cldn-18 or another protein in osteoclasts to affect osteoclast differentiation.
Other factors besides RANKL can regulate osteoclast differentiation. Therefore, it would
be insightful to ascertain whether Cldn-18 mediates osteoclast differentiation via RANKL
independent mechanisms by evaluating the actions of vitamin D, cytokines (e.g. TNF-α
and Il-1), and prostaglandins.
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In this dissertation, I have presented experimental evidence that Grx5, DOR, and
Cldn-18 are important genes involved in the regulation of osteoblast and osteoclast
functions. However, it is also interesting to speculate how these genes may be related
outside of bone physiology. Given the importance of these genes in regulating
differentiation and apoptosis in bone, we predict that these molecules may also serve an
important role in these same biological processes in other systems. The ability to form
specialized cell types and to regulate the rate of cell death are key regulatory processes
that affect cell fate and lifespan, respectively, of a cell. Thus, it is likely that disruption
of these genes may increase apoptosis or block the development and/or function in other
cells besides those committed to the bone lineage. It remains to be determined whether
Grx5, DOR, and Cldn-18 are associated via a coordinated gene regulatory network. Gene
expression profiling experiments may assist in determining whether overlapping
downstream targets for these molecules exist. In summary, these genes may function in
part as important regulators of differentiation and apoptosis, which are critical
determinants of an organism’s lifespan.
In conclusion, the results of this dissertation provide valuable insight into
potential molecular mechanisms that regulate bone formation (Grx5 and DOR) and bone
resorption (Cldn-18). Moreover, these studies provide an important advancement to
understanding the processes of osteoblast differentiation and osteoclast differentiation.
These regulatory axes may represent potential targets for the development of novel drug
therapies and/or the refinement of existing treatments for clinical manipulation of skeletal
disorders.
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